Document_and_Entity_Informatio
Document and Entity Information (USD $) | 12 Months Ended | ||
Sep. 30, 2013 | Oct. 31, 2013 | Mar. 31, 2013 | |
Document And Entity Information [Abstract] | ' | ' | ' |
Entity Registrant Name | 'AMERISOURCEBERGEN CORP | ' | ' |
Entity Central Index Key | '0001140859 | ' | ' |
Document Fiscal Year Focus | '2013 | ' | ' |
Document Fiscal Period Focus | 'FY | ' | ' |
Current Fiscal Year End Date | '--09-30 | ' | ' |
Entity Well Known Seasoned Issuer | 'Yes | ' | ' |
Entity Voluntary Filers | 'No | ' | ' |
Entity Current Reporting Status | 'Yes | ' | ' |
Entity Filer Category | 'Large Accelerated Filer | ' | ' |
Entity Public Float | ' | ' | $10,325,295,935 |
Entity Common Stock Shares Outstanding | ' | 230,032,094 | ' |
Document Period End Date | 30-Sep-13 | ' | ' |
Document Type | '10-K | ' | ' |
Amendment Flag | 'false | ' | ' |
Consolidated_Balance_Sheets
Consolidated Balance Sheets (USD $) | Sep. 30, 2013 | Sep. 30, 2012 |
In Thousands, unless otherwise specified | ||
Current assets: | ' | ' |
Cash and cash equivalents | $1,231,006 | $1,066,608 |
Accounts receivable, less allowances for returns and doubtful accounts: 2013 - $358,161; 2012 - $338,245 | 6,051,920 | 3,784,619 |
Merchandise inventories | 6,981,494 | 5,472,010 |
Prepaid expenses and other | 129,231 | 72,374 |
Assets held for sale | 0 | 662,853 |
Total current assets | 14,393,651 | 11,058,464 |
Property and equipment, at cost: | ' | ' |
Land | 37,538 | 33,009 |
Buildings and improvements | 324,150 | 324,264 |
Machinery, equipment and other | 1,109,731 | 942,604 |
Total property and equipment | 1,471,419 | 1,299,877 |
Less accumulated depreciation | -667,858 | -556,193 |
Property and equipment, net | 803,561 | 743,684 |
Goodwill and other intangible assets | 3,499,713 | 3,523,432 |
Other assets | 221,713 | 116,676 |
TOTAL ASSETS | 18,918,638 | 15,442,256 |
Current liabilities: | ' | ' |
Accounts payable | 13,335,792 | 9,492,589 |
Accrued expenses and other | 532,564 | 570,210 |
Deferred income taxes | 1,002,279 | 963,081 |
Liabilities held for sale | 0 | 239,706 |
Total current liabilities | 14,870,635 | 11,265,586 |
Long-term debt | 1,396,606 | 1,395,931 |
Other liabilities | 331,652 | 325,897 |
Stockholders equity: | ' | ' |
Common stock, $0.01 par value - authorized, issued and outstanding: 600,000,000 shares, 267,789,992 shares and 229,994,216 shares at September 30, 2013, respectively, and 600,000,000 shares, 262,542,659 shares and 235,394,281 shares at September 30, 2012, respectively | 2,678 | 2,625 |
Additional paid-in capital | 2,360,992 | 2,252,470 |
Retained earnings | 1,508,414 | 1,270,423 |
Accumulated other comprehensive loss | -35,483 | -32,657 |
Treasury stock, at cost: 2013 - 37,795,776 shares; 2012 - 27,148,378 shares | -1,516,856 | -1,038,019 |
Total stockholders equity | 2,319,745 | 2,454,842 |
TOTAL LIABILITIES AND STOCKHOLDERS EQUITY | $18,918,638 | $15,442,256 |
Consolidated_Balance_Sheets_Pa
Consolidated Balance Sheets (Parentheticals) (USD $) | Sep. 30, 2013 | Sep. 30, 2012 |
In Thousands, except Share data, unless otherwise specified | ||
Current assets: | ' | ' |
Allowances for returns and doubtful accounts | $358,161 | $338,245 |
Stockholders equity: | ' | ' |
Common stock, par value | $0.01 | $0.01 |
Common stock, shares authorized | 600,000,000 | 600,000,000 |
Common stock, shares issued | 267,789,992 | 262,542,659 |
Common stock, shares outstanding | 229,994,216 | 235,394,281 |
Treasury stock, shares held | 37,795,776 | 27,148,378 |
Consolidated_Statements_of_Ope
Consolidated Statements of Operations (USD $) | 3 Months Ended | 12 Months Ended | |||||||||
In Thousands, except Per Share data, unless otherwise specified | Sep. 30, 2013 | Jun. 30, 2013 | Mar. 31, 2013 | Dec. 31, 2012 | Sep. 30, 2012 | Jun. 30, 2012 | Mar. 31, 2012 | Dec. 31, 2011 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2011 |
CONSOLIDATED STATEMENTS OF OPERATIONS | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Revenue | $24,469,040 | $21,906,648 | $20,523,668 | $21,059,811 | $19,064,443 | $19,326,807 | $19,708,371 | $19,981,185 | $87,959,167 | $78,080,806 | $78,695,659 |
Cost of goods sold | 23,901,488 | 21,344,198 | 19,806,679 | 20,398,983 | 18,350,626 | 18,658,941 | 19,028,630 | 19,407,923 | 85,451,348 | 75,446,120 | 76,236,682 |
Gross profit | 567,552 | 562,450 | 716,989 | 660,828 | 713,817 | 667,866 | 679,741 | 573,262 | 2,507,819 | 2,634,686 | 2,458,977 |
Operating expenses: | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Distribution, selling and administrative | 358,303 | 331,173 | 323,536 | 320,700 | 329,138 | 303,812 | 262,421 | 257,185 | 1,333,712 | 1,152,556 | 1,138,022 |
Depreciation | 35,710 | 34,395 | 33,069 | 31,873 | 31,550 | 29,552 | 26,603 | 25,123 | 135,047 | 112,828 | 88,760 |
Amortization | 6,786 | 6,743 | 6,799 | 6,811 | 6,944 | 5,981 | 4,630 | 3,992 | 27,139 | 21,547 | 12,602 |
Warrants | 50,479 | 35,815 | 3,761 | 0 | ' | ' | ' | ' | 90,055 | 0 | 0 |
Employee severance, litigation and other | 2,084 | 19,678 | -299 | 2,004 | 27,419 | 4,135 | 9,027 | 3,559 | 23,467 | 44,140 | 23,567 |
Intangible asset impairments | ' | ' | ' | ' | ' | ' | ' | ' | 0 | 0 | 6,506 |
Operating income | 114,190 | 134,646 | 350,123 | 299,440 | 318,766 | 324,386 | 377,060 | 283,403 | 898,399 | 1,303,615 | 1,189,520 |
Other loss (income) | -1,207 | 525 | 749 | -23 | -910 | -4,785 | -131 | -1 | 44 | -5,827 | -4,617 |
Interest expense, net | 18,672 | 18,190 | 18,510 | 18,525 | 23,137 | 23,771 | 23,375 | 22,286 | 73,897 | 92,569 | 76,148 |
Income from continuing operations before income taxes | 96,725 | 115,931 | 330,864 | 280,938 | 296,539 | 305,400 | 353,816 | 261,118 | 824,458 | 1,216,873 | 1,117,989 |
Income taxes | 46,164 | 51,821 | 126,721 | 106,317 | 106,090 | 115,223 | 134,673 | 99,526 | 331,023 | 455,512 | 420,494 |
Income from continuing operations | 50,561 | 64,110 | 204,143 | 174,621 | 190,449 | 190,177 | 219,143 | 161,592 | 493,435 | 761,361 | 697,495 |
(Loss) income from discontinued operations, net of income tax expense of $9,638, $4,841, and $3,523 for fiscal 2013, 2012, and 2011, respectively | 462 | 104,329 | -158,509 | -6,010 | -26,955 | -8,906 | -7,038 | 524 | -59,728 | -42,375 | 9,129 |
Net income | $51,023 | $168,439 | $45,634 | $168,611 | $163,494 | $181,271 | $212,105 | $162,116 | $433,707 | $718,986 | $706,624 |
Basic earnings per share: | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Continuing operations | $0.22 | $0.28 | $0.89 | $0.75 | $0.78 | $0.75 | $0.85 | $0.63 | $2.14 | $3.01 | $2.56 |
Discontinued operations | $0 | $0.45 | ($0.69) | ($0.03) | ($0.11) | ($0.04) | ($0.03) | ' | ($0.26) | ($0.17) | $0.03 |
Rounding | ' | ' | ' | $0.01 | ' | $0.01 | ' | ' | ' | ' | ' |
Total | $0.22 | $0.73 | $0.20 | $0.73 | $0.67 | $0.72 | $0.82 | $0.63 | $1.88 | $2.84 | $2.59 |
Diluted earnings per share: | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Continuing operations | $0.22 | $0.27 | $0.87 | $0.74 | $0.77 | $0.74 | $0.84 | $0.61 | $2.10 | $2.96 | $2.51 |
Discontinued operations | $0 | $0.44 | ($0.68) | ($0.03) | ($0.11) | ($0.03) | ($0.03) | ' | ($0.25) | ($0.16) | $0.03 |
Rounding | ' | ' | ' | ' | ' | ' | ' | $0.01 | ($0.01) | $0 | $0 |
Total | $0.22 | $0.71 | $0.19 | $0.71 | $0.66 | $0.71 | $0.81 | $0.62 | $1.84 | $2.80 | $2.54 |
Weighted average common shares outstanding: | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Basic | ' | ' | ' | ' | ' | ' | ' | ' | 231,067 | 252,906 | 272,471 |
Diluted | ' | ' | ' | ' | ' | ' | ' | ' | 235,345 | 256,903 | 277,717 |
Consolidated_Statements_of_Ope1
Consolidated Statements of Operations (Parentheticals) (USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2011 |
Income Loss From Discontinued Operations Net Of Tax Abstract | ' | ' | ' |
Income tax expense | $9,638 | $4,841 | $3,523 |
Consolidated_Statements_of_Com
Consolidated Statements of Comprehensive Income (USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2011 |
statement of income and comprehensive income abstract | ' | ' | ' |
Net income | $433,707 | $718,986 | $706,624 |
Other comprehensive (loss) income: | ' | ' | ' |
Net change in foreign currency translation adjustments | -14,181 | 15,838 | -4,521 |
Benefit plan funded status adjustments, net of tax of $7,992, $1,096, and $5,472, respectively | 11,216 | 1,538 | -3,139 |
Other | 139 | 108 | 108 |
Total other comprehensive (loss) income | -2,826 | 17,484 | -7,552 |
Total comprehensive income | $430,881 | $736,470 | $699,072 |
Consolidated_Statements_of_Com1
Consolidated Statements of Comprehensive Income (Parentheticals) (USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2011 |
Other Comprehensive Income Loss Tax Portion Attributable to Parent | ' | ' | ' |
Other Comprehensive Income Defined Benefit Plans Tax | $7,992 | $1,096 | $5,472 |
Consolidated_Statements_of_Cha
Consolidated Statements of Changes in Stockholders Equity (USD $) | Total | Total | Common Stock | Additional Paid-in Capital | Retained Earnings | Accumulated Other Comprehensive Loss | Treasury Stock |
In Thousands | |||||||
Total stockholders equity at Sep. 30, 2010 | ' | $2,954,244 | $4,898 | $3,899,381 | $3,465,886 | ($42,589) | ($4,373,332) |
Net income | 706,624 | 706,624 | ' | ' | 706,624 | ' | ' |
Total other comprehensive income (loss) | -7,552 | -7,552 | ' | ' | ' | -7,552 | ' |
Cash dividends, $0.43 per share, $0.52 per share, and $0.84 per share, respectively, for fiscal years ended September 30, 2011, 2012 and 2013 | ' | -117,624 | ' | ' | -117,624 | ' | ' |
Exercise of stock options | ' | 115,820 | 64 | 115,756 | ' | ' | ' |
Excess tax benefit from exercise of stock options | ' | 39,711 | ' | 39,711 | ' | ' | ' |
Share-based compensation expense | ' | 28,365 | ' | 28,365 | ' | ' | ' |
Common stock purchases for employee stock purchase plan | ' | -232 | ' | -232 | ' | ' | ' |
Warrants | 0 | ' | ' | ' | ' | ' | ' |
Purchases of common stock | ' | -848,614 | ' | ' | ' | ' | -848,614 |
Employee tax withholdings related to restricted share vesting | ' | -3,935 | ' | ' | ' | ' | -3,935 |
Other | ' | 778 | 3 | -3 | 778 | ' | ' |
Total stockholders equity at Sep. 30, 2011 | ' | 2,867,585 | 4,965 | 4,082,978 | 4,055,664 | -50,141 | -5,225,881 |
Net income | 718,986 | 718,986 | ' | ' | 718,986 | ' | ' |
Total other comprehensive income (loss) | 17,484 | 17,484 | ' | ' | ' | 17,484 | ' |
Cash dividends, $0.43 per share, $0.52 per share, and $0.84 per share, respectively, for fiscal years ended September 30, 2011, 2012 and 2013 | ' | -132,760 | ' | ' | -132,760 | ' | ' |
Exercise of stock options | ' | 89,521 | 45 | 89,476 | ' | ' | ' |
Excess tax benefit from exercise of stock options | ' | 25,703 | ' | 25,703 | ' | ' | ' |
Share-based compensation expense | ' | 26,645 | ' | 26,645 | ' | ' | ' |
Common stock purchases for employee stock purchase plan | ' | -299 | ' | -299 | ' | ' | ' |
Warrants | 0 | ' | ' | ' | ' | ' | ' |
Treasury stock retirement | ' | 0 | -2,388 | -1,972,030 | -3,371,467 | ' | 5,345,885 |
Purchases of common stock | ' | -1,154,208 | ' | ' | ' | ' | -1,154,208 |
Employee tax withholdings related to restricted share vesting | ' | -3,815 | ' | ' | ' | ' | -3,815 |
Other | ' | 0 | 3 | -3 | ' | ' | ' |
Total stockholders equity at Sep. 30, 2012 | 2,454,842 | 2,454,842 | 2,625 | 2,252,470 | 1,270,423 | -32,657 | -1,038,019 |
Net income | 433,707 | 433,707 | ' | ' | 433,707 | ' | ' |
Total other comprehensive income (loss) | -2,826 | -2,826 | ' | ' | ' | -2,826 | ' |
Cash dividends, $0.43 per share, $0.52 per share, and $0.84 per share, respectively, for fiscal years ended September 30, 2011, 2012 and 2013 | ' | -195,716 | ' | ' | -195,716 | ' | ' |
Exercise of stock options | ' | 114,491 | 50 | 114,441 | ' | ' | ' |
Excess tax benefit from exercise of stock options | ' | 41,222 | ' | 41,222 | ' | ' | ' |
Share-based compensation expense | ' | 36,751 | ' | 36,751 | ' | ' | ' |
Settlement of accelerated stock repurchase agreement | ' | -10,312 | ' | -10,312 | ' | ' | ' |
Common stock purchases for employee stock purchase plan | ' | -260 | ' | -260 | ' | ' | ' |
Warrants | 90,055 | 90,055 | ' | 90,055 | ' | ' | ' |
Purchases of capped call options | ' | -163,372 | ' | -163,372 | ' | ' | ' |
Purchases of common stock | ' | -473,864 | ' | ' | ' | ' | -473,864 |
Employee tax withholdings related to restricted share vesting | ' | -4,973 | ' | ' | ' | ' | -4,973 |
Other | ' | 0 | 3 | -3 | ' | ' | ' |
Total stockholders equity at Sep. 30, 2013 | $2,319,745 | $2,319,745 | $2,678 | $2,360,992 | $1,508,414 | ($35,483) | ($1,516,856) |
Consolidated_Statements_of_Cha1
Consolidated Statements of Changes in Stockholders' Equity (Parenthetical) (USD $) | 1 Months Ended | 12 Months Ended | ||
Oct. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2011 | |
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS EQUITY | ' | ' | ' | ' |
Common Stock Dividends Per Share Cash Paid | $0.24 | $0.84 | $0.52 | $0.43 |
Consolidated_Statements_of_Cas
Consolidated Statements of Cash Flows (USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2011 |
OPERATING ACTIVITIES | ' | ' | ' |
Net income | $433,707 | $718,986 | $706,624 |
Loss (income) from discontinued operations | 59,728 | 42,375 | -9,129 |
Income from continuing operations | 493,435 | 761,361 | 697,495 |
Adjustments to reconcile income from continuing operations to net cash provided by operating activities: | ' | ' | ' |
Depreciation, including amounts charged to cost of goods sold | 138,690 | 113,765 | 89,659 |
Amortization, including amounts charged to interest expense | 32,103 | 26,750 | 17,310 |
Provision for doubtful accounts | 20,118 | 23,058 | 37,878 |
Provision for deferred income taxes | 25,573 | 61,278 | 194,797 |
Warrants | 90,055 | 0 | 0 |
Share-based compensation | 36,275 | 25,954 | 27,279 |
Loss on disposal of property and equipment | 1,663 | 249 | 855 |
Other, including intangible asset impairments | 2,064 | -9,433 | 5,758 |
Changes in operating assets and liabilities, excluding the effects of acquisitions: | ' | ' | ' |
Accounts receivable | -2,312,518 | 71,510 | -23,934 |
Merchandise inventories | -1,486,572 | -116,174 | -228,303 |
Prepaid expenses and other assets | -169,745 | 49,716 | -26,284 |
Accounts payable, accrued expenses, and income taxes | 3,818,288 | 416,100 | 388,687 |
Other liabilities | 12,559 | -7,177 | -3,799 |
Net cash provided by operating activities-continuing operations | 701,988 | 1,416,957 | 1,177,398 |
Net cash provided by (used in) operating activities-discontinued operations | 86,137 | -111,508 | -9,450 |
NET CASH PROVIDED BY OPERATING ACTIVITIES | 788,125 | 1,305,449 | 1,167,948 |
INVESTING ACTIVITIES | ' | ' | ' |
Capital expenditures | -202,450 | -133,292 | -156,142 |
Cost of acquired companies, net of cash acquired | 0 | -775,670 | -45,380 |
Proceeds from sales of property and equipment | 1,402 | 23 | 868 |
Proceeds from sales of businesses | 329,980 | 0 | 0 |
Net cash provided by (used in) investing activities-continuing operations | 128,932 | -908,939 | -200,654 |
Net cash used in investing activities-discontinued operations | -11,672 | -39,010 | -11,764 |
NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES | 117,260 | -947,949 | -212,418 |
FINANCING ACTIVITIES | ' | ' | ' |
Long-term debt borrowings | 0 | 499,290 | 0 |
Long-term debt repayments | 0 | -447,326 | 0 |
Borrowings under revolving and securitization credit facilities | 2,330,000 | 60,500 | 35,026 |
Repayments under revolving and securitization credti facilities | -2,330,000 | -60,500 | -35,068 |
Purchases of common stock | -484,176 | -1,162,246 | -840,577 |
Exercises of stock options, including excess tax benefits of $41,222, $25,703, and $39,711 in fiscal 2013, 2012, and 2011 respectively | 155,713 | 115,224 | 155,531 |
Cash dividends on common stock | -195,716 | -132,760 | -117,624 |
Purchases of capped call options | -157,295 | 0 | 0 |
Debt issuance costs and other | -8,975 | -10,658 | -7,439 |
Net cash used in financing activities-continuing operations | -690,449 | -1,138,476 | -810,151 |
Net cash (used in) provided by financing activities-discontinued operations | -50,538 | 21,594 | 22,429 |
NET CASH USED IN FINANCING ACTIVITIES | -740,987 | -1,116,882 | -787,722 |
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS | 164,398 | -759,382 | 167,808 |
Cash and cash equivalents at beginning of year | 1,066,608 | 1,825,990 | 1,658,182 |
CASH AND CASH EQUIVALENTS AT END OF YEAR | $1,231,006 | $1,066,608 | $1,825,990 |
Consolidated_Statements_of_Cas1
Consolidated Statements of Cash Flows (Parenthetical) (USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2011 |
FINANCING ACTIVITIES | ' | ' | ' |
Excess tax benefit from the exercise of stock options | $41,222 | $25,703 | $39,711 |
Summary_of_Significant_Account
Summary of Significant Accounting Policies | 12 Months Ended |
Sep. 30, 2013 | |
Accounting Policies [Abstract] | ' |
Significant Accounting Policies Text Block | ' |
Note 1. Summary of Significant Accounting Policies | |
AmerisourceBergen Corporation (the “Company”) is one of the largest global pharmaceutical sourcing and distribution services companies, helping both healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care. The Company delivers innovative programs and services designed to increase the effectiveness and efficiency of the pharmaceutical supply chain. | |
Basis of Presentation | |
The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries as of the dates and for the fiscal years indicated. All intercompany accounts and transactions have been eliminated in consolidation. | |
The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect amounts reported in the financial statements and accompanying notes. Actual amounts could differ from these estimated amounts due to uncertainties inherent in such estimates. Management periodically evaluates estimates used in the preparation of the financial statements for continued reasonableness. | |
Certain reclassifications have been made to prior year amounts in order to conform to the current year presentation. | |
Business Combinations | |
The purchase price of an acquired company, including the fair value of contingent consideration, is allocated between tangible and intangible assets acquired and liabilities assumed from the acquired business based on their estimated fair values, with the residual of the purchase price recorded as goodwill. The results of operations of the acquired businesses are included in the Company's operating results from the dates of acquisition (see Note 2). | |
Cash Equivalents | |
The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. The carrying value of cash equivalents approximates fair value. | |
Concentrations of Credit Risk and Allowance for Doubtful Accounts | |
The Company sells its merchandise inventories to a large number of customers in the healthcare industry that include institutional and retail healthcare providers. Institutional healthcare providers include acute care hospitals, health systems, mail order pharmacies, long-term care and other alternate care pharmacies and providers of pharmacy services to such facilities, and physician offices. Retail healthcare providers include national and regional retail drugstore chains, independent community pharmacies and pharmacy departments of supermarkets and mass merchandisers. The financial condition of the Company's customers can be affected by changes in government reimbursement policies as well as by other economic pressures in the healthcare industry. | |
The Company's trade accounts receivable are exposed to credit risk, but the risk is moderated because the Company's customer base is diverse and geographically widespread primarily within the U.S. The Company generally does not require collateral for trade receivables. In determining the appropriate allowance for doubtful accounts, the Company considers a combination of factors, such as the aging of trade receivables, industry trends, its customers' financial strength, credit standing, and payment and default history. Changes in these factors, among others, may lead to adjustments in the Company's allowance for doubtful accounts. The calculation of the required allowance requires judgment by Company management as to the impact of those and other factors on the ultimate realization of its trade receivables. Each of the Company's business units performs ongoing credit evaluations of its customers' financial condition and maintains reserves for probable bad debt losses based on historical experience and for specific credit problems when they arise. There were no significant changes to this process during the fiscal years ended September 30, 2013, 2012, and 2011 and bad debt expense was computed in a consistent manner during these periods. The bad debt expense for any period presented is equal to the changes in the period end allowance for doubtful accounts, net of write-offs, recoveries and other adjustments. Schedule II of this Form 10-K sets forth a rollforward of the allowance for doubtful accounts. The Company's largest customer in fiscal 2013, Express Scripts, Inc., accounted for 24% of revenue and represented approximately 13% of accounts receivable, net as of September 30, 2013. Walgreen Co. (“Walgreens”), the Company's second largest customer in fiscal 2013, represented approximately 32% of accounts receivable net as of September 30, 2013. | |
The Company maintains cash and cash equivalents with several financial institutions. Deposits held with banks may exceed the amount of insurance provided on such deposits. These deposits may be redeemed upon demand, and are maintained with financial institutions with reputable credit, and, therefore, bear minimal credit risk. The Company seeks to mitigate such risks by monitoring the risk profiles of these counterparties. The Company also seeks to mitigate risk by monitoring the investment strategy of money market accounts that it is invested in, which are classified as cash equivalents. | |
Contingencies | |
Loss Contingencies: In the ordinary course of its business, the Company becomes involved in lawsuits, administrative proceedings, government subpoenas, and government investigations, including antitrust, commercial, environmental, product liability, intellectual property, regulatory, employment discrimination, and other matters. Significant damages or penalties may be sought from the Company in some matters, and some matters may require years for the Company to resolve. The Company records a liability when it is probable that a loss has been incurred and the amount is reasonably estimable. The Company also performs an assessment of the materiality of loss contingencies where a loss is either not probable or it is reasonably possible that a loss could be incurred in excess of amounts accrued. If a loss or an additional loss has at least a reasonable possibility of occurring and the impact on the financial statements would be material, the Company provides disclosure of the loss contingency in the footnotes to its financial statements. The Company reviews all contingencies at least quarterly to determine whether the likelihood of loss has changed and to assess whether a reasonable estimate of the loss or the range of the loss can be made (see Note 12). | |
Gain Contingencies: The Company records gain contingencies when they are realized. Gains from antitrust litigation settlements are realized upon the receipt of cash and recorded as a reduction to cost of goods sold because they represent a recovery of amounts historically paid to manufacturers to originally acquire the pharmaceuticals that were the subject of the antitrust litigation settlements (see Note 13). | |
Derivative Financial Instruments | |
The Company records all derivative financial instruments on the balance sheet at fair value and complies with established criteria for designation and effectiveness of hedging relationships. The Company's policy prohibits it from entering into derivative financial instruments for speculative or trading purposes. | |
As of September 30, 2013, the Company had one foreign currency denominated contract outstanding that hedges the foreign currency exchange risk of the C$50.0 million note that the Company received in conjunction with the sale of AmerisourceBergen Canada Corporation (see Note 3). | |
As of September 30, 2012, there were no outstanding derivative financial instruments. | |
Equity Investments | |
The Company uses the equity method of accounting for its investments in entities in which it has significant influence; generally, this represents an ownership interest of between 20% and 50%. The Company's investments in marketable equity securities in which the Company does not have significant influence are classified as “available for sale” and are carried at fair value within the Other Assets line item on the consolidated balance sheet, with unrealized gains and losses excluded from earnings and reported in the accumulated other comprehensive loss component of stockholders' equity. Unrealized losses that are determined to be other-than-temporary impairment losses are recorded as a component of earnings in the period in which that determination is made. | |
Foreign Currency | |
The functional currency of the Company's foreign operations is generally the applicable local currency. Assets and liabilities are translated into U.S. dollars using the current exchange rates in effect at the balance sheet date, while revenues and expenses are translated at the weighted average exchange rates for the period. The resulting translation adjustments are recorded as a component of accumulated other comprehensive loss within stockholders' equity. | |
Goodwill and Other Intangible Assets | |
Goodwill and other intangible assets with indefinite lives, primarily trademarks and trade names, are not amortized; rather, they are tested for impairment at least annually. For the purpose of these impairment tests, the Company can elect to perform a qualitative analysis to determine if it is more likely than not that the fair values of its reporting units and indefinite lived intangible assets are less than the respective carrying values of those reporting units and indefinite lived intangible assets. The Company elected to bypass performing the qualitative screen and went directly to performing the first step quantitative analysis of the goodwill and indefinite lived intangible asset impairment tests in the current year. The Company may elect to perform the qualitative analysis in future periods. | |
The first step in the quantitative process for the goodwill impairment test is to compare the carrying amount of the reporting unit's net assets to the fair value of the reporting unit. If the fair value exceeds the carrying value, no further evaluation is required and no impairment loss is recognized. If the carrying amount exceeds the fair value, then the second step must be completed, which involves allocating the fair value of the reporting unit to each asset and liability, with the excess being implied goodwill. An impairment loss occurs if the amount of the recorded goodwill exceeds the implied goodwill. The Company would be required to record any such impairment losses. | |
The Company identifies its reporting units at the operating segment level. Generally, goodwill arises from acquisitions of specific operating companies and is assigned to the reporting unit in which a particular operating company resides. | |
The Company utilizes a combination of income and market-based approaches to valuation for its reporting units. The income approach to valuation relies on a discounted cash flow analysis to determine the fair value of each reporting unit, which considers forecasted cash flows discounted at an appropriate discount rate. The Company believes that market participants would use a discounted cash flow analysis to determine the fair value of its reporting units in a sale transaction. The annual goodwill impairment test requires the Company to make a number of assumptions and estimates concerning future levels of revenue growth, operating margins, depreciation, amortization and working capital requirements, which are based upon the Company's long-range plan. The discount rate is an estimate of the overall after-tax rate of return required by a market participant whose weighted average cost of capital includes both equity and debt, including a risk premium. While the Company uses the best available information to prepare its cash flow and discount rate assumptions, actual future cash flows or market conditions could differ significantly resulting in future impairment charges related to recorded goodwill balances. While there are always changes in assumptions to reflect changing business and market conditions, the Company's overall methodology and the population of assumptions used have remained unchanged. | |
The impairment test for indefinite-lived intangibles other than goodwill (primarily trademarks and trade names) consists of a comparison of the fair value of the indefinite-lived intangible asset to the carrying value of the asset as of the impairment testing date. The Company estimates the fair value of its indefinite-lived intangibles using the relief from royalty method. The Company believes the relief from royalty method is a widely used valuation technique for such assets. The fair value derived from the relief from royalty method is measured as the discounted cash flow savings realized from owning such trademarks and trade names and not having to pay a royalty for their use. | |
The Company completed its required annual impairment tests relating to goodwill and other intangible assets in the fiscal years ended September 30, 2013, 2012, and 2011, and, as a result, recorded $6.5 million of impairment charges in fiscal 2011. | |
Income Taxes | |
The Company accounts for income taxes using a method that requires recognition of deferred tax assets and liabilities for expected future tax consequences of temporary differences that currently exist between tax bases and financial reporting bases of the Company's assets and liabilities (commonly known as the asset and liability method). In assessing the ability to realize deferred tax assets, the Company considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. | |
The Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained upon examination by the taxing authorities, including resolutions of any related appeals or litigation processes, based on the technical merits of the position. Tax benefits associated with uncertain tax positions that have met the recognition criteria are measured and recorded based on the highest probable outcome that is more than 50% likely to be realized after full disclosure and resolution of a tax examination. | |
Manufacturer Incentives | |
The Company accounts for fees and other incentives received from its suppliers, relating to the purchase or distribution of inventory, as a reduction to cost of goods sold. The Company considers these fees and other incentives to represent product discounts, and as a result, they are capitalized as product costs and relieved through cost of goods sold upon the sale of the related inventory. | |
Merchandise Inventories | |
Inventories are stated at the lower of cost or market. Cost for approximately 83% and 82% of the Company's inventories at September 30, 2013 and 2012, respectively, has been determined using the last-in, first-out (LIFO) method. If the Company had used the first-in, first-out (FIFO) method of inventory valuation, which approximates current replacement cost, inventories would have been approximately $533.7 million and $256.7 million higher than the amounts reported at September 30, 2013 and 2012, respectively. The Company recorded a LIFO charge of $277.0 million, $0.7 million, and $34.7 million in fiscal 2013, 2012, and 2011, respectively. The annual LIFO provision is affected by changes in inventory quantities, product mix, and manufacturing pricing practices, which may be impacted by market and other external influences, many of which are difficult to predict. The Company's LIFO charge in fiscal 2013 was significant due to the additional branded inventory it was required to purchase for the new Walgreens distribution contract and the impact the branded inventory had on the Company's annual inflation index, as well as higher brand drug price inflation and generic drug price deflation. | |
Property and Equipment | |
Property and equipment are stated at cost and depreciated using the straight-line method over the estimated useful lives of the assets, which range from 3 to 40 years for buildings and improvements and from 3 to 10 years for machinery, equipment and other. The costs of repairs and maintenance are charged to expense as incurred. | |
The Company capitalizes project costs relating to computer software developed or obtained for internal use when the activities related to the project reach the application development stage. Costs that are associated with preliminary stage activities, training, maintenance, and all other post-implementation stage activities are expensed as they are incurred. Software development costs are depreciated using the straight-line method over the estimated useful lives, which range from 3 to 10 years. | |
Revenue Recognition | |
The Company recognizes revenue when persuasive evidence of an arrangement exists, product has been delivered or services have been rendered, the price is fixed or determinable and collectability is reasonably assured. Revenue as reflected in the accompanying consolidated statements of operations is net of estimated sales returns and allowances. | |
The Company's customer sales return policy generally allows customers to return products only if the products can be resold at full value or returned to suppliers for full credit. The Company records an accrual for estimated customer sales returns at the time of sale to the customer. At September 30, 2013 and 2012, the Company's accrual for estimated customer sales returns was $275.8 million and $252.5 million, respectively. | |
The Company reports the gross dollar amount of bulk deliveries to customer warehouses in revenue and the related costs in cost of goods sold. Bulk delivery transactions are arranged by the Company at the express direction of the customer, and involve either drop shipments from the supplier directly to customers' warehouse sites or cross-dock shipments from the supplier to the Company for immediate shipment to the customers' warehouse sites. The Company is a principal to these transactions because it is the primary obligor and has the ultimate and contractual responsibility for fulfillment and acceptability of the products purchased, and bears full risk of delivery and loss for products, whether the products are drop-shipped or shipped via cross-dock. The Company also bears full credit risk associated with the creditworthiness of any bulk delivery customer. As a result, the Company records bulk deliveries to customer warehouses as gross revenues. Gross profit earned by the Company on bulk deliveries was not material in any year presented. | |
Share-Based Compensation | |
The Company accounts for the compensation cost of all share-based payments at fair value and reports the related expense within distribution, selling and administrative expenses to correspond with the same line item as the cash compensation paid to employees. The benefits of tax deductions in excess of recognized compensation expense are reported as a financing cash flow ($41.2 million, $25.7 million, and $39.7 million for the fiscal years ended September 30, 2013, 2012, and 2011, respectively). | |
Shipping and Handling Costs | |
Shipping and handling costs include all costs to warehouse, pick, pack and deliver inventory to customers. These costs, which were $267.3 million, $259.1 million and $270.2 million for the fiscal years ended September 30, 2013, 2012, and 2011, respectively, are included in distribution, selling and administrative expenses. | |
Supplier Reserves | |
The Company establishes reserves against amounts due from its suppliers relating to various price and rebate incentives, including deductions or billings taken against payments otherwise due them from the Company. These reserve estimates are established based on the judgment of Company management after carefully considering the status of current outstanding claims, historical experience with the suppliers, the specific incentive programs and any other pertinent information available to the Company. The Company evaluates the amounts due from its suppliers on a continual basis and adjusts the reserve estimates when appropriate based on changes in factual circumstances. The ultimate outcome of any outstanding claim may be different than the Company's estimate. | |
Warrants | |
The Company accounts for the Warrants issued to subsidiaries of Walgreens and Alliance Boots GmbH (“Alliance Boots”) in accordance with the guidance for equity-based payments to non-employees. The various agreements and arrangements with Walgreens and Alliance Boots established various performance commitments that they must satisfy during the vesting periods of the Warrants, and if not fulfilled, the Company has the right to cancel the Warrants. Using a binomial lattice model approach, the fair value of the Warrants was initially measured at the date of issuance, and is being expensed over the three and four year vesting periods as an operating expense. The fair value of the Warrants are re-measured at the end of each quarterly reporting period, and an adjustment is recorded in the statement of operations to record the impact as if the newly measured fair value of the awards had been used in recognizing expense starting when the awards were originally issued and through the remeasurement date. In total, the Warrants were valued at $572.0 million as of September 30, 2013. The valuation of the Warrants considers the Company's Common Stock price and various assumptions, such as the volatility of the Company's Common Stock, the expected remaining life of the Warrants, the expected dividend yield, and the risk-free interest rate. As a result, future Warrant expense could fluctuate significantly (see Note 7). | |
Acquisitions
Acquisitions | 12 Months Ended |
Sep. 30, 2013 | |
Acquisitions [Abstract] | ' |
Acquisitions | ' |
Note 2. Acquisitions | |
TheraCom, LLC | |
In November 2011, the Company acquired TheraCom, LLC (“TheraCom”), a former subsidiary of CVS Caremark Corporation, for a purchase price of $257.2 million, net of a working capital adjustment. TheraCom is a leading provider of commercialization support services for the biotechnology and pharmaceutical industry, specifically providing reimbursement and patient support services. TheraCom's capabilities complement those of the Lash Group, a business within ABCS, and significantly increase the size and scope of its consulting services. The majority of TheraCom's revenues are provided by the specialized distribution component of the integrated reimbursement support services for certain unique prescription products. For segment presentation, TheraCom is included in Other. | |
The purchase price was allocated to the underlying assets acquired and liabilities assumed based upon their fair values at the date of the acquisition. The purchase price exceeded the fair value of the net tangible and intangible assets acquired by $180.2 million, which was allocated to goodwill. The fair values of significant tangible assets acquired and liabilities assumed were as follows: accounts receivable of $119.3 million, merchandise inventories of $41.7 million, and accounts payable of $153.2 million. The fair value of intangible assets acquired of $68.8 million consists of customer relationships of $57.1 million, software technology of $7.9 million, and trade names of $3.8 million. The Company is amortizing the fair values of the acquired customer relationships over their remaining useful lives of 15 years, and amortizing the fair values of software technology and trade names over their remaining useful lives of 5 years. All of the goodwill resulting from the acquisition is expected to be deductible for income tax purposes. | |
World Courier | |
In April 2012, the Company acquired World Courier for a purchase price of $518.0 million, net of a working capital adjustment. World Courier is a leading global specialty transportation and logistics provider for the biopharmaceutical industry. World Courier further strengthens the Company's service offerings to global pharmaceutical manufacturers and provides an established platform for the introduction of the Company's specialty services outside North America. It operates in over 50 countries and has approximately 2,400 employees. For segment presentation, World Courier is included in Other. | |
The purchase price has been allocated to the underlying assets acquired and liabilities assumed based upon their estimated fair values at the date of the acquisition. The purchase price exceeded the fair value of the net tangible and intangible assets acquired by $266.7 million, which was allocated to goodwill. The fair value of intangible assets acquired of $250.0 million consists of a trade name of $110.5 million, customer relationships of $130.5 million, and software technology of $9.0 million. The trade name has been determined to have an indefinite life. The Company is amortizing the estimated fair values of the acquired customer relationships and software technology over the remaining estimated useful lives of 16 years and 5 years, respectively. Goodwill resulting from the acquisition is not expected to be deductible for income tax purposes. | |
Discontinued_Operations
Discontinued Operations | 12 Months Ended | ||||||||||
Sep. 30, 2013 | |||||||||||
Discontinued Operation Income Loss From Discontinued Operation Disclosures Abstract | ' | ||||||||||
Disposal Groups Including Discontinued Operations Disclosure Text Block | ' | ||||||||||
Note 3. Discontinued Operations | |||||||||||
In May 2013, the Company completed the divestiture of its packaging and clinical trials services business, AndersonBrecon (“AB”), and completed the divestiture of AmerisourceBergen Canada Corporation (“ABCC”). The Company has classified AB and ABCC's assets and liabilities as held for sale in the accompanying fiscal 2012 consolidated balance sheet and classified AB and ABCC's operating results, net of tax, as discontinued operations in the accompanying consolidated statements of operations for all periods presented. Prior to being classified within discontinued operations, AB was included in Other and ABCC was included in Pharmaceutical Distribution for segment reporting. AB and ABCC's revenue and (loss) income before income taxes were as follows: | |||||||||||
Fiscal Year Ended September 30, | |||||||||||
(in thousands) | 2013 | 2012 | 2011 | ||||||||
Revenue | $ | 1,181,231 | $ | 1,639,684 | $ | 1,521,899 | |||||
(Loss) income before income taxes | $ | -50,090 | $ | -37,534 | $ | 12,652 | |||||
The loss before income taxes in the fiscal year ended September 30, 2013 includes an ABCC goodwill impairment charge of $26.9 million and a $143.7 million loss on the sale of ABCC. The loss is net of a $114.1 million gain on the sale of AB. | |||||||||||
The gain on the sale of AB and the loss on the sale of ABCC include the reclassification of $9.3 million of cumulative foreign currency translation losses previously included within accumulated other comprehensive income. The tax loss on the sale of ABCC more than offsets the tax gain on the sale of AB. There is no impact on income tax expense, as a valuation allowance on the excess capital tax loss was recorded. | |||||||||||
The Company sold AB for $306.5 million, net of a final purchase price working capital adjustment, and sold ABCC for $67.9 million, including a C$50.0 million note due from the buyer, with interest accruing at 3% annually, and scheduled monthly payments to be made over a seven-year term that commenced in June 2013. The Company entered into a foreign currency denominated contract to hedge the foreign currency exchange risk associated with the Canadian Note. The ABCC divestiture continues to be subject to a final purchase price working capital adjustment. | |||||||||||
The following table summarizes the assets and liabilities of AB and ABCC when they were classified as held for sale (in thousands): | |||||||||||
September 30, | |||||||||||
2012 | |||||||||||
Assets: | |||||||||||
Accounts receivable | $187,179 | ||||||||||
Merchandise inventories | 249,463 | ||||||||||
Property and equipment, net | 131,907 | ||||||||||
Goodwill and other intangible assets | 85,163 | ||||||||||
Other assets | 9,141 | ||||||||||
Assets held for sale | 662,853 | ||||||||||
Liabilities: | |||||||||||
Accounts payable | 152,110 | ||||||||||
Accrued expenses and other | 16,554 | ||||||||||
Other liabilities | 71,042 | ||||||||||
Liabilities held for sale | 239,706 | ||||||||||
Net assets | $423,147 |
Income_Taxes
Income Taxes | 12 Months Ended | |||||||||
Sep. 30, 2013 | ||||||||||
Income Tax Disclosure [Abstract] | ' | |||||||||
Income Tax Disclosure Text Block | ' | |||||||||
Note 4. Income Taxes | ||||||||||
The following illustrates domestic and foreign income from continuing operations before income taxes (in thousands): | ||||||||||
Fiscal year ended September 30, | ||||||||||
2013 | 2012 | 2011 | ||||||||
Domestic | $793,137 | $1,193,047 | $1,105,481 | |||||||
Foreign | 31,321 | 23,826 | 12,508 | |||||||
Total | $824,458 | $1,216,873 | $1,117,989 | |||||||
The income tax provision is as follows (in thousands): | ||||||||||
Fiscal Year Ended September 30, | ||||||||||
2013 | 2012 | 2011 | ||||||||
Current provision: | ||||||||||
Federal | $259,457 | $356,843 | $194,816 | |||||||
State and local | 37,602 | 32,438 | 26,527 | |||||||
Foreign | 8,391 | 4,953 | 4,354 | |||||||
305,450 | 394,234 | 225,697 | ||||||||
Deferred provision: | ||||||||||
Federal | 29,189 | 47,348 | 174,412 | |||||||
State and local | -3,375 | 11,959 | 20,462 | |||||||
Foreign | -241 | 1,971 | -77 | |||||||
25,573 | 61,278 | 194,797 | ||||||||
Provision for income taxes | $331,023 | $455,512 | $420,494 | |||||||
A reconciliation of the statutory U.S. federal income tax rate to the effective income tax rate is as follows: | ||||||||||
Fiscal Year Ended September 30, | ||||||||||
2013 | 2012 | 2011 | ||||||||
Statutory U.S. federal income tax rate | 35 | % | 35 | % | 35 | % | ||||
State and local income tax rate, net of federal tax benefit | 3 | 2.3 | 1.7 | |||||||
Foreign | -0.3 | -0.1 | - | |||||||
Warrants | 2.3 | - | - | |||||||
Other | 0.2 | 0.2 | 0.9 | |||||||
Effective income tax rate | 40.2 | % | 37.4 | % | 37.6 | % | ||||
In March 2013, the Company issued Warrants in connection with various agreements and arrangements with Walgreens and Alliance Boots. See Note 7 for further details. As of the date of issuance, the Warrants were valued at $242.4 million, which approximates the amount that will be deductible for tax purposes. The fair value of the Warrants as of September 30, 2013 was $572.0 million. The excess of the fair value as of September 30, 2013 over the initial value of $242.4 million is not tax deductible. As a result, the Company's current effective income tax rate is higher than its historic rate. This increase in the income tax rate is reflected in Warrants in the above effective income tax rate reconciliation. | ||||||||||
Deferred income taxes reflect the future tax consequences of differences between the tax bases of assets and liabilities and their financial reporting amounts. Significant components of the Company's deferred tax liabilities (assets) are as follows (in thousands): | ||||||||||
September 30, | ||||||||||
2013 | 2012 | |||||||||
Merchandise inventories | $1,016,522 | $985,571 | ||||||||
Property and equipment | 128,289 | 132,732 | ||||||||
Goodwill and other intangible assets | 260,357 | 249,913 | ||||||||
Other | 1,322 | 705 | ||||||||
Gross deferred tax liabilities | 1,406,490 | 1,368,921 | ||||||||
Net operating loss and tax credit carryforwards | -61,726 | -59,994 | ||||||||
Capital loss carryforwards | -297,806 | -230,395 | ||||||||
Allowance for doubtful accounts | -30,073 | -30,856 | ||||||||
Accrued expenses | -16,731 | -9,651 | ||||||||
Employee and retiree benefits | -4,884 | -17,392 | ||||||||
Stock options | -29,356 | -28,197 | ||||||||
Other | -66,537 | -57,596 | ||||||||
Gross deferred tax assets | -507,113 | -434,081 | ||||||||
Valuation allowance for deferred tax assets | 327,546 | 254,182 | ||||||||
Deferred tax assets, net of valuation allowance | -179,567 | -179,899 | ||||||||
Net deferred tax liabilities | $1,226,923 | $1,189,022 | ||||||||
The following tax carryforward information is presented as of September 30, 2013. The Company had $14.5 million of potential tax benefits from federal net operating loss carryforwards expiring in 8 to 18 years, $59.8 million of potential tax benefits from state net operating loss carryforwards expiring in 1 to 20 years and $6.4 million of potential tax benefits from foreign net operating loss carryforwards, which have varying expiration dates. Included in the state net operating loss carryforwards is $9.3 million of potential tax benefits that if realized would be an increase to additional paid-in-capital. The Company had $297.8 million of potential tax benefits from capital loss carryforwards expiring in 1 to 5 years. The Company had $5.9 million of foreign tax credit carryforwards expiring in 5 to 10 years. The Company had $1.4 million of state tax credit carryforwards. | ||||||||||
In connection with the acquisition of World Courier, the Company acquired net operating loss carryforwards totaling approximately $78 million. The Company agreed with the sellers of World Courier to reimburse them for the Company's utilization of all U.S. net operating loss carryforwards and certain foreign net operating loss carryforwards that existed as of the acquisition date and will be realized by the Company through 2017. As such, the Company recorded a deferred tax asset, net of valuation allowance, for the net operating losses expected to be realized and an offsetting liability for the amount to be repaid to the sellers as part of the purchase price allocation for World Courier. | ||||||||||
In fiscal 2013, the Company increased the valuation allowance on deferred tax assets by $73.4 million primarily due to the addition of capital loss carryforwards resulting from the sale of ABCC. In fiscal 2012, the Company increased the valuation allowance on deferred tax assets by $4.3 million primarily due to the addition of certain foreign net operating loss carryforwards. | ||||||||||
In fiscal 2013, 2012, and 2011, tax benefits of $41.2 million, $25.7 million, and $39.7 million, respectively, related to the exercise of employee stock options and lapse of restricted shares, were recorded as additional paid-in capital. | ||||||||||
Income tax payments, net of refunds, were $313.7 million, $302.1 million and $214.6 million in the fiscal years ended September 30, 2013, 2012 and 2011, respectively. | ||||||||||
The Company and its subsidiaries file income tax returns in the U.S. federal jurisdiction, and various states and foreign jurisdictions. With few exceptions, the Company is no longer subject to U.S. federal, state and local, or foreign income tax examinations by tax authorities for years before 2009. | ||||||||||
As of September 30, 2013 and 2012, the Company had unrecognized tax benefits, defined as the aggregate tax effect of differences between tax return positions and the benefits recognized in the Company's financial statements, of $55.4 million and $43.3 million, respectively, ($39.1 million and $30.1 million, net of federal benefit, respectively). If recognized, these tax benefits would reduce income tax expense and the effective tax rate. As of September 30, 2013 and 2012, included in these amounts are $9.1 million and $6.3 million of interest and penalties, respectively, which the Company records in income tax expense. | ||||||||||
A reconciliation of the beginning and ending amount of unrecognized tax benefits, excluding interest and penalties, in fiscal 2013, 2012, and 2011 is as follows (in thousands): | ||||||||||
Balance at September 30, 2010 | $36,830 | |||||||||
Additions of tax positions of the current year | 5,866 | |||||||||
Additions of tax positions of the prior years | 3,592 | |||||||||
Reductions of tax positions of the prior years | -386 | |||||||||
Settlements with taxing authorities | -7,136 | |||||||||
Expiration of statutes of limitations | -2,963 | |||||||||
Balance at September 30, 2011 | 35,803 | |||||||||
Additions of tax positions of the current year | 6,094 | |||||||||
Additions of tax positions of the prior years | 1,045 | |||||||||
Additions of tax positions due to acquisitions | 2,748 | |||||||||
Reductions of tax positions of the prior years | -5,177 | |||||||||
Settlements with taxing authorities | -2,286 | |||||||||
Expiration of statutes of limitations | -1,237 | |||||||||
Balance at September 30, 2012 | 36,990 | |||||||||
Additions of tax positions of the current year | 5,272 | |||||||||
Additions of tax positions of the prior years | 2,825 | |||||||||
Additions of tax positions due to acquisitions | 2,500 | |||||||||
Settlements with taxing authorities | -519 | |||||||||
Expiration of statutes of limitations | -801 | |||||||||
Balance at September 30, 2013 | $46,267 | |||||||||
During the next 12 months, it is reasonably possible that state tax audit resolutions and the expiration of statutes of limitations could result in a reduction of unrecognized tax benefits by approximately $8.2 million. | ||||||||||
Cumulative undistributed earnings of international subsidiaries were $125.6 million at September 30, 2013. No deferred Federal income taxes were provided for the undistributed earnings as they are permanently reinvested in the Company's international operations. It is not practicable to estimate the amount of U.S. tax that would result upon the eventual repatriation of such earnings. |
Goodwill_and_Other_Intangible_
Goodwill and Other Intangible Assets | 12 Months Ended | |||||||||||||||||
Sep. 30, 2013 | ||||||||||||||||||
Goodwill and Intangible Assets Disclosure [Abstract] | ' | |||||||||||||||||
Goodwill And Intangible Assets Disclosure Text Block | ' | |||||||||||||||||
Note 5. Goodwill and Other Intangible Assets | ||||||||||||||||||
Following is a summary of the changes in the carrying value of goodwill for the fiscal years ended September 30, 2013 and 2012 (in thousands): | ||||||||||||||||||
Pharmaceutical | ||||||||||||||||||
Distribution | Other | Total | ||||||||||||||||
Goodwill at September 30, 2011 | $2,421,707 | $75,455 | $2,497,162 | |||||||||||||||
Goodwill recognized in connection with acquisitions (see Note 2) | -134 | 444,554 | 444,420 | |||||||||||||||
Foreign currency translation | 1,402 | - | 1,402 | |||||||||||||||
Goodwill at September 30, 2012 | 2,422,975 | 520,009 | 2,942,984 | |||||||||||||||
Goodwill recognized in connection with acquisitions (see Note 2) | - | 3,000 | 3,000 | |||||||||||||||
Foreign currency translation | -1,014 | - | -1,014 | |||||||||||||||
Goodwill at September 30, 2013 | $2,421,961 | $523,009 | $2,944,970 | |||||||||||||||
Following is a summary of other intangible assets (in thousands): | ||||||||||||||||||
September 30, 2013 | September 30, 2012 | |||||||||||||||||
Gross | Net | Gross | Net | |||||||||||||||
Carrying | Accumulated | Carrying | Carrying | Accumulated | Carrying | |||||||||||||
Amount | Amortization | Amount | Amount | Amortization | Amount | |||||||||||||
Indefinite-lived intangibles — trade names | $ | 343,892 | $ | - | $ | 343,892 | $ | 344,004 | $ | - | $ | 344,004 | ||||||
Finite-lived intangibles: | ||||||||||||||||||
Customer relationships | 265,810 | -80,767 | 185,043 | 265,981 | -61,865 | 204,116 | ||||||||||||
Other | 69,350 | -43,542 | 25,808 | 67,896 | -35,568 | 32,328 | ||||||||||||
Total other intangible assets | $ | 679,052 | $ | -124,309 | $ | 554,743 | $ | 677,881 | $ | -97,433 | $ | 580,448 | ||||||
During the fiscal year ended September 30, 2011, the Company recorded a goodwill impairment charge of $3.0 million and a customer relationship impairment charge of $3.5 million relating to one of its smaller business units. For segment presentation, this charge was included in Other. | ||||||||||||||||||
Amortization expense for other intangible assets was $27.1 million, $21.5 million, and $12.6 million in the fiscal years ended September 30, 2013, 2012, and 2011, respectively. Amortization expense for other intangible assets is estimated to be $25.6 million in fiscal 2014, $21.7 million in fiscal 2015, $20.8 million in fiscal 2016, $17.0 million in fiscal 2017, $14.8 million in 2018 and $111.0 million thereafter. |
Debt
Debt | 12 Months Ended | ||||||
Sep. 30, 2013 | |||||||
Debt Disclosure [Abstract] | ' | ||||||
Debt Disclosure Text Block | ' | ||||||
Note 6. Debt | |||||||
Debt consisted of the following: | |||||||
September 30, | |||||||
2013 | 2012 | ||||||
(Dollars in thousands) | |||||||
Receivables securitization facility due 2016 | $ | - | $ | - | |||
Multi-currency revolving credit facility due 2018 | - | - | |||||
Revolving credit note | - | - | |||||
$500,000, 5 7/8% senior notes due 2015 | 499,377 | 499,091 | |||||
$400,000, 4 7/8% senior notes due 2019 | 397,803 | 397,485 | |||||
$500,000, 3 1/2% senior notes due 2021 | 499,426 | 499,355 | |||||
Total debt | $ | 1,396,606 | $ | 1,395,931 | |||
Long-Term Debt | |||||||
The Company has a $1.4 billion multi-currency senior unsecured credit facility, which is scheduled to expire in July 2018 (the “Multi-Currency Revolving Credit Facility”), with a syndicate of lenders. Interest on borrowings under the Multi-Currency Revolving Credit Facility accrues at specified rates based on the Company's debt rating and ranges from 68 basis points to 130 basis points over LIBOR/EURIBOR/Bankers Acceptance Stamping Fee, as applicable (90 basis points over LIBOR/EURIBOR/Bankers Acceptance Stamping Fee at September 30, 2013). Additionally, interest on borrowings denominated in Canadian dollars may accrue at the greater of the Canadian prime rate or the CDOR rate. The Company pays facility fees to maintain the availability under the Multi-Currency Revolving Credit Facility at specified rates based on its debt rating, ranging from 7 basis points to 20 basis points, annually, of the total commitment (10 basis points at September 30, 2013). The Company may choose to repay or reduce its commitments under the Multi-Currency Revolving Credit Facility at any time. The Multi-Currency Revolving Credit Facility contains covenants, including compliance with a financial leverage ratio test, as well as others that impose limitations on, among other things, indebtedness of excluded subsidiaries and asset sales, with which the Company was compliant as of September 30, 2013. | |||||||
The Company has $500 million of 5 7/8% senior notes due September 15, 2015 (the “2015 Notes”), $400 million of 4 7/8% senior notes due November 15, 2019 (the “2019 Notes”), and $500 million of 3½% senior notes due November 15, 2021 (the “2021 Notes”) (together, the “Notes”). The 2015 Notes, 2019 Notes, and 2021 Notes were sold at 99.5%, 99.2%, and 99.858% of the principal amount, respectively, and have effective interest yields of 5.94%, 4.98%, and 3.52% respectively. Interest on the Notes is payable semiannually in arrears. Costs incurred in connection with the issuance of the Notes were deferred and are being amortized over the terms of the Notes. | |||||||
The indentures governing the Multi-Currency Revolving Credit Facility and the Notes contain restrictions and covenants which include limitations on additional indebtedness; distributions to stockholders; the repurchase of stock and the making of other restricted payments; issuance of preferred stock; creation of certain liens; transactions with subsidiaries and other affiliates; and certain corporate acts such as mergers, consolidations, and the sale of substantially all assets. An additional covenant requires compliance with a financial leverage ratio test. | |||||||
Receivables Securitization Facility | |||||||
The Company has a $950 million receivables securitization facility (“Receivables Securitization Facility”), which is scheduled to expire in June 2016. The Company has available to it an accordion feature whereby the commitment on the Receivables Securitization Facility may be increased by up to $250 million, subject to lender approval, for seasonal needs during the December and March quarters. Interest rates are based on prevailing market rates for short-term commercial paper or LIBOR plus a program fee of 75 basis points. The Company pays an unused fee of 40 basis points, annually, to maintain the availability under the Receivables Securitization Facility. At September 30, 2013, there were no borrowings outstanding under the Receivables Securitization Facility. In connection with the Receivables Securitization Facility, AmerisourceBergen Drug Corporation sells on a revolving basis certain accounts receivable to Amerisource Receivables Financial Corporation, a wholly owned special purpose entity, which in turn sells a percentage ownership interest in the receivables to commercial paper conduits sponsored by financial institutions. AmerisourceBergen Drug Corporation is the servicer of the accounts receivable under the Receivables Securitization Facility. After the maximum limit of receivables sold has been reached and as sold receivables are collected, additional receivables may be sold up to the maximum amount available under the facility. The facility is a financing vehicle utilized by the Company because it generally offers an attractive interest rate relative to other financing sources. The Company securitizes its trade accounts, which are generally non-interest bearing, in transactions that are accounted for as borrowings. The Receivables Securitization Facility contains similar covenants to the Multi-Currency Revolving Credit Facility. | |||||||
Commercial Paper Program | |||||||
The Company has a commercial paper program whereby it may from time to time issue short-term promissory notes in an aggregate amount of up to $700 million at any one time. Amounts available under the program may be borrowed, repaid, and re-borrowed from time to time. The maturities on the notes will vary, but may not exceed 365 days from the date of issuance. The notes will bear interest rates, if interest bearing, or will be sold at a discount from their face amounts. The commercial paper program does not increase the Company's borrowing capacity as it is fully backed by the Company's Multi-Currency Revolving Credit Facility. There were no borrowings under the commercial paper program at September 30, 2013. | |||||||
Revolving Credit Note | |||||||
The Company has an uncommitted, unsecured line of credit available to it pursuant to a revolving credit note (“Revolving Credit Note”) for an aggregate principal amount not to exceed $45 million. The Revolving Credit Note provides the Company with the ability to request short-term, unsecured revolving credit loans from time to time in a principal amount not to exceed $45 million at any time outstanding. At September 30, 2013, there were no borrowings outstanding under the Revolving Credit Note. | |||||||
Other Information | |||||||
Scheduled future principal payments of long-term debt are $500.0 million in fiscal 2015 and $900.0 million in fiscal 2020 and thereafter. | |||||||
Interest paid on the above indebtedness during the fiscal years ended September 30, 2013, 2012, and 2011 was $68.5 million, $84.5 million, and $74.2 million, respectively. | |||||||
Total amortization of financing fees and the accretion of original issue discounts, which are recorded as components of interest expense, were $4.2 million, $5.2 million, and $4.7 million, for the fiscal years ended September 30, 2013, 2012, and 2011, respectively. |
Stockholders_Equity_and_Earnin
Stockholders Equity and Earnings per Share | 12 Months Ended | ||||||
Sep. 30, 2013 | |||||||
Stockholders Equity and Earnings Per Share [Abstract] | ' | ||||||
Stockholders Equity and Earnings per Share [Text Block] | ' | ||||||
Note 7. Stockholders' Equity and Earnings per Share | |||||||
The authorized capital stock of the Company consists of 600,000,000 shares of common stock, par value $0.01 per share (the “Common Stock”), and 10,000,000 shares of preferred stock, par value $0.01 per share (the “Preferred Stock”). | |||||||
The board of directors is authorized to provide for the issuance of shares of Preferred Stock in one or more series with various designations, preferences and relative, participating, optional or other special rights and qualifications, limitations or restrictions. Except as required by law, or as otherwise provided by the board of directors of the Company, the holders of Preferred Stock will have no voting rights and will not be entitled to notice of meetings of stockholders. Holders of Preferred Stock will be entitled to receive, when declared by the board of directors, out of legally available funds, dividends at the rates fixed by the board of directors for the respective series of Preferred Stock, and no more, before any dividends will be declared and paid, or set apart for payment, on Common Stock with respect to the same dividend period. No shares of Preferred Stock have been issued as of September 30, 2013. | |||||||
The holders of the Company's Common Stock are entitled to one vote per share and have the exclusive right to vote for the board of directors and for all other purposes as provided by law. Subject to the rights of holders of the Company's Preferred Stock, holders of Common Stock are entitled to receive ratably on a per share basis such dividends and other distributions in cash, stock or property of the Company as may be declared by the board of directors from time to time out of the legally available assets or funds of the Company. | |||||||
The following table illustrates the components of accumulated other comprehensive loss, net of income taxes, as of September 30, 2013 and 2012 (in thousands): | |||||||
September 30, | |||||||
2013 | 2012 | ||||||
Pension and postretirement adjustments (See Note 8) | ($34,612) | ($45,828) | |||||
Foreign currency translation | -844 | 13,337 | |||||
Other | -27 | -166 | |||||
Total accumulated other comprehensive loss | ($35,483) | ($32,657) | |||||
In November 2009, the Company's board of directors authorized a program allowing the Company to purchase up to $500 million of its outstanding shares of Common Stock, subject to market conditions. During the fiscal year ended September 30, 2010, the Company purchased 14.4 million shares of its Common Stock under this program for a total of $401.9 million. During the fiscal year ended September 30, 2011, the Company purchased 3.2 million shares of its Common Stock for a total of $98.1 million to complete its authorization under this program. | |||||||
In September 2010, the Company's board of directors authorized a program allowing the Company to purchase up to $500 million of its outstanding shares of Common Stock, subject to market conditions. During the fiscal year ended September 30, 2011, the Company purchased 13.3 million shares of its Common Stock for a total of $500.0 million to complete its authorization under this program. | |||||||
In August 2011, the Company's board of directors authorized a program allowing the Company to purchase up to $750 million of its outstanding shares of Common Stock, subject to market conditions. During the fiscal year ended September 30, 2011, the Company purchased 6.6 million shares of its Common Stock for a total of $250.0 million. During the fiscal year ended September 30, 2012, the Company purchased 13.4 million shares of its Common Stock for $500.0 million to complete its authorization under this program. | |||||||
In May 2012, the Company's board of directors authorized a program allowing the Company to purchase up to $750 million of its outstanding shares of Common Stock, subject to market conditions. In August 2012, the Company entered into an Accelerated Share Repurchase (“ASR”) transaction with a financial institution and paid $650 million for the initial delivery of 16.8 million shares. The initial payment of $650 million funded stock purchases of $647.2 million, $2.0 million of previously declared dividends that were scheduled to be paid in September 2012, and $0.8 million in other fees. The number of shares ultimately purchased was based on the volume-weighted average price of the Company's Common Stock during the term of the ASR. The ASR transaction was settled in October 2012, at which time the Company received 0.1 million incremental shares. In addition to the ASR transaction, during the fiscal year ended September 30, 2012, the Company purchased 0.2 million shares of its Common Stock for a total of $5.9 million. During the fiscal year ended September 30, 2013, the Company purchased 0.6 million shares of its Common Stock for a total of $25.7 million under this program. This program was closed during the fiscal year ended September 2013 as a result of the November 2012 ASR transaction (see below). | |||||||
In November 2012, the Company's board of directors authorized a program allowing the Company to purchase up to $750 million of its outstanding shares of Common Stock, subject to market conditions. Subsequently, in November 2012, the Company entered into an ASR transaction with a financial institution and paid $250 million for a delivery of 6.2 million shares. The initial payment of $250 million funded stock purchases of $248.5 million, $1.3 million of previously declared dividends that were scheduled to be paid in December 2012, and $0.2 million in other fees. The amount ultimately paid was based on the volume-weighted average price of the Company's Common Stock during the term of the ASR. The ASR transaction was settled in December 2012, at which time the Company paid the financial institution a cash settlement of $10.3 million. The Company applied 1.7 million shares for $71.2 million to the May 2012 share repurchase program, which completed its authorization under that program. The Company applied the remaining 4.5 million shares from the November 2012 ASR for $187.6 million to the November 2012 share repurchase program. In addition to the ASR transaction, during the fiscal year ended September 30, 2013, the Company purchased 3.6 million shares of its Common Stock for a total of $199.4 million. The Company had $363.0 million of availability remaining under this share repurchase program as of September 30, 2013. | |||||||
In August 2013, the Company's board of directors authorized the Company to purchase up to $750 million of its outstanding shares of Common Stock, subject to market conditions. This new program increased the total availability remaining under all approved share repurchase programs to $1,113.0 million as of September 30, 2013. | |||||||
In March 2013, the Company, Walgreens, and Alliance Boots entered into various agreements and arrangements pursuant to which Walgreens and Alliance Boots together were granted the right to purchase a minority equity position in the Company, beginning with the right, but not the obligation, to purchase up to 19,859,795 shares of the Company's Common Stock (approximately 7% of the Company's Common Stock, on a fully diluted basis as of the date of issuance, assuming the exercise in full of the Warrants, as defined below) in open market transactions. In connection with these arrangements, Walgreens Pharmacy Strategies, LLC, a wholly owned subsidiary of Walgreens, was issued (a) a warrant to purchase up to 11,348,456 shares of the Company's Common Stock at an exercise price of $51.50 per share exercisable during a six-month period beginning in March 2016, and (b) a warrant to purchase up to 11,348,456 shares of the Company's Common Stock at an exercise price of $52.50 per share exercisable during a six-month period beginning in March 2017 and Alliance Boots Luxembourg S.à.r.l., a wholly owned subsidiary of Alliance Boots, was issued (a) a warrant to purchase up to 11,348,456 shares of the Company's common Stock at an exercise price of $51.50 per share exercisable during a six-month period beginning in March 2016, and (b) a warrant to purchase up to 11,348,456 shares of the Company's Common Stock at an exercise price of $52.50 per share exercisable during a six-month period beginning March 2017 (collectively, the “Warrants). | |||||||
The Company valued these Warrants as of March 18, 2013 (date of issuance) and revised the valuation each subsequent quarter. As of September 30, 2013, the Warrants with an exercise price of $51.50 were valued at $12.30 per share and the Warrants with an exercise price of $52.50 were valued at $12.90 per share. In total, the Warrants were valued at $572.0 million as of September 30, 2013. | |||||||
The Company intends to mitigate the potentially dilutive effect that exercise of the Warrants could have by hedging a portion of its future obligation to deliver Common Stock with a financial institution and repurchasing additional shares of its Common Stock for the Company's own account over time. In June 2013, the Company commenced its hedging strategy by entering into a contract with a financial institution pursuant to which it will execute a series of issuer capped call transactions (“Capped Calls”). The Capped Calls give the Company the right to buy approximately 60% of the shares of its Common Stock subject to the Warrants at specified prices at maturity, should the Warrants be exercised in 2016 and 2017 and assuming the Company's future share price does not exceed the Capped Call limits. | |||||||
Through September 30, 2013, the Company purchased Capped Calls on 15.3 million shares of its Common Stock for a total premium of $163.4 million, which was recorded as a reduction of additional paid-in-capital. The Capped Calls permit the Company to acquire shares of its Common Stock at strike prices of $51.50 and $52.50 and have expiration dates ranging from February 2016 through October 2017. The Capped Calls permit net share settlement, which is limited by caps in the market price of the Company's Common Stock. The Company has accounted for the Capped Calls as equity contracts. | |||||||
In December 2011, the Company retired 238.8 million shares of its treasury stock. | |||||||
Basic earnings per share is computed on the basis of the weighted average number of shares of Common Stock outstanding during the periods presented. Diluted earnings per share is computed on the basis of the weighted average number of shares of Common Stock outstanding during the periods plus the dilutive effect of stock options, restricted stock, restricted stock units, and the Warrants. The following table (in thousands) is a reconciliation of the numerator and denominator of the computation of basic and diluted earnings per share. | |||||||
September 30, | |||||||
2013 | 2012 | 2011 | |||||
Weighted average common shares outstanding — basic | 231,067 | 252,906 | 272,471 | ||||
Effect of dilutive securities — stock options, restricted stock, | |||||||
and restricted stock units | 4,278 | 3,997 | 5,246 | ||||
Weighted average common shares outstanding — diluted | 235,345 | 256,903 | 277,717 | ||||
There were no potentially dilutive stock options that were antidilutive for fiscal 2013. The potentially dilutive employee stock options that were antidilutive for fiscal 2012 and 2011 were 2.1 million and 2.0 million, respectively. | |||||||
For each reporting period, the dilutive impact of the shares potentially issuable upon exercise of the Warrants is required to be calculated using the treasury stock method. Under this approach, the diluted number of shares is determined by dividing the assumed proceeds of the Warrants by the average stock price during the reporting period and then comparing that amount against the number of the Warrants issued. The assumed proceeds are calculated by multiplying the number of shares underlying the Warrants by the exercise price, plus the amount of unrecognized expense during the period. The unrecognized expense represents the difference between the fair value of the Warrants as of the balance sheet date and the cumulative amount of Warrant expense recognized in the Company's Consolidated Statements of Operations. The inclusion of the unrecognized expense in the calculation of assumed proceeds has the effect of reducing the dilutive impact of the Warrants, particularly in the earlier periods of the life of the Warrants. As a result, the Warrants were antidilutive for the fiscal year ended September 30, 2013. |
Pension_and_Other_Benefit_Plan
Pension and Other Benefit Plans | 12 Months Ended | ||||||||||||
Sep. 30, 2013 | |||||||||||||
Compensation and Retirement Disclosure [Abstract] | ' | ||||||||||||
Pension And Other Postretirement Benefits Disclosure Text Block | ' | ||||||||||||
Note 8. Pension and Other Benefit Plans | |||||||||||||
The Company sponsors various retirement benefit plans, including defined benefit pension plans, defined contribution plans, postretirement medical plans and a deferred compensation plan covering eligible employees. Expenses relating to these plans were $22.1 million, $20.3 million, and $19.3 million in fiscal 2013, 2012, and 2011, respectively. | |||||||||||||
The Company recognizes the funded status (the difference between the fair value of plan assets and the projected benefit obligations) of its defined benefit pension plans and postretirement benefit plans in its balance sheet, with a corresponding adjustment to accumulated other comprehensive loss, net of income taxes. Included in accumulated other comprehensive loss at September 30, 2013 are net actuarial losses of $59.3 million ($34.6 million, net of income taxes). The net actuarial loss in accumulated other comprehensive loss that is expected to be amortized into fiscal 2014 net periodic pension expense is $3.6 million ($2.1 million, net of income taxes). | |||||||||||||
Defined Benefit Plans | |||||||||||||
The Company provides a benefit for certain employees under two different noncontributory defined benefit pension plans consisting of a salaried plan and a supplemental executive retirement plan. Both plans are closed to new participants and benefits that can be earned by active participants in the plans are limited. For each employee, the benefits are based on years of service and average compensation. Pension costs, which are computed using the projected unit credit cost method, are funded to at least the minimum level required by government regulations. | |||||||||||||
The Company has an unfunded supplemental executive retirement plan for certain former officers and key employees. This plan is closed to new participants and benefits that can be earned by active participants are limited. This plan is a “target” benefit plan, with the annual lifetime benefit based upon a percentage of salary during the five final years of pay at age 62, offset by several other sources of income including benefits payable under a prior supplemental retirement plan. | |||||||||||||
The following table sets forth (in thousands) a reconciliation of the changes in the Company-sponsored defined benefit pension plans: | |||||||||||||
Fiscal Year Ended | |||||||||||||
September 30, | |||||||||||||
2013 | 2012 | ||||||||||||
Change in Projected Benefit Obligations: | |||||||||||||
Benefit obligation at beginning of year | $ | 166,244 | $ | 154,887 | |||||||||
Interest cost | 6,104 | 6,560 | |||||||||||
Actuarial (gains) losses | -15,560 | 17,942 | |||||||||||
Benefit payments | -7,384 | -13,134 | |||||||||||
Other | - | -11 | |||||||||||
Benefit obligation at end of year | $ | 149,404 | $ | 166,244 | |||||||||
Change in Plan Assets: | |||||||||||||
Fair value of plan assets at beginning of year | $ | 158,391 | $ | 122,242 | |||||||||
Actual return on plan assets | 8,005 | 26,775 | |||||||||||
Employer contributions | 2,173 | 23,444 | |||||||||||
Expenses | -1,219 | -936 | |||||||||||
Benefit payments | -7,384 | -13,134 | |||||||||||
Fair value of plan assets at end of year | $ | 159,966 | $ | 158,391 | |||||||||
Funded Status and Amounts Recognized: | |||||||||||||
Funded status | $ | 10,562 | $ | -7,853 | |||||||||
Net amount recognized | $ | 10,562 | $ | -7,853 | |||||||||
Amounts recognized in the balance sheets consist of: | |||||||||||||
Noncurrent assets | $ | 16,563 | $ | - | |||||||||
Current liabilities | -2,826 | -4,456 | |||||||||||
Noncurrent liabilities | -3,175 | -3,397 | |||||||||||
Net amount recognized | $ | 10,562 | $ | -7,853 | |||||||||
Weighted average assumptions used (as of the end of the fiscal year) in computing the benefit obligation were as follows: | |||||||||||||
2013 | 2012 | ||||||||||||
Discount rate | 4.65 | % | 3.7 | % | |||||||||
Rate of increase in compensation levels | N/A | N/A | |||||||||||
The following table provides components of net periodic benefit cost for the Company-sponsored defined benefit pension plans together with contributions charged to expense for multi-employer union-administered defined benefit pension plans that the Company participates in (in thousands): | |||||||||||||
Fiscal Year Ended September 30, | |||||||||||||
2013 | 2012 | 2011 | |||||||||||
Components of Net Periodic Benefit Cost: | |||||||||||||
Interest cost on projected benefit obligation | $ | 6,104 | $ | 6,560 | $ | 7,036 | |||||||
Expected return on plan assets | -9,955 | -10,475 | -9,289 | ||||||||||
Recognized net actuarial loss | 5,963 | 4,758 | 4,768 | ||||||||||
Loss due to curtailments, settlements and other | 985 | 1,518 | 828 | ||||||||||
Net periodic pension cost of defined benefit pension plans | 3,097 | 2,361 | 3,343 | ||||||||||
Net pension cost of multi-employer plans | 156 | 294 | 340 | ||||||||||
Total pension expense | $ | 3,253 | $ | 2,655 | $ | 3,683 | |||||||
Weighted average assumptions used (as of the beginning of the fiscal year) in computing the net periodic benefit cost were as follows: | |||||||||||||
2013 | 2012 | 2011 | |||||||||||
Discount rate | 3.7 | % | 4.6 | % | 5 | % | |||||||
Rate of increase in compensation levels | N/A | N/A | N/A | ||||||||||
Expected long-term rate of return on assets | 6.75 | % | 8 | % | 8 | % | |||||||
To determine the expected long-term rate of return on assets, the Company considered the current and expected asset allocations, as well as historical and expected returns on various categories of plan assets. The Company expects to change its asset category mix in fiscal 2014, and as a result, the expected long-term rate of return on assets will decrease to 5.75%. | |||||||||||||
The Compensation and Succession Planning Committee (“Compensation Committee”) of the Company's board of directors has delegated the administration of the pension and benefit plans to the Company's Benefits Committee, an internal committee, composed of senior finance, human resources and legal executives. The Benefits Committee is responsible for oversight of the investment management of the assets of the Company's pension plans and the investment options under the Company's savings plans as well as the performance of the investment advisers and plan administrators. The Benefits Committee has adopted an investment policy for the Company's pension plan, which includes guidelines regarding, among other things, the selection of acceptable asset classes, allowable ranges of holdings, rebalancing of assets, the definition of acceptable securities within each class, and investment performance expectations. | |||||||||||||
The investment portfolio contains a diversified portfolio of investment categories, including equities, fixed income securities and cash. Securities are also diversified in terms of domestic and international securities and large cap and small cap stocks. The actual and target asset allocations expressed as a percentage of the plans' assets at the measurement date are as follows: | |||||||||||||
Pension Asset | Target | ||||||||||||
Allocation | Allocation | ||||||||||||
2013 | 2012 | 2013 | 2012 | ||||||||||
Asset Category: | |||||||||||||
Equity securities | 42 | % | 42 | % | 41 | % | 41 | % | |||||
Debt securities | 57 | 57 | 58 | 58 | |||||||||
Cash and cash equivalents | 1 | 1 | 1 | 1 | |||||||||
Total | 100 | % | 100 | % | 100 | % | 100 | % | |||||
The investment goals are to achieve the optimal return possible within the specific risk parameters and, at a minimum, produce results, which achieve the plans' assumed interest rate for funding the plans over a full market cycle. High levels of risk and volatility are reduced by maintaining diversified portfolios. Allowable investments include government-backed fixed income securities, investment grade corporate bonds, residential backed mortgage securities, equity securities and cash equivalents. Prohibited investments include unregistered or restricted stock, commodities, margin trading, options and futures, short-selling, venture capital, private placements, real estate and other high risk investments. | |||||||||||||
The fair value of the Company's pension plan assets, totaling $160.0 million and $158.4 million at September 30, 2013 and 2012, respectively, is determined using a fair value hierarchy by asset class. The fair value hierarchy has three levels based on the reliability of the inputs to determine fair value. Level 1 refers to fair values determined based on unadjusted quoted prices in active markets for identical assets. Level 2 refers to fair values estimated using significant other observable inputs and Level 3 includes fair values estimated using significant non-observable inputs. | |||||||||||||
The Company's pension plan assets at September 30, 2013 were comprised of $1.5 million invested in money market funds, $66.8 million invested in commingled equity funds, and $91.7 million invested in commingled fixed-income funds. The Company's pension plan assets at September 30, 2012 were comprised of $0.9 million invested in money market funds, $66.4 million invested in commingled equity funds, and $91.1 million invested in commingled fixed income funds. The fair values of the money market funds were determined using the Level 1 hierarchy. The fair values of the equity and fixed-income commingled funds, which have daily net asset values derived from the underlying securities, were determined by using the Level 2 hierarchy. | |||||||||||||
As of September 30, 2013, all of the Company's defined benefit pension plans had plan assets in excess of the projected plan benefit obligations. As of September 30, 2012 all of the Company's defined benefit pension plans had accumulated and projected benefit obligations in excess of plan assets. The amounts related to these plans were as follows (in thousands): | |||||||||||||
2013 | 2012 | ||||||||||||
Accumulated benefit obligation | $ | 149,404 | $ | 166,244 | |||||||||
Projected benefit obligation | $ | 149,404 | $ | 166,244 | |||||||||
Plan assets at fair value | $ | 159,966 | $ | 158,391 | |||||||||
The Company was not required to contribute to its salaried benefit plan in fiscal 2013 or 2012. During fiscal 2013, the Company made no contributions to its salaried benefit plan. During fiscal 2012, the Company elected to make a contribution of $15.0 million. Expected benefit payments over the next ten years, are anticipated to be paid as follows (in thousands): | |||||||||||||
Pension Benefits | |||||||||||||
Fiscal Year: | |||||||||||||
2014 | $ | 9,071 | |||||||||||
2015 | 6,794 | ||||||||||||
2016 | 7,548 | ||||||||||||
2017 | 7,897 | ||||||||||||
2018 | 7,514 | ||||||||||||
2019-2023 | 42,582 | ||||||||||||
Total | $ | 81,406 | |||||||||||
Expected benefit payments are based on the same assumptions used to measure the benefit obligations. | |||||||||||||
Postretirement Benefit Plans | |||||||||||||
The Company provides medical benefits to certain retirees. The plans are closed to new participants and benefits that can be earned by active participants are limited. Employees became eligible for such postretirement benefits after meeting certain age and years of service criteria. As a result of special termination benefit packages previously offered, the Company also provides dental and life insurance benefits to a limited number of retirees and their dependents. These benefit plans are unfunded. | |||||||||||||
The following table sets forth (in thousands) a reconciliation of the changes in the Company-sponsored postretirement benefit plans: | |||||||||||||
Fiscal Year Ended | |||||||||||||
September 30, | |||||||||||||
2013 | 2012 | ||||||||||||
Change in Accumulated Benefit Obligations: | |||||||||||||
Benefit obligation at beginning of year | $ | 10,810 | $ | 11,500 | |||||||||
Interest cost | 383 | 501 | |||||||||||
Actuarial (gain) loss | -539 | 116 | |||||||||||
Benefit payments | -1,200 | -1,307 | |||||||||||
Benefit obligation at end of year | $ | 9,454 | $ | 10,810 | |||||||||
Change in Plan Assets: | |||||||||||||
Fair value of plan assets at beginning of year | $ | - | $ | - | |||||||||
Employer contributions | 1,200 | 1,307 | |||||||||||
Benefit payments | -1,200 | -1,307 | |||||||||||
Fair value of plan assets at end of year | $ | - | $ | - | |||||||||
Funded Status and Amounts Recognized: | |||||||||||||
Funded status | $ | -9,454 | $ | -10,810 | |||||||||
Net amount recognized | $ | -9,454 | $ | -10,810 | |||||||||
Amounts recognized in the balance sheets consist of: | |||||||||||||
Current liabilities | $ | -729 | $ | -943 | |||||||||
Noncurrent liabilities | -8,725 | -9,867 | |||||||||||
Net amount recognized | $ | -9,454 | $ | -10,810 | |||||||||
Weighted average assumptions used (as of the end of the fiscal year) in computing the funded status of the plans were as follows: | |||||||||||||
2013 | 2012 | ||||||||||||
Discount rate | 4.65 | % | 3.7 | % | |||||||||
Health care trend rate assumed for next year | 7.54 | % | 7.82 | % | |||||||||
Rate to which the cost trend rate is assumed to decline | 4.5 | % | 4.5 | % | |||||||||
Year that the rate reaches the ultimate trend rate | 2023 | 2022 | |||||||||||
Assumed health care trend rates have a significant effect on the amounts reported for the health care plans. A one-percentage-point change in assumed health care cost trend rates would have the following effect (in thousands): | |||||||||||||
One Percentage Point | |||||||||||||
Increase | Decrease | ||||||||||||
Effect on total service and interest cost components | $44 | ($37) | |||||||||||
Effect on benefit obligation | $975 | ($834) | |||||||||||
The following table provides components of net periodic benefit cost for the Company-sponsored postretirement benefit plans (in thousands): | |||||||||||||
Fiscal Year Ended | |||||||||||||
September 30, | |||||||||||||
2013 | 2012 | 2011 | |||||||||||
Components of Net Periodic Benefit Cost: | |||||||||||||
Interest cost on projected benefit obligation | $ | 383 | $ | 501 | $ | 604 | |||||||
Recognized net actuarial gains | -669 | -958 | -455 | ||||||||||
Total postretirement (income)/benefit expense | $ | -286 | $ | -457 | $ | 149 | |||||||
Weighted average assumptions used (as of the beginning of the fiscal year) in computing the net periodic benefit cost were as follows: | |||||||||||||
2013 | 2012 | 2011 | |||||||||||
Discount rate | 3.7 | % | 4.6 | % | 5 | % | |||||||
Health care trend rate assumed for next year | 7.82 | % | 8.1 | % | 8.39 | % | |||||||
Rate to which the cost trend rate is assumed to decline | 4.5 | % | 4.5 | % | 4.5 | % | |||||||
Year that the rate reaches the ultimate trend rate | 2023 | 2022 | 2021 | ||||||||||
Expected postretirement benefit payments over the next ten years are anticipated to be paid as follows (in thousands): | |||||||||||||
Postretirement Benefits | |||||||||||||
Fiscal Year: | |||||||||||||
2014 | $ | 765 | |||||||||||
2015 | 733 | ||||||||||||
2016 | 702 | ||||||||||||
2017 | 644 | ||||||||||||
2018 | 636 | ||||||||||||
2019-2023 | 3,121 | ||||||||||||
Total | $ | 6,601 | |||||||||||
Defined Contribution Plans | |||||||||||||
The Company sponsors the AmerisourceBergen Employee Investment Plan, which is a defined contribution 401(k) plan covering salaried and certain hourly employees. Eligible participants may contribute to the plan from 1% to 25% of their regular compensation before taxes. The Company contributes $1.00 for each $1.00 invested by the participant up to the first 3% of the participant's salary and $0.50 for each additional $1.00 invested by the participant of up to an additional 2% of salary. An additional discretionary contribution, in an amount not to exceed the limits established by the Internal Revenue Code, may also be made depending upon the Company's performance. All contributions are invested at the direction of the employee in one or more funds. All contributions vest immediately except for the discretionary contributions made by the Company that vest in full after five years of credited service. | |||||||||||||
The Company also sponsors the AmerisourceBergen Corporation Supplemental 401(k) Plan. This unfunded plan provides benefits for selected key management, including all of the Company's executive officers. This plan will provide eligible participants with an annual amount equal to 4% of the participant's base salary and bonus incentive to the extent that his or her compensation exceeds the annual compensation limit established by Section 401(a) (17) of the Internal Revenue Code. | |||||||||||||
Costs of the defined contribution plans charged to expense for the fiscal years ended September 30, 2013, 2012, and 2011 were $17.4 million, $16.4 million, and $15.4 million, respectively. | |||||||||||||
Deferred Compensation Plan | |||||||||||||
The Company sponsors the AmerisourceBergen Corporation 2001 Deferred Compensation Plan. This unfunded plan, under which 2.96 million shares of Common Stock are authorized for issuance, allows eligible officers, directors and key management employees to defer a portion of their annual compensation. The amount deferred may be allocated by the employee to cash, mutual funds or stock credits. Stock credits, including dividend equivalents, are equal to the full and fractional number of shares of Common Stock that could be purchased with the participant's compensation allocated to stock credits based on the average of closing prices of Common Stock during each month, plus, at the discretion of the board of directors, up to one-half of a share of Common Stock for each full share credited. Stock credit distributions are made in shares of Common Stock. No shares of Common Stock have been issued under the deferred compensation plan through September 30, 2013. The Company's liability relating to its deferred compensation plan as of September 30, 2013 and 2012 was $13.3 million and $10.5 million, respectively. | |||||||||||||
ShareBased_Compensation
Share-Based Compensation | 12 Months Ended | |||||||||
Sep. 30, 2013 | ||||||||||
Share Based Compensation Abstract | ' | |||||||||
Disclosure Of Compensation Related Costs Share Based Payments Text Block | ' | |||||||||
Note 9. Share-Based Compensation | ||||||||||
Stock Options | ||||||||||
The Company's employee stock option plans provide for the granting of incentive and nonqualified stock options to acquire shares of Common Stock to employees at a price not less than the fair market value of the Common Stock on the date the option is granted. Option terms and vesting periods are determined at the date of grant by the Compensation Committee of the board of directors. Employee options generally vest ratably, in equal amounts, over a four-year service period and expire in seven years (ten years for all grants issued prior to February 2008). The Company's non-employee director stock option plans provide for the granting of nonqualified stock options to acquire shares of Common Stock to non-employee directors at the fair market value of the Common Stock on the date of the grant. Non-employee director options vest ratably, in equal amounts, over a three-year service period and expire in ten years. | ||||||||||
At September 30, 2013, employee and non-employee director stock options for an additional 28.0 million shares may be granted under the AmerisourceBergen Corporation Equity Incentive Plan. | ||||||||||
The estimated fair values of options granted are expensed as compensation on a straight-line basis over the requisite service periods of the awards and are net of estimated forfeitures. The Company estimates the fair values of option grants using a binomial option pricing model. Expected volatilities are based on the historical volatility of the Company's Common Stock and other factors, such as implied market volatility. The Company uses historical exercise data, taking into consideration the optionees' ages at grant date, to estimate the terms for which the options are expected to be outstanding. The Company anticipates that the terms of options granted in the future will be similar to those granted in the past. The risk-free rates during the terms of such options are based on the U.S. Treasury yield curve in effect at the time of grant. | ||||||||||
The weighted average fair values of the options granted during the fiscal years ended September 30, 2013, 2012, and 2011 were $6.54, $6.36, and $7.43, respectively. The following assumptions were used to estimate the fair values of options granted: | ||||||||||
Fiscal Year Ended September 30, | ||||||||||
2013 | 2012 | 2011 | ||||||||
Weighted average risk-free interest rate | 0.44 | % | 0.59 | % | 1.8 | % | ||||
Expected dividend yield | 1.29 | % | 1.39 | % | 1.1 | % | ||||
Weighted average volatility of common stock | 24.22 | % | 25.63 | % | 26.46 | % | ||||
Weighted average expected life of the options | 3.69 years | 3.69 years | 3.83 years | |||||||
Changes to the above valuation assumptions could have a significant impact on share-based compensation expense. During the fiscal years ended September 30, 2013, 2012, and 2011, the Company recorded stock option expense of $20.2 million, $15.4 million, and $18.8 million, respectively. | ||||||||||
A summary of the Company's stock option activity and related information for its option plans for the fiscal year ended September 30, 2013 is presented below: | ||||||||||
Weighted | ||||||||||
Weighted | Average | |||||||||
Average | Remaining | Aggregate | ||||||||
Exercise | Contractual | Intrinsic | ||||||||
Options | Price | Term | Value | |||||||
(000’s) | (000’s) | |||||||||
Outstanding at September 30, 2012 | 16,086 | $28 | 5 years | |||||||
Granted | 3,856 | $41 | ||||||||
Exercised | -4,926 | $23 | ||||||||
Forfeited | -897 | $38 | ||||||||
Outstanding at September 30, 2013 | 14,119 | $33 | 4 years | $402,257 | ||||||
Exercisable at September 30, 2013 | 6,452 | $26 | 3 years | $225,143 | ||||||
Expected to vest after September 30, 2013 | 7,104 | $38 | 5 years | $164,089 | ||||||
The intrinsic value of stock option exercises during fiscal 2013, 2012, and 2011 was $131.8 million, $82.1 million, and $118.5 million, respectively. | ||||||||||
A summary of the status of the Company's nonvested options as of September 30, 2013 and changes during the fiscal year ended September 30, 2013 is presented below: | ||||||||||
Weighted | ||||||||||
Average | ||||||||||
Grant Date | ||||||||||
Options | Fair Value | |||||||||
(000’s) | ||||||||||
Nonvested at September 30, 2012 | 7,601 | $6 | ||||||||
Granted | 3,856 | $7 | ||||||||
Vested | -2,906 | $6 | ||||||||
Forfeited | -884 | $6 | ||||||||
Nonvested at September 30, 2013 | 7,667 | $7 | ||||||||
During the fiscal years ended September 30, 2013, 2012, and 2011, the total fair values of options vested were $17.4 million, $17.2 million, and $18.0 million, respectively. Expected future compensation expense relating to the 7.7 million nonvested options outstanding as of September 30, 2013 is $35.8 million, which will be recognized over a weighted average period of 2.4 years. | ||||||||||
Restricted Stock and Restricted Stock Units | ||||||||||
Restricted shares vest in full after three years. The estimated fair value of restricted shares under the Company's restricted stock plans is determined by the product of the number of shares granted and the grant date market price of the Company's Common Stock. The estimated fair value of restricted shares is expensed on a straight-line basis over the requisite service period of three years. During the fiscal years ended September 30, 2013, 2012, and 2011, the Company recorded restricted stock expense of $12.1 million, $9.0 million, and $8.5 million, respectively. | ||||||||||
A summary of the status of the Company's restricted shares as of September 30, 2013 and changes during the fiscal year ended September 30, 2013 is presented below: | ||||||||||
Weighted | ||||||||||
Average | ||||||||||
Restricted | Grant Date | |||||||||
Shares | Fair Value | |||||||||
(000’s) | ||||||||||
Nonvested at September 30, 2012 | 1,058 | $34 | ||||||||
Granted | 448 | $44 | ||||||||
Vested | -318 | $30 | ||||||||
Forfeited | -65 | $37 | ||||||||
Nonvested at September 30, 2013 | 1,123 | $39 | ||||||||
During the fiscal years ended September 30, 2013, 2012, and 2011, the total fair values of restricted shares vested were $9.7 million, $6.1 million, and $7.3 million, respectively. Expected future compensation expense relating to the 1.1 million restricted shares outstanding as of September 30, 2013 is $19.3 million, which will be recognized over a weighted average period of 1.5 years. | ||||||||||
Performance Stock Units | ||||||||||
Beginning in fiscal 2012, performance stock units were granted to certain executive employees under the Plan, which represent Common Stock potentially issuable in the future. Performance stock units vest at the end of a three-year performance period based on achievement of specific performance goals. Based on the extent to which the targets are achieved, vested shares may range from 0 percent to 150 percent of the target award amount. The fair value of performance stock units is determined by the grant date market price of the Company's Common Stock and the compensation expense associated with nonvested performance stock units is dependent on the Company's periodic assessment of the probability of the targets being achieved and its estimate of the number of shares that will ultimately be issued. During the fiscal years ended September 30, 2013 and 2012, the Company recognized $3.7 million and $1.5 million of compensation expense, respectively, related to these performance stock units. | ||||||||||
Employee Stock Purchase Plan | ||||||||||
The AmerisourceBergen Corporation Employee Stock Purchase Plan provides for an aggregate of 4,000,000 shares of Common Stock that may be sold to eligible employees (generally defined as employees with at least 30 days of service with the Company). The participants may elect to have the Company withhold up to 25% of base salary to purchase shares of the Company's Common Stock at a price equal to 95% of the fair market value of the stock on the last business day of each six-month purchase period. Each participant is limited to $25,000 of purchases during each calendar year. During the fiscal years ended September 30, 2013, 2012, and 2011, the Company acquired 93,813 shares, 113,692 shares, and 106,959 shares, respectively, from the open market for issuance to participants in this plan. As of September 30, 2013, the Company has withheld $1.1 million from eligible employees for the purchase of additional shares of Common Stock. |
Leases_and_Other_Commitments
Leases and Other Commitments | 12 Months Ended |
Sep. 30, 2013 | |
Commitments and Contingencies Disclosure [Abstract] | ' |
Commitments Disclosure [Text Block] | ' |
Note 10. Leases and Other Commitments | |
At September 30, 2013, future minimum payments totaling $284.0 million under noncancelable operating leases with remaining terms of more than one fiscal year were due as follows: 2014 — $54.5 million; 2015 — $49.2 million; 2016 — $42.3 million; 2017 — $32.3 million; 2018 — $29.7 million; and thereafter — $76.0 million. In the normal course of business, operating leases are generally renewed or replaced by other leases. Certain operating leases include escalation clauses. Total rental expense was $79.6 million in fiscal 2013, $65.3 million in fiscal 2012, and $53.3 million in fiscal 2011. | |
The Company has commitments to purchase product from influenza vaccine manufacturers through the 2014/2015 flu season. The Company is required to purchase doses at prices it believes will represent market prices. The Company currently estimates its remaining purchase commitment under these agreements will be approximately $36.9 million as of September 30, 2013. | |
The Company outsources to IBM Global Services (“IBM”) a significant portion of its corporate and AmerisourceBergen Drug Corporation information technology activities. The remaining commitment under the Company's ten-year arrangement, as amended, which expires in June 2015, is approximately $54.1 million as of September 30, 2013, of which $31.3 million represents the Company's commitment in fiscal 2014. |
Employee_Severance_Litigation_
Employee Severance, Litigation, and Other | 12 Months Ended | |||||||||
Sep. 30, 2013 | ||||||||||
Restructuring Charges Abstract | ' | |||||||||
Restructuring And Related Activities Disclosure Text Block | ' | |||||||||
Note 11. Employee Severance, Litigation and Other | ||||||||||
The following table illustrates the charges incurred by the Company relating to employee severance, litigation and other for the three fiscal years ended September 30, 2013 (in thousands): | ||||||||||
2013 | 2012 | 2011 | ||||||||
Employee severance | $ | 491 | $ | 33,040 | $ | 4,382 | ||||
Litigation costs | - | - | 16,000 | |||||||
Deal-related transaction costs | 22,976 | 11,100 | 3,185 | |||||||
Total employee severance, litigation and other | $ | 23,467 | $ | 44,140 | $ | 23,567 | ||||
During fiscal 2011, the Company introduced its Energiz program, which encompassed a combination of initiatives, to maximize salesforce productivity, improve customer contractual compliance, and drive efficiency by linking the Company's information technology capabilities more effectively with its operations. In connection with the Energiz program, which the Company completed as of September 30, 2011, the Company terminated 103 employees and incurred $4.4 million of severance costs. Additionally, in fiscal 2011, the Company accrued $16.0 million related to a preliminary settlement agreement with respect to a qui tam litigation matter. | ||||||||||
During fiscal 2012, the Company introduced a number of initiatives, some of which were made possible as a result of efficiencies gained through the implementation of the Company's enterprise resource planning system, to improve its operating efficiency across many of its businesses and certain administrative functions. In connection with these initiatives, the Company recorded $33.0 million of employee severance and other related costs in fiscal 2012. Other costs included an estimated $10.3 million liability to exit the Company's participation in a multi-employer pension plan resulting from a distribution facility closure in fiscal 2013. Through September 30, 2013, a total of 314 employees were severed relating to the fiscal 2012 initiatives. | ||||||||||
During fiscal 2013, the Company incurred $23.0 million of deal-related transaction costs (primarily related to professional fees with respect to the Walgreens and Alliance Boots transaction) and $0.5 million of employee severance and other related costs. During fiscal 2012, the Company incurred $11.1 million of deal-related transaction costs in connection with business combinations. | ||||||||||
Employees receive their severance benefits over a period of time, generally not in excess of 12 months, or in the form of a lump-sum payment. | ||||||||||
The following table displays the activity recorded within accrued expenses and other from September 30, 2011 to September 30, 2013 related to the matters discussed above (in thousands): | ||||||||||
Employee | Litigation and | |||||||||
Severance | Other | Total | ||||||||
Balance as of September 30, 2011 | $3,610 | $20,290 | $23,900 | |||||||
Expense recorded during the period | 33,040 | 11,100 | 44,140 | |||||||
Payments made during the period | -5,668 | -13,537 | -19,205 | |||||||
Balance as of September 30, 2012 | 30,982 | 17,853 | 48,835 | |||||||
Expense recorded during the period | 491 | 22,976 | 23,467 | |||||||
Payments made during the period | -15,671 | -39,597 | -55,268 | |||||||
Balance as of September 30, 2013 | $15,802 | $1,232 | $17,034 |
Legal_Matters_and_Contingencie
Legal Matters and Contingencies | 12 Months Ended |
Sep. 30, 2013 | |
Loss Contingency [Abstract] | ' |
Legal Matters and Contingencies [Text Block] | ' |
Note 12. Legal Matters and Contingencies | |
In the ordinary course of its business, the Company becomes involved in lawsuits, administrative proceedings, government subpoenas, and government investigations, including antitrust, commercial, environmental, product liability, intellectual property, regulatory, employment discrimination, and other matters. Significant damages or penalties may be sought from the Company in some matters, and some matters may require years for the Company to resolve. The Company establishes reserves based on its periodic assessment of estimates of probable losses. There can be no assurance that an adverse resolution of one or more matters during any subsequent reporting period will not have a material adverse effect on the Company's results of operations for that period or on the Company's financial condition. | |
Qui Tam | |
The qui tam provisions of the federal civil False Claims Act and various state and local civil False Claims Acts permit a private person, known as a “relator” or whistleblower, to file civil actions under these statutes on behalf of the federal, state and local governments. Such cases may involve allegations around the marketing, sale and/or purchase of pharmaceutical products. Qui tam complaints are initially filed by the relator under seal (or on a confidential basis) and the filing of the complaint imposes obligations on government authorities to investigate the allegations in the complaint and to determine whether or not to intervene in the action. Qui tam complaints remain sealed until the court in which the case was filed orders otherwise. | |
The Company has learned that there are filings in one or more federal district courts, including a qui tam complaint filed by one of its former employees, that are under seal and may involve allegations against the Company (and/or subsidiaries or businesses of the Company, including its group purchasing organization for oncologists and its oncology distribution business) relating to its distribution of certain pharmaceutical products to providers. The Company and ABSG have also received subpoenas from the United States Attorney's Office for the Eastern District of New York (“USAO”) requesting production of documents and information relating to ABSG's oncology distribution center and pharmacy in Dothan, Alabama, its group purchasing organization for oncologists, and intercompany transfers of certain oncology products, which the Company believes could be related to one or more of the qui tam actions that remain under seal. The Company is in the process of responding to the subpoenas and is cooperating fully with the USAO. The Company cannot predict the outcome of any pending action in which any AmerisourceBergen entity is or may become a defendant. | |
Subpoenas from United States Attorney's Offices | |
In fiscal 2012, the Company's subsidiary, ABDC, received a subpoena from the United States Attorney's Office in New Jersey (the “USAO”) in connection with a grand jury proceeding requesting documents concerning ABDC's program for controlling and monitoring diversion of controlled substances into channels other than for legitimate medical, scientific, and industrial purposes. ABDC also received a subpoena from the Drug Enforcement Administration (“DEA”) in connection with the matter. In addition to requesting information on ABDC's diversion control program generally, the subpoenas also request documents concerning specific customers' purchases of controlled substances. ABDC has responded to the subpoenas and is cooperating fully with the USAO and the DEA. On August 30, 2013, ABDC received a second subpoena from the USAO requesting additional information related to the documents produced in response to the first subpoena, as well as information regarding additional specific customers' purchases of controlled substances. The Company cannot predict the outcome of this matter. | |
In fiscal 2013, the Company or ABDC has also received similar subpoenas from the United States Attorney's Office in the District of Kansas and the United States Attorney's Office in the Northern District of Ohio in connection with grand jury proceedings requesting documents in concerning ABDC's program for controlling and monitoring diversion of controlled substances into channels other than for legitimate medical, scientific and industrial purposes. As in the New Jersey matter described above, in addition to requesting information on ABDC's diversion control program generally, the subpoenas also request documents concerning specific customers' purchases of controlled substances. The Company is in the process of responding to the subpoenas and cannot predict the outcome of these matters. | |
West Virginia Complaint | |
On June 26, 2012, the Attorney General of the State of West Virginia (“West Virginia”) filed a complaint (the “Complaint”) in the Circuit Court of Boone County, West Virginia, against a number of pharmaceutical wholesale distributors, including the Company's subsidiary, ABDC, alleging, among other things, that the distributors failed to provide effective controls and procedures to guard against diversion of controlled substances for illegitimate purposes in West Virginia. The Complaint also alleges that the distributors acted negligently by distributing controlled substances to pharmacies that serve individuals who abuse prescription pain medication and were unjustly enriched by such conduct, violated consumer credit and protection laws, created a public nuisance, and violated state antitrust laws in connection with the distribution of controlled substances. West Virginia is seeking injunctive relief to enjoin alleged violations of state regulations requiring suspicious order monitoring and reporting and to require defendants to fund a medical monitoring treatment program. The Complaint also seeks a jury trial to determine any losses and damages sustained by West Virginia as a result of the defendants' alleged conduct. On July 26, 2012, one of the defendants, J.M. Smith Corporation d/b/a Smith Drug Company, filed a Notice of Removal from the Circuit Court of Boone County, West Virginia to the United States District Court for the Southern District of West Virginia, and ABDC and all other defendants filed Consents to Removal. On August 27, 2012, West Virginia filed a Motion to Remand, to which J.M. Smith Corporate d/b/a Smith Drug Company, joined by all other defendants, filed a reply. On March 27, 2013, the Court granted West Virginia's Motion to Remand and West Virginia notified the parties that they intend to file an amended complaint. The parties are currently litigating certain procedural matters relating to discovery request. The Company cannot predict the outcome of this matter. |
Litigation_Settlements
Litigation Settlements | 12 Months Ended |
Sep. 30, 2013 | |
Gain (Loss) Related to Litigation Settlement [Abstract] | ' |
Commitments And Contingencies Disclosure Text Block | ' |
Note 13. Litigation Settlements | |
Antitrust Settlements | |
Numerous class action lawsuits have been filed against certain brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs from entering the market. The Company has not been a named plaintiff in any of these class actions, but has been a member of the direct purchasers' class (i.e., those purchasers who purchase directly from these pharmaceutical manufacturers). None of the class actions has gone to trial, but some have settled in the past with the Company receiving proceeds from the settlement funds. During the fiscal years ended September 30, 2013, 2012, and 2011, the Company recognized gains of $22.9 million, $14.8 million, and $2.1 million, respectively, relating to the above-mentioned class action lawsuits. These gains, which are net of attorney fees and estimated payments due to other parties, were recorded as reductions to cost of goods sold in the Company's consolidated statements of operations. | |
Business_Segment_Information
Business Segment Information | 12 Months Ended | ||||||||||
Sep. 30, 2013 | |||||||||||
Segment Reporting [Abstract] | ' | ||||||||||
Segment Reporting Disclosure Text Block | ' | ||||||||||
Note 14. Business Segment Information | |||||||||||
The Company is organized based upon the products and services it provides to its customers. The Company's operations are comprised the Pharmaceutical Distribution reportable segment and Other. The Pharmaceutical Distribution reportable segment consists of the AmerisourceBergen Drug Corporation (“ABDC”) and AmerisourceBergen Specialty Group (“ABSG”) operating segments. Other consists of the AmerisourceBergen Consulting Services (“ABCS”) and World Courier operating segments. | |||||||||||
The Company has aggregated the operating segments of ABDC and ABSG into one reportable segment, the Pharmaceutical Distribution segment. The results of operations of the ABCS and World Courier operating segments are not significant enough to require separate reportable segment disclosure, and therefore have been included in Other for the purpose of reportable segment presentation. | |||||||||||
The Company's ability to aggregate ABDC and ABSG into one reportable segment was based on the following: | |||||||||||
• the objective and basic principles of ASC 280; | |||||||||||
• the aggregation criteria as noted in ASC 280; and | |||||||||||
• the fact that ABDC and ABSG have similar economic characteristics. | |||||||||||
The chief operating decision maker for the Company is the President and Chief Executive Officer of the Company whose function is to allocate resources to, and assess the performance of, the ABDC and ABSG operating segments. ABDC and ABSG each have an executive who functions as an operating segment manager whose role includes reporting directly to the President and Chief Executive Officer of the Company on their respective operating segment's business activities, financial results and operating plans. | |||||||||||
The businesses of the Pharmaceutical Distribution operating segments are similar in that they service both healthcare providers and pharmaceutical manufacturers in the pharmaceutical supply channel. The distribution of pharmaceutical drugs has historically represented more than 95% of the Company's revenues. ABDC and ABSG each operate in a high volume and low margin environment and, as a result, their economic characteristics are similar. Each operating segment warehouses and distributes products in a similar manner. Additionally, each operating segment is subject, in whole or in part, to the same extensive regulatory environment under which the pharmaceutical distribution industry operates. | |||||||||||
ABDC distributes a comprehensive offering of brand-name pharmaceuticals (including specialty pharmaceutical products) and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to a wide variety of healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and other alternate site pharmacies and other customers. ABDC also provides pharmacy management, staffing and other consulting services; scalable automated pharmacy dispensing equipment; medication and supply dispensing cabinets; and supply management software to a variety of retail and institutional healthcare providers. Additionally, ABDC delivers packaging solutions to institutional and retail healthcare providers. | |||||||||||
ABSG, through a number of operating businesses, provides distribution and other services primarily to physicians who specialize in a variety of disease states, especially oncology, and to other healthcare providers, including dialysis clinics. ABSG also distributes plasma and other blood products, injectible pharmaceuticals and vaccines. Additionally, ABSG provides third party logistics and outcomes research, and other services for biotechnology and other pharmaceutical manufacturers. | |||||||||||
The Company's use of the terms “specialty” and “specialty pharmaceutical products” refers to drugs used to treat complex diseases, such as cancer, diabetes, and multiple sclerosis. Specialty pharmaceutical products are part of complex treatment regimens for serious conditions and diseases that generally require ongoing clinical monitoring. The Company believes the terms “specialty” and “specialty pharmaceutical products” are used consistently by industry participants and its competitors. However, the Company cannot be certain that other distributors of specialty products define these and other similar terms in exactly the same manner as the Company does. | |||||||||||
Both ABDC and ABSG distribute specialty drugs to their customers, with the principal difference between these two operating segments being that ABSG operates distribution facilities that focus primarily on complex disease treatment regimens. Therefore, a product distributed from one of ABSG's distribution facilities results in revenue reported under ABSG, and a product distributed from one of ABDC's distribution centers results in revenue reported under ABDC. Essentially, all of ABSG's sales consist of specialty pharmaceutical products. ABDC sales of specialty pharmaceutical products are a relatively small component of its overall revenue. | |||||||||||
As noted above, Other consists of the ABCS and World Courier operating segments. ABCS, through a number of operating businesses, provides commercialization support services including reimbursement support programs, outcomes research, contract field staffing, patient assistance and copay assistance programs, adherence programs, risk mitigation services, and other market access programs to pharmaceutical and biotechnology manufacturers. World Courier, which operates in over 50 countries, is a leading global specialty transportation and logistics provider for the biopharmaceutical industry. | |||||||||||
The following tables illustrate reportable segment information for the periods indicated (in thousands): | |||||||||||
Revenue | |||||||||||
Fiscal year ended September 30, | 2013 | 2012 | 2011 | ||||||||
Pharmaceutical Distribution | $ | 86,387,950 | $ | 76,940,544 | $ | 78,444,933 | |||||
Other | 1,763,549 | 1,324,744 | 302,012 | ||||||||
Intersegment eliminations | -192,332 | -184,482 | -51,286 | ||||||||
Revenue | $ | 87,959,167 | $ | 78,080,806 | $ | 78,695,659 | |||||
Intersegment eliminations primarily represent the elimination of certain ABCS sales to the Pharmaceutical Distribution segment. | |||||||||||
Operating Income | |||||||||||
Fiscal year ended September 30, | 2013 | 2012 | 2011 | ||||||||
Pharmaceutical Distribution | $ | 919,455 | $ | 1,275,636 | $ | 1,184,673 | |||||
Other | 92,466 | 72,119 | 28,414 | ||||||||
Warrants | -90,055 | - | - | ||||||||
Employee severance, litigation and other | -23,467 | -44,140 | -23,567 | ||||||||
Operating income | 898,399 | 1,303,615 | 1,189,520 | ||||||||
Other loss (income) | 44 | -5,827 | -4,617 | ||||||||
Interest expense, net | 73,897 | 92,569 | 76,148 | ||||||||
Income from continuing operations before income taxes | $ | 824,458 | $ | 1,216,873 | $ | 1,117,989 | |||||
Segment operating income is evaluated before Warrant expense; employee severance, litigation and other; other loss (income); and interest expense, net. All corporate office expenses are allocated to the operating segments within Pharmaceutical Distribution and Other. | |||||||||||
Assets | |||||||||||
At September 30, | 2013 | 2012 | |||||||||
Pharmaceutical Distribution | $ | 17,589,320 | $ | 13,429,646 | |||||||
Other | 1,329,318 | 1,349,757 | |||||||||
Assets held for sale | - | 662,853 | |||||||||
Total assets | $ | 18,918,638 | $ | 15,442,256 | |||||||
Depreciation & Amortization | |||||||||||
Fiscal year ended September 30, | 2013 | 2012 | 2011 | ||||||||
Pharmaceutical Distribution | $ | 116,672 | $ | 106,028 | $ | 90,005 | |||||
Other | 45,514 | 28,347 | 11,357 | ||||||||
Total depreciation and amortization | $ | 162,186 | $ | 134,375 | $ | 101,362 | |||||
Depreciation and amortization includes depreciation and amortization of property and equipment and intangible assets, but excludes amortization of deferred financing costs and other debt-related items which are included in interest expense. | |||||||||||
Capital Expenditures | |||||||||||
Fiscal year ended September 30, | 2013 | 2012 | 2011 | ||||||||
Pharmaceutical Distribution | $ | 172,549 | $ | 85,980 | $ | 143,584 | |||||
Other | 29,901 | 47,312 | 12,558 | ||||||||
Total capital expenditures | $ | 202,450 | $ | 133,292 | $ | 156,142 |
Fair_Value_of_Financial_Instru
Fair Value of Financial Instruments | 12 Months Ended |
Sep. 30, 2013 | |
Fair Value Disclosures [Abstract] | ' |
Fair Value Disclosures Text Block | ' |
Note 15. Fair Value of Financial Instruments | |
The recorded amounts of the Company's cash and cash equivalents, accounts receivable and accounts payable at September 30, 2013 and 2012 approximate fair value based upon the relatively short-term nature of these financial instruments. Within cash and cash equivalents, the Company had no investments in money market accounts as of September 30, 2013. The Company had $230.0 million of investments in money market accounts as of September 30, 2012. The fair values of the money market accounts were determined on unadjusted quoted prices in active markets for identical assets, otherwise known as Level 1 inputs. The recorded amount of debt (see Note 6) and the corresponding fair value as of September 30, 2013 were $1,396.6 million and $1,502.0 million, respectively. The recorded amount of debt and the corresponding fair value as of September 30, 2012 were $1,395.9 million and $1,584.7 million, respectively. The fair values of debt were determined based on quoted market prices, otherwise known as Level 2 inputs. |
Quarterly_Financial_Informatio
Quarterly Financial Information (Unaudited) | 12 Months Ended | |||||||||||||||
Sep. 30, 2013 | ||||||||||||||||
Quarterly Financial Information Disclosure [Abstract] | ' | |||||||||||||||
Quarterly Financial Information Text Block | ' | |||||||||||||||
Note 16. Quarterly Financial Information (Unaudited) | ||||||||||||||||
Fiscal Year Ended September 30, 2013 | ||||||||||||||||
First | Second | Third | Fourth | Fiscal | ||||||||||||
Quarter | Quarter | Quarter | Quarter | Year | ||||||||||||
(In thousands, except per share amounts) | ||||||||||||||||
Revenue | $ | 21,059,811 | $ | 20,523,668 | $ | 21,906,648 | $ | 24,469,040 | $ | 87,959,167 | ||||||
Gross profit (a) | $ | 660,828 | $ | 716,989 | $ | 562,450 | $ | 567,552 | $ | 2,507,819 | ||||||
Distribution, selling and | ||||||||||||||||
administrative expenses, | ||||||||||||||||
depreciation, and | ||||||||||||||||
amortization | 359,384 | 363,404 | 372,311 | 400,799 | 1,495,898 | |||||||||||
Warrants | - | 3,761 | 35,815 | 50,479 | 90,055 | |||||||||||
Employee severance, | ||||||||||||||||
litigation and other | 2,004 | -299 | 19,678 | 2,084 | 23,467 | |||||||||||
Operating income | $ | 299,440 | $ | 350,123 | $ | 134,646 | $ | 114,190 | $ | 898,399 | ||||||
Income from continuing operations | $ | 174,621 | $ | 204,143 | $ | 64,110 | $ | 50,561 | $ | 493,435 | ||||||
(Loss) income from discontinued | ||||||||||||||||
operations, net of tax (b) | -6,010 | -158,509 | 104,329 | 462 | -59,728 | |||||||||||
Net income | $ | 168,611 | $ | 45,634 | $ | 168,439 | $ | 51,023 | $ | 433,707 | ||||||
Earnings per share from continuing | ||||||||||||||||
operations: | ||||||||||||||||
Basic | $ | 0.75 | $ | 0.89 | $ | 0.28 | $ | 0.22 | $ | 2.14 | ||||||
Diluted | $ | 0.74 | $ | 0.87 | $ | 0.27 | $ | 0.22 | $ | 2.1 | ||||||
Earnings per share: | ||||||||||||||||
Basic | $ | 0.73 | $ | 0.2 | $ | 0.73 | $ | 0.22 | $ | 1.88 | ||||||
Diluted | $ | 0.71 | $ | 0.19 | $ | 0.71 | $ | 0.22 | $ | 1.84 | ||||||
____________ | ||||||||||||||||
(a) | ||||||||||||||||
(b) | ||||||||||||||||
The first, second, third and fourth quarters of 2013 include gains of $12.3 million, $3.5 million, $6.0 million, and $1.1 million, respectively, from antitrust litigation settlements. The first, second, third, and fourth quarters of 2013 include a LIFO charge of $1.1 million, a LIFO credit of $0.2 million, a LIFO charge of $122.1 million, and a LIFO charge of $154.0 million, respectively. | ||||||||||||||||
Includes (loss) income from AB and ABCC, both of which were divested in May 2013 (see Note 3). | ||||||||||||||||
Fiscal Year Ended September 30, 2012 | ||||||||||||||||
First | Second | Third | Fourth | Fiscal | ||||||||||||
Quarter | Quarter | Quarter | Quarter | Year | ||||||||||||
(In thousands, except per share amounts) | ||||||||||||||||
Revenue | $ | 19,981,185 | $ | 19,708,371 | $ | 19,326,807 | $ | 19,064,443 | $ | 78,080,806 | ||||||
Gross profit (a) | $ | 573,262 | $ | 679,741 | $ | 667,866 | $ | 713,817 | $ | 2,634,686 | ||||||
Distribution, selling and | ||||||||||||||||
administrative expenses, | ||||||||||||||||
depreciation and amortization | 286,300 | 293,654 | 339,345 | 367,632 | 1,286,931 | |||||||||||
Employee severance, litigation | ||||||||||||||||
and other | 3,559 | 9,027 | 4,135 | 27,419 | 44,140 | |||||||||||
Operating income | $ | 283,403 | $ | 377,060 | $ | 324,386 | $ | 318,766 | $ | 1,303,615 | ||||||
Income from continuing operations | $ | 161,592 | $ | 219,143 | $ | 190,177 | $ | 190,449 | $ | 761,361 | ||||||
Income (loss) from discontinued | ||||||||||||||||
operations, net of tax (b) | 524 | -7,038 | -8,906 | -26,955 | -42,375 | |||||||||||
Net income | $ | 162,116 | $ | 212,105 | $ | 181,271 | $ | 163,494 | $ | 718,986 | ||||||
Earnings per share from continuing | ||||||||||||||||
operations: | ||||||||||||||||
Basic | $ | 0.63 | $ | 0.85 | $ | 0.75 | $ | 0.78 | $ | 3.01 | ||||||
Diluted | $ | 0.61 | $ | 0.84 | $ | 0.74 | $ | 0.77 | $ | 2.96 | ||||||
Earnings per share: | ||||||||||||||||
Basic | $ | 0.63 | $ | 0.82 | $ | 0.72 | $ | 0.67 | $ | 2.84 | ||||||
Diluted | $ | 0.62 | $ | 0.81 | $ | 0.71 | $ | 0.66 | $ | 2.8 | ||||||
____________ | ||||||||||||||||
The fourth quarter of fiscal 2012 includes a gain of $14.8 million from antitrust litigation settlements. | ||||||||||||||||
Includes income (loss) from AB and ABCC, both of which were classified as discontinued operations. | ||||||||||||||||
Subsequent_Events
Subsequent Events | 12 Months Ended |
Sep. 30, 2013 | |
Subsequent Events [Abstract] | ' |
Subsequent Events [Text Block] | ' |
Note 17. Subsequent Event | |
Dividend Increase | |
In November 2013, the Company's board of directors increased the quarterly dividend paid on Common Stock by 12% and declared a regular quarterly cash dividend of $0.235 payable on December 2, 2013 to shareholders of record on November 18, 2013. | |
Schedule_II_Valuation_and_Qual
Schedule II - Valuation and Qualifying Accounts | 12 Months Ended | |||||||||||||||
Sep. 30, 2013 | ||||||||||||||||
Valuation and Qualifying Accounts [Abstract] | ' | |||||||||||||||
Schedule Of Valuation And Qualifying Accounts Disclosure Text Block | ' | |||||||||||||||
AMERISOURCEBERGEN CORPORATION AND SUBSIDIARIES | ||||||||||||||||
SCHEDULE II — VALUATION AND QUALIFYING ACCOUNTS | ||||||||||||||||
Additions | ||||||||||||||||
Balance at | Charged to | Charged to | Balance at | |||||||||||||
Beginning | Costs and | Other | Deductions- | End of | ||||||||||||
Description | of Period | Expenses (1) | Accounts (2) | Describe (3) | Period | |||||||||||
(In thousands) | ||||||||||||||||
Year Ended September 30, 2013 | ||||||||||||||||
Allowance for doubtful accounts | $ | 85,741 | $ | 20,118 | $ | - | $ | -23,479 | $ | 82,380 | ||||||
Year Ended September 30, 2012 | ||||||||||||||||
Allowance for doubtful accounts | $ | 88,833 | $ | 23,058 | $ | - | $ | -26,150 | $ | 85,741 | ||||||
Year Ended September 30, 2011 | ||||||||||||||||
Allowance for doubtful accounts | $ | 93,849 | $ | 37,878 | $ | 62 | $ | -42,956 | $ | 88,833 | ||||||
___________ | ||||||||||||||||
(1) Represents the provision for doubtful accounts. | ||||||||||||||||
(2) Represents the aggregate allowances of acquired entities at the respective acquisition dates. | ||||||||||||||||
(3) Represents accounts written off during year, net of recoveries. |
Summary_of_Significant_Account1
Summary of Significant Accounting Policies (Policies) | 12 Months Ended |
Sep. 30, 2013 | |
Accounting Policies [Abstract] | ' |
Nature Of Operations | ' |
AmerisourceBergen Corporation (the “Company”) is one of the largest global pharmaceutical sourcing and distribution services companies, helping both healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care. The Company delivers innovative programs and services designed to increase the effectiveness and efficiency of the pharmaceutical supply chain. | |
Consolidation Policy Text Block | ' |
The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries as of the dates and for the fiscal years indicated. All intercompany accounts and transactions have been eliminated in consolidation. | |
Use of Estimates, Policy [Policy Text Block] | ' |
The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect amounts reported in the financial statements and accompanying notes. Actual amounts could differ from these estimated amounts due to uncertainties inherent in such estimates. Management periodically evaluates estimates used in the preparation of the financial statements for continued reasonableness. | |
Reclassifications [Text Block] | ' |
Certain reclassifications have been made to prior year amounts in order to conform to the current year presentation. | |
Business Combination Policy [Text Block] | ' |
The purchase price of an acquired company, including the fair value of contingent consideration, is allocated between tangible and intangible assets acquired and liabilities assumed from the acquired business based on their estimated fair values, with the residual of the purchase price recorded as goodwill. The results of operations of the acquired businesses are included in the Company's operating results from the dates of acquisition (see Note 2). | |
Cash And Cash Equivalents Policy Text Block | ' |
The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. The carrying value of cash equivalents approximates fair value. | |
Receivables Policy Text Block | ' |
The Company sells its merchandise inventories to a large number of customers in the healthcare industry that include institutional and retail healthcare providers. Institutional healthcare providers include acute care hospitals, health systems, mail order pharmacies, long-term care and other alternate care pharmacies and providers of pharmacy services to such facilities, and physician offices. Retail healthcare providers include national and regional retail drugstore chains, independent community pharmacies and pharmacy departments of supermarkets and mass merchandisers. The financial condition of the Company's customers can be affected by changes in government reimbursement policies as well as by other economic pressures in the healthcare industry. | |
The Company's trade accounts receivable are exposed to credit risk, but the risk is moderated because the Company's customer base is diverse and geographically widespread primarily within the U.S. The Company generally does not require collateral for trade receivables. In determining the appropriate allowance for doubtful accounts, the Company considers a combination of factors, such as the aging of trade receivables, industry trends, its customers' financial strength, credit standing, and payment and default history. Changes in these factors, among others, may lead to adjustments in the Company's allowance for doubtful accounts. The calculation of the required allowance requires judgment by Company management as to the impact of those and other factors on the ultimate realization of its trade receivables. Each of the Company's business units performs ongoing credit evaluations of its customers' financial condition and maintains reserves for probable bad debt losses based on historical experience and for specific credit problems when they arise. There were no significant changes to this process during the fiscal years ended September 30, 2013, 2012, and 2011 and bad debt expense was computed in a consistent manner during these periods. The bad debt expense for any period presented is equal to the changes in the period end allowance for doubtful accounts, net of write-offs, recoveries and other adjustments. Schedule II of this Form 10-K sets forth a rollforward of the allowance for doubtful accounts. The Company's largest customer in fiscal 2013, Express Scripts, Inc., accounted for 24% of revenue and represented approximately 13% of accounts receivable, net as of September 30, 2013. Walgreen Co. (“Walgreens”), the Company's second largest customer in fiscal 2013, represented approximately 32% of accounts receivable net as of September 30, 2013. | |
The Company maintains cash and cash equivalents with several financial institutions. Deposits held with banks may exceed the amount of insurance provided on such deposits. These deposits may be redeemed upon demand, and are maintained with financial institutions with reputable credit, and, therefore, bear minimal credit risk. The Company seeks to mitigate such risks by monitoring the risk profiles of these counterparties. The Company also seeks to mitigate risk by monitoring the investment strategy of money market accounts that it is invested in, which are classified as cash equivalents. | |
Commitments And Contingencies Policy Text Block | ' |
Loss Contingencies: In the ordinary course of its business, the Company becomes involved in lawsuits, administrative proceedings, government subpoenas, and government investigations, including antitrust, commercial, environmental, product liability, intellectual property, regulatory, employment discrimination, and other matters. Significant damages or penalties may be sought from the Company in some matters, and some matters may require years for the Company to resolve. The Company records a liability when it is probable that a loss has been incurred and the amount is reasonably estimable. The Company also performs an assessment of the materiality of loss contingencies where a loss is either not probable or it is reasonably possible that a loss could be incurred in excess of amounts accrued. If a loss or an additional loss has at least a reasonable possibility of occurring and the impact on the financial statements would be material, the Company provides disclosure of the loss contingency in the footnotes to its financial statements. The Company reviews all contingencies at least quarterly to determine whether the likelihood of loss has changed and to assess whether a reasonable estimate of the loss or the range of the loss can be made (see Note 12). | |
Gain Contingencies: The Company records gain contingencies when they are realized. Gains from antitrust litigation settlements are realized upon the receipt of cash and recorded as a reduction to cost of goods sold because they represent a recovery of amounts historically paid to manufacturers to originally acquire the pharmaceuticals that were the subject of the antitrust litigation settlements (see Note 13). | |
Derivatives Policy Text Block | ' |
The Company records all derivative financial instruments on the balance sheet at fair value and complies with established criteria for designation and effectiveness of hedging relationships. The Company's policy prohibits it from entering into derivative financial instruments for speculative or trading purposes. | |
As of September 30, 2013, the Company had one foreign currency denominated contract outstanding that hedges the foreign currency exchange risk of the C$50.0 million note that the Company received in conjunction with the sale of AmerisourceBergen Canada Corporation (see Note 3). | |
As of September 30, 2012, there were no outstanding derivative financial instruments. | |
Equity Method Investments Policy | ' |
The Company uses the equity method of accounting for its investments in entities in which it has significant influence; generally, this represents an ownership interest of between 20% and 50%. The Company's investments in marketable equity securities in which the Company does not have significant influence are classified as “available for sale” and are carried at fair value within the Other Assets line item on the consolidated balance sheet, with unrealized gains and losses excluded from earnings and reported in the accumulated other comprehensive loss component of stockholders' equity. Unrealized losses that are determined to be other-than-temporary impairment losses are recorded as a component of earnings in the period in which that determination is made. | |
Foreign Currency Transactions And Translations Policy Text Block | ' |
The functional currency of the Company's foreign operations is generally the applicable local currency. Assets and liabilities are translated into U.S. dollars using the current exchange rates in effect at the balance sheet date, while revenues and expenses are translated at the weighted average exchange rates for the period. The resulting translation adjustments are recorded as a component of accumulated other comprehensive loss within stockholders' equity. | |
Goodwill And Intangible Assets Policy Text Block | ' |
Goodwill and other intangible assets with indefinite lives, primarily trademarks and trade names, are not amortized; rather, they are tested for impairment at least annually. For the purpose of these impairment tests, the Company can elect to perform a qualitative analysis to determine if it is more likely than not that the fair values of its reporting units and indefinite lived intangible assets are less than the respective carrying values of those reporting units and indefinite lived intangible assets. The Company elected to bypass performing the qualitative screen and went directly to performing the first step quantitative analysis of the goodwill and indefinite lived intangible asset impairment tests in the current year. The Company may elect to perform the qualitative analysis in future periods. | |
The first step in the quantitative process for the goodwill impairment test is to compare the carrying amount of the reporting unit's net assets to the fair value of the reporting unit. If the fair value exceeds the carrying value, no further evaluation is required and no impairment loss is recognized. If the carrying amount exceeds the fair value, then the second step must be completed, which involves allocating the fair value of the reporting unit to each asset and liability, with the excess being implied goodwill. An impairment loss occurs if the amount of the recorded goodwill exceeds the implied goodwill. The Company would be required to record any such impairment losses. | |
The Company identifies its reporting units at the operating segment level. Generally, goodwill arises from acquisitions of specific operating companies and is assigned to the reporting unit in which a particular operating company resides. | |
The Company utilizes a combination of income and market-based approaches to valuation for its reporting units. The income approach to valuation relies on a discounted cash flow analysis to determine the fair value of each reporting unit, which considers forecasted cash flows discounted at an appropriate discount rate. The Company believes that market participants would use a discounted cash flow analysis to determine the fair value of its reporting units in a sale transaction. The annual goodwill impairment test requires the Company to make a number of assumptions and estimates concerning future levels of revenue growth, operating margins, depreciation, amortization and working capital requirements, which are based upon the Company's long-range plan. The discount rate is an estimate of the overall after-tax rate of return required by a market participant whose weighted average cost of capital includes both equity and debt, including a risk premium. While the Company uses the best available information to prepare its cash flow and discount rate assumptions, actual future cash flows or market conditions could differ significantly resulting in future impairment charges related to recorded goodwill balances. While there are always changes in assumptions to reflect changing business and market conditions, the Company's overall methodology and the population of assumptions used have remained unchanged. | |
The impairment test for indefinite-lived intangibles other than goodwill (primarily trademarks and trade names) consists of a comparison of the fair value of the indefinite-lived intangible asset to the carrying value of the asset as of the impairment testing date. The Company estimates the fair value of its indefinite-lived intangibles using the relief from royalty method. The Company believes the relief from royalty method is a widely used valuation technique for such assets. The fair value derived from the relief from royalty method is measured as the discounted cash flow savings realized from owning such trademarks and trade names and not having to pay a royalty for their use. | |
The Company completed its required annual impairment tests relating to goodwill and other intangible assets in the fiscal years ended September 30, 2013, 2012, and 2011, and, as a result, recorded $6.5 million of impairment charges in fiscal 2011. | |
Income Tax Policy Text Block | ' |
The Company accounts for income taxes using a method that requires recognition of deferred tax assets and liabilities for expected future tax consequences of temporary differences that currently exist between tax bases and financial reporting bases of the Company's assets and liabilities (commonly known as the asset and liability method). In assessing the ability to realize deferred tax assets, the Company considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. | |
The Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained upon examination by the taxing authorities, including resolutions of any related appeals or litigation processes, based on the technical merits of the position. Tax benefits associated with uncertain tax positions that have met the recognition criteria are measured and recorded based on the highest probable outcome that is more than 50% likely to be realized after full disclosure and resolution of a tax examination. | |
Cost Of Sales Vendor Allowances Policy | ' |
The Company accounts for fees and other incentives received from its suppliers, relating to the purchase or distribution of inventory, as a reduction to cost of goods sold. The Company considers these fees and other incentives to represent product discounts, and as a result, they are capitalized as product costs and relieved through cost of goods sold upon the sale of the related inventory. | |
Inventory Policy Text Block | ' |
Inventories are stated at the lower of cost or market. Cost for approximately 83% and 82% of the Company's inventories at September 30, 2013 and 2012, respectively, has been determined using the last-in, first-out (LIFO) method. If the Company had used the first-in, first-out (FIFO) method of inventory valuation, which approximates current replacement cost, inventories would have been approximately $533.7 million and $256.7 million higher than the amounts reported at September 30, 2013 and 2012, respectively. The Company recorded a LIFO charge of $277.0 million, $0.7 million, and $34.7 million in fiscal 2013, 2012, and 2011, respectively. The annual LIFO provision is affected by changes in inventory quantities, product mix, and manufacturing pricing practices, which may be impacted by market and other external influences, many of which are difficult to predict. The Company's LIFO charge in fiscal 2013 was significant due to the additional branded inventory it was required to purchase for the new Walgreens distribution contract and the impact the branded inventory had on the Company's annual inflation index, as well as higher brand drug price inflation and generic drug price deflation. | |
Property Plant And Equipment Policy Text Block | ' |
Property and equipment are stated at cost and depreciated using the straight-line method over the estimated useful lives of the assets, which range from 3 to 40 years for buildings and improvements and from 3 to 10 years for machinery, equipment and other. The costs of repairs and maintenance are charged to expense as incurred. | |
The Company capitalizes project costs relating to computer software developed or obtained for internal use when the activities related to the project reach the application development stage. Costs that are associated with preliminary stage activities, training, maintenance, and all other post-implementation stage activities are expensed as they are incurred. Software development costs are depreciated using the straight-line method over the estimated useful lives, which range from 3 to 10 years. | |
Revenue Recognition Policy Text Block | ' |
The Company recognizes revenue when persuasive evidence of an arrangement exists, product has been delivered or services have been rendered, the price is fixed or determinable and collectability is reasonably assured. Revenue as reflected in the accompanying consolidated statements of operations is net of estimated sales returns and allowances. | |
The Company's customer sales return policy generally allows customers to return products only if the products can be resold at full value or returned to suppliers for full credit. The Company records an accrual for estimated customer sales returns at the time of sale to the customer. At September 30, 2013 and 2012, the Company's accrual for estimated customer sales returns was $275.8 million and $252.5 million, respectively. | |
The Company reports the gross dollar amount of bulk deliveries to customer warehouses in revenue and the related costs in cost of goods sold. Bulk delivery transactions are arranged by the Company at the express direction of the customer, and involve either drop shipments from the supplier directly to customers' warehouse sites or cross-dock shipments from the supplier to the Company for immediate shipment to the customers' warehouse sites. The Company is a principal to these transactions because it is the primary obligor and has the ultimate and contractual responsibility for fulfillment and acceptability of the products purchased, and bears full risk of delivery and loss for products, whether the products are drop-shipped or shipped via cross-dock. The Company also bears full credit risk associated with the creditworthiness of any bulk delivery customer. As a result, the Company records bulk deliveries to customer warehouses as gross revenues. Gross profit earned by the Company on bulk deliveries was not material in any year presented. | |
Share Based Compensation Option And Incentive Plans Policy | ' |
The Company accounts for the compensation cost of all share-based payments at fair value and reports the related expense within distribution, selling and administrative expenses to correspond with the same line item as the cash compensation paid to employees. The benefits of tax deductions in excess of recognized compensation expense are reported as a financing cash flow ($41.2 million, $25.7 million, and $39.7 million for the fiscal years ended September 30, 2013, 2012, and 2011, respectively). | |
Shipping And Handling Cost Policy Text Block | ' |
Shipping and handling costs include all costs to warehouse, pick, pack and deliver inventory to customers. These costs, which were $267.3 million, $259.1 million and $270.2 million for the fiscal years ended September 30, 2013, 2012, and 2011, respectively, are included in distribution, selling and administrative expenses. | |
Supplier Reserves Policy [Text Block] | ' |
The Company establishes reserves against amounts due from its suppliers relating to various price and rebate incentives, including deductions or billings taken against payments otherwise due them from the Company. These reserve estimates are established based on the judgment of Company management after carefully considering the status of current outstanding claims, historical experience with the suppliers, the specific incentive programs and any other pertinent information available to the Company. The Company evaluates the amounts due from its suppliers on a continual basis and adjusts the reserve estimates when appropriate based on changes in factual circumstances. The ultimate outcome of any outstanding claim may be different than the Company's estimate. | |
Warrant Accounting Policy [Text Block] | ' |
The Company accounts for the Warrants issued to subsidiaries of Walgreens and Alliance Boots GmbH (“Alliance Boots”) in accordance with the guidance for equity-based payments to non-employees. The various agreements and arrangements with Walgreens and Alliance Boots established various performance commitments that they must satisfy during the vesting periods of the Warrants, and if not fulfilled, the Company has the right to cancel the Warrants. Using a binomial lattice model approach, the fair value of the Warrants was initially measured at the date of issuance, and is being expensed over the three and four year vesting periods as an operating expense. The fair value of the Warrants are re-measured at the end of each quarterly reporting period, and an adjustment is recorded in the statement of operations to record the impact as if the newly measured fair value of the awards had been used in recognizing expense starting when the awards were originally issued and through the remeasurement date. In total, the Warrants were valued at $572.0 million as of September 30, 2013. The valuation of the Warrants considers the Company's Common Stock price and various assumptions, such as the volatility of the Company's Common Stock, the expected remaining life of the Warrants, the expected dividend yield, and the risk-free interest rate. As a result, future Warrant expense could fluctuate significantly (see Note 7). | |
Discontinued_Operations_Tables
Discontinued Operations (Tables) | 12 Months Ended | ||||||||||
Sep. 30, 2013 | |||||||||||
Discontinued Operation Income Loss From Discontinued Operation Disclosures Abstract | ' | ||||||||||
Schedule of Disposal Groups Including Disccontinued Operations Income Statement Disclosures [Text Block] | ' | ||||||||||
Fiscal Year Ended September 30, | |||||||||||
(in thousands) | 2013 | 2012 | 2011 | ||||||||
Revenue | $ | 1,181,231 | $ | 1,639,684 | $ | 1,521,899 | |||||
(Loss) income before income taxes | $ | -50,090 | $ | -37,534 | $ | 12,652 | |||||
Schedule of Disposal Groups Including Discontinued Operations Balance Sheet Disclosures [Text Block] | ' | ||||||||||
September 30, | |||||||||||
2012 | |||||||||||
Assets: | |||||||||||
Accounts receivable | $187,179 | ||||||||||
Merchandise inventories | 249,463 | ||||||||||
Property and equipment, net | 131,907 | ||||||||||
Goodwill and other intangible assets | 85,163 | ||||||||||
Other assets | 9,141 | ||||||||||
Assets held for sale | 662,853 | ||||||||||
Liabilities: | |||||||||||
Accounts payable | 152,110 | ||||||||||
Accrued expenses and other | 16,554 | ||||||||||
Other liabilities | 71,042 | ||||||||||
Liabilities held for sale | 239,706 | ||||||||||
Net assets | $423,147 |
Income_Taxes_Tables
Income Taxes (Tables) | 12 Months Ended | |||||||||
Sep. 30, 2013 | ||||||||||
Income Tax Disclosure [Abstract] | ' | |||||||||
schedule of income before income tax | ' | |||||||||
Fiscal year ended September 30, | ||||||||||
2013 | 2012 | 2011 | ||||||||
Domestic | $793,137 | $1,193,047 | $1,105,481 | |||||||
Foreign | 31,321 | 23,826 | 12,508 | |||||||
Total | $824,458 | $1,216,873 | $1,117,989 | |||||||
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] | ' | |||||||||
Fiscal Year Ended September 30, | ||||||||||
2013 | 2012 | 2011 | ||||||||
Current provision: | ||||||||||
Federal | $259,457 | $356,843 | $194,816 | |||||||
State and local | 37,602 | 32,438 | 26,527 | |||||||
Foreign | 8,391 | 4,953 | 4,354 | |||||||
305,450 | 394,234 | 225,697 | ||||||||
Deferred provision: | ||||||||||
Federal | 29,189 | 47,348 | 174,412 | |||||||
State and local | -3,375 | 11,959 | 20,462 | |||||||
Foreign | -241 | 1,971 | -77 | |||||||
25,573 | 61,278 | 194,797 | ||||||||
Provision for income taxes | $331,023 | $455,512 | $420,494 | |||||||
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] | ' | |||||||||
Fiscal Year Ended September 30, | ||||||||||
2013 | 2012 | 2011 | ||||||||
Statutory U.S. federal income tax rate | 35 | % | 35 | % | 35 | % | ||||
State and local income tax rate, net of federal tax benefit | 3 | 2.3 | 1.7 | |||||||
Foreign | -0.3 | -0.1 | - | |||||||
Warrants | 2.3 | - | - | |||||||
Other | 0.2 | 0.2 | 0.9 | |||||||
Effective income tax rate | 40.2 | % | 37.4 | % | 37.6 | % | ||||
Schedule of Deferred Tax Assets and Liabilities [Table Text Block] | ' | |||||||||
September 30, | ||||||||||
2013 | 2012 | |||||||||
Merchandise inventories | $1,016,522 | $985,571 | ||||||||
Property and equipment | 128,289 | 132,732 | ||||||||
Goodwill and other intangible assets | 260,357 | 249,913 | ||||||||
Other | 1,322 | 705 | ||||||||
Gross deferred tax liabilities | 1,406,490 | 1,368,921 | ||||||||
Net operating loss and tax credit carryforwards | -61,726 | -59,994 | ||||||||
Capital loss carryforwards | -297,806 | -230,395 | ||||||||
Allowance for doubtful accounts | -30,073 | -30,856 | ||||||||
Accrued expenses | -16,731 | -9,651 | ||||||||
Employee and retiree benefits | -4,884 | -17,392 | ||||||||
Stock options | -29,356 | -28,197 | ||||||||
Other | -66,537 | -57,596 | ||||||||
Gross deferred tax assets | -507,113 | -434,081 | ||||||||
Valuation allowance for deferred tax assets | 327,546 | 254,182 | ||||||||
Deferred tax assets, net of valuation allowance | -179,567 | -179,899 | ||||||||
Net deferred tax liabilities | $1,226,923 | $1,189,022 | ||||||||
Summary of Income Tax Contingencies [Table Text Block] | ' | |||||||||
Balance at September 30, 2010 | $36,830 | |||||||||
Additions of tax positions of the current year | 5,866 | |||||||||
Additions of tax positions of the prior years | 3,592 | |||||||||
Reductions of tax positions of the prior years | -386 | |||||||||
Settlements with taxing authorities | -7,136 | |||||||||
Expiration of statutes of limitations | -2,963 | |||||||||
Balance at September 30, 2011 | 35,803 | |||||||||
Additions of tax positions of the current year | 6,094 | |||||||||
Additions of tax positions of the prior years | 1,045 | |||||||||
Additions of tax positions due to acquisitions | 2,748 | |||||||||
Reductions of tax positions of the prior years | -5,177 | |||||||||
Settlements with taxing authorities | -2,286 | |||||||||
Expiration of statutes of limitations | -1,237 | |||||||||
Balance at September 30, 2012 | 36,990 | |||||||||
Additions of tax positions of the current year | 5,272 | |||||||||
Additions of tax positions of the prior years | 2,825 | |||||||||
Additions of tax positions due to acquisitions | 2,500 | |||||||||
Settlements with taxing authorities | -519 | |||||||||
Expiration of statutes of limitations | -801 | |||||||||
Balance at September 30, 2013 | $46,267 |
Goodwill_and_Other_Intangible_1
Goodwill and Other Intangible Assets (Tables) | 12 Months Ended | |||||||||||||||||
Sep. 30, 2013 | ||||||||||||||||||
Goodwill and Intangible Assets Disclosure [Abstract] | ' | |||||||||||||||||
Schedule Of Goodwill Text Block | ' | |||||||||||||||||
Pharmaceutical | ||||||||||||||||||
Distribution | Other | Total | ||||||||||||||||
Goodwill at September 30, 2011 | $2,421,707 | $75,455 | $2,497,162 | |||||||||||||||
Goodwill recognized in connection with acquisitions (see Note 2) | -134 | 444,554 | 444,420 | |||||||||||||||
Foreign currency translation | 1,402 | - | 1,402 | |||||||||||||||
Goodwill at September 30, 2012 | 2,422,975 | 520,009 | 2,942,984 | |||||||||||||||
Goodwill recognized in connection with acquisitions (see Note 2) | - | 3,000 | 3,000 | |||||||||||||||
Foreign currency translation | -1,014 | - | -1,014 | |||||||||||||||
Goodwill at September 30, 2013 | $2,421,961 | $523,009 | $2,944,970 | |||||||||||||||
Schedule of Other Intangible Assets [Text Block] | ' | |||||||||||||||||
September 30, 2013 | September 30, 2012 | |||||||||||||||||
Gross | Net | Gross | Net | |||||||||||||||
Carrying | Accumulated | Carrying | Carrying | Accumulated | Carrying | |||||||||||||
Amount | Amortization | Amount | Amount | Amortization | Amount | |||||||||||||
Indefinite-lived intangibles — trade names | $ | 343,892 | $ | - | $ | 343,892 | $ | 344,004 | $ | - | $ | 344,004 | ||||||
Finite-lived intangibles: | ||||||||||||||||||
Customer relationships | 265,810 | -80,767 | 185,043 | 265,981 | -61,865 | 204,116 | ||||||||||||
Other | 69,350 | -43,542 | 25,808 | 67,896 | -35,568 | 32,328 | ||||||||||||
Total other intangible assets | $ | 679,052 | $ | -124,309 | $ | 554,743 | $ | 677,881 | $ | -97,433 | $ | 580,448 |
Debt_Tables
Debt (Tables) | 12 Months Ended | ||||||
Sep. 30, 2013 | |||||||
Debt Disclosure [Abstract] | ' | ||||||
Schedule Of Debt Instruments Text Block | ' | ||||||
September 30, | |||||||
2013 | 2012 | ||||||
(Dollars in thousands) | |||||||
Receivables securitization facility due 2016 | $ | - | $ | - | |||
Multi-currency revolving credit facility due 2018 | - | - | |||||
Revolving credit note | - | - | |||||
$500,000, 5 7/8% senior notes due 2015 | 499,377 | 499,091 | |||||
$400,000, 4 7/8% senior notes due 2019 | 397,803 | 397,485 | |||||
$500,000, 3 1/2% senior notes due 2021 | 499,426 | 499,355 | |||||
Total debt | $ | 1,396,606 | $ | 1,395,931 |
Stockholders_Equity_and_Earnin1
Stockholders Equity and Earnings per Share (Tables) | 12 Months Ended | ||||||
Sep. 30, 2013 | |||||||
Stockholders Equity and Earnings per Share Tables [Abstract] | ' | ||||||
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] | ' | ||||||
September 30, | |||||||
2013 | 2012 | ||||||
Pension and postretirement adjustments (See Note 8) | ($34,612) | ($45,828) | |||||
Foreign currency translation | -844 | 13,337 | |||||
Other | -27 | -166 | |||||
Total accumulated other comprehensive loss | ($35,483) | ($32,657) | |||||
Schedule of Weighted Average Number of Shares [Table Text Block] | ' | ||||||
September 30, | |||||||
2013 | 2012 | 2011 | |||||
Weighted average common shares outstanding — basic | 231,067 | 252,906 | 272,471 | ||||
Effect of dilutive securities — stock options, restricted stock, | |||||||
and restricted stock units | 4,278 | 3,997 | 5,246 | ||||
Weighted average common shares outstanding — diluted | 235,345 | 256,903 | 277,717 |
Pension_and_Other_Benefit_Plan1
Pension and Other Benefit Plans (Tables) | 12 Months Ended | ||||||||||||
Sep. 30, 2013 | |||||||||||||
General Discussion of Pension and Other Postretirement Benefits [Abstract] | ' | ||||||||||||
Reconciliation of Changes in Company Sponsored Defined Benefit Pension Plans [Text Block] | ' | ||||||||||||
Fiscal Year Ended | |||||||||||||
September 30, | |||||||||||||
2013 | 2012 | ||||||||||||
Change in Projected Benefit Obligations: | |||||||||||||
Benefit obligation at beginning of year | $ | 166,244 | $ | 154,887 | |||||||||
Interest cost | 6,104 | 6,560 | |||||||||||
Actuarial (gains) losses | -15,560 | 17,942 | |||||||||||
Benefit payments | -7,384 | -13,134 | |||||||||||
Other | - | -11 | |||||||||||
Benefit obligation at end of year | $ | 149,404 | $ | 166,244 | |||||||||
Change in Plan Assets: | |||||||||||||
Fair value of plan assets at beginning of year | $ | 158,391 | $ | 122,242 | |||||||||
Actual return on plan assets | 8,005 | 26,775 | |||||||||||
Employer contributions | 2,173 | 23,444 | |||||||||||
Expenses | -1,219 | -936 | |||||||||||
Benefit payments | -7,384 | -13,134 | |||||||||||
Fair value of plan assets at end of year | $ | 159,966 | $ | 158,391 | |||||||||
Funded Status and Amounts Recognized: | |||||||||||||
Funded status | $ | 10,562 | $ | -7,853 | |||||||||
Net amount recognized | $ | 10,562 | $ | -7,853 | |||||||||
Amounts recognized in the balance sheets consist of: | |||||||||||||
Noncurrent assets | $ | 16,563 | $ | - | |||||||||
Current liabilities | -2,826 | -4,456 | |||||||||||
Noncurrent liabilities | -3,175 | -3,397 | |||||||||||
Net amount recognized | $ | 10,562 | $ | -7,853 | |||||||||
Weighted Average Assumptions Used In Computing Benefit Obligation [Text Block] | ' | ||||||||||||
2013 | 2012 | ||||||||||||
Discount rate | 4.65 | % | 3.7 | % | |||||||||
Rate of increase in compensation levels | N/A | N/A | |||||||||||
Schedule of Net Benefit Costs [Table Text Block] | ' | ||||||||||||
Fiscal Year Ended September 30, | |||||||||||||
2013 | 2012 | 2011 | |||||||||||
Components of Net Periodic Benefit Cost: | |||||||||||||
Interest cost on projected benefit obligation | $ | 6,104 | $ | 6,560 | $ | 7,036 | |||||||
Expected return on plan assets | -9,955 | -10,475 | -9,289 | ||||||||||
Recognized net actuarial loss | 5,963 | 4,758 | 4,768 | ||||||||||
Loss due to curtailments, settlements and other | 985 | 1,518 | 828 | ||||||||||
Net periodic pension cost of defined benefit pension plans | 3,097 | 2,361 | 3,343 | ||||||||||
Net pension cost of multi-employer plans | 156 | 294 | 340 | ||||||||||
Total pension expense | $ | 3,253 | $ | 2,655 | $ | 3,683 | |||||||
Weighted Average Assumptions Used in Computing Net Periodic Benefit Cost [Text Block] | ' | ||||||||||||
2013 | 2012 | 2011 | |||||||||||
Discount rate | 3.7 | % | 4.6 | % | 5 | % | |||||||
Rate of increase in compensation levels | N/A | N/A | N/A | ||||||||||
Expected long-term rate of return on assets | 6.75 | % | 8 | % | 8 | % | |||||||
Schedule of Allocation of Plan Assets [Table Text Block] | ' | ||||||||||||
Pension Asset | Target | ||||||||||||
Allocation | Allocation | ||||||||||||
2013 | 2012 | 2013 | 2012 | ||||||||||
Asset Category: | |||||||||||||
Equity securities | 42 | % | 42 | % | 41 | % | 41 | % | |||||
Debt securities | 57 | 57 | 58 | 58 | |||||||||
Cash and cash equivalents | 1 | 1 | 1 | 1 | |||||||||
Total | 100 | % | 100 | % | 100 | % | 100 | % | |||||
Accumulated and Projected Benefit Obligations in Excess of Plan Assets [Text Block] | ' | ||||||||||||
2013 | 2012 | ||||||||||||
Accumulated benefit obligation | $ | 149,404 | $ | 166,244 | |||||||||
Projected benefit obligation | $ | 149,404 | $ | 166,244 | |||||||||
Plan assets at fair value | $ | 159,966 | $ | 158,391 | |||||||||
Schedule of Expected Benefit Payments [Table Text Block] | ' | ||||||||||||
Pension Benefits | |||||||||||||
Fiscal Year: | |||||||||||||
2014 | $ | 9,071 | |||||||||||
2015 | 6,794 | ||||||||||||
2016 | 7,548 | ||||||||||||
2017 | 7,897 | ||||||||||||
2018 | 7,514 | ||||||||||||
2019-2023 | 42,582 | ||||||||||||
Total | $ | 81,406 | |||||||||||
Reconciliation of Changes in Company Sponsored Postretirement Benefit Plans [Text Block] | ' | ||||||||||||
Fiscal Year Ended | |||||||||||||
September 30, | |||||||||||||
2013 | 2012 | ||||||||||||
Change in Accumulated Benefit Obligations: | |||||||||||||
Benefit obligation at beginning of year | $ | 10,810 | $ | 11,500 | |||||||||
Interest cost | 383 | 501 | |||||||||||
Actuarial (gain) loss | -539 | 116 | |||||||||||
Benefit payments | -1,200 | -1,307 | |||||||||||
Benefit obligation at end of year | $ | 9,454 | $ | 10,810 | |||||||||
Change in Plan Assets: | |||||||||||||
Fair value of plan assets at beginning of year | $ | - | $ | - | |||||||||
Employer contributions | 1,200 | 1,307 | |||||||||||
Benefit payments | -1,200 | -1,307 | |||||||||||
Fair value of plan assets at end of year | $ | - | $ | - | |||||||||
Funded Status and Amounts Recognized: | |||||||||||||
Funded status | $ | -9,454 | $ | -10,810 | |||||||||
Net amount recognized | $ | -9,454 | $ | -10,810 | |||||||||
Amounts recognized in the balance sheets consist of: | |||||||||||||
Current liabilities | $ | -729 | $ | -943 | |||||||||
Noncurrent liabilities | -8,725 | -9,867 | |||||||||||
Net amount recognized | $ | -9,454 | $ | -10,810 | |||||||||
Weighted Average Assumptions Used in Computing Funded Status [Text Block] | ' | ||||||||||||
2013 | 2012 | ||||||||||||
Discount rate | 4.65 | % | 3.7 | % | |||||||||
Health care trend rate assumed for next year | 7.54 | % | 7.82 | % | |||||||||
Rate to which the cost trend rate is assumed to decline | 4.5 | % | 4.5 | % | |||||||||
Year that the rate reaches the ultimate trend rate | 2023 | 2022 | |||||||||||
Schedule of Effect of One-Percentage-Point Change in Assumed Health Care Cost Trend Rates [Table Text Block] | ' | ||||||||||||
One Percentage Point | |||||||||||||
Increase | Decrease | ||||||||||||
Effect on total service and interest cost components | $44 | ($37) | |||||||||||
Effect on benefit obligation | $975 | ($834) | |||||||||||
Components of Net Periodic Benefit Costs For Company Sponsored Postretirement Benefit Plans [Text Block] | ' | ||||||||||||
Fiscal Year Ended | |||||||||||||
September 30, | |||||||||||||
2013 | 2012 | 2011 | |||||||||||
Components of Net Periodic Benefit Cost: | |||||||||||||
Interest cost on projected benefit obligation | $ | 383 | $ | 501 | $ | 604 | |||||||
Recognized net actuarial gains | -669 | -958 | -455 | ||||||||||
Total postretirement (income)/benefit expense | $ | -286 | $ | -457 | $ | 149 | |||||||
Weighted Average Assumptions Used in Computing Postretirement Benefit Plans Net Periodic Benefit [Text Block] | ' | ||||||||||||
2013 | 2012 | 2011 | |||||||||||
Discount rate | 3.7 | % | 4.6 | % | 5 | % | |||||||
Health care trend rate assumed for next year | 7.82 | % | 8.1 | % | 8.39 | % | |||||||
Rate to which the cost trend rate is assumed to decline | 4.5 | % | 4.5 | % | 4.5 | % | |||||||
Year that the rate reaches the ultimate trend rate | 2023 | 2022 | 2021 | ||||||||||
Expected Post Retirement Benefit Payments [Text Block] | ' | ||||||||||||
Postretirement Benefits | |||||||||||||
Fiscal Year: | |||||||||||||
2014 | $ | 765 | |||||||||||
2015 | 733 | ||||||||||||
2016 | 702 | ||||||||||||
2017 | 644 | ||||||||||||
2018 | 636 | ||||||||||||
2019-2023 | 3,121 | ||||||||||||
Total | $ | 6,601 |
ShareBased_Compensation_Tables
Share-Based Compensation (Tables) | 12 Months Ended | |||||||||
Sep. 30, 2013 | ||||||||||
Disclosure of Compensation Related Costs, Share-based Payments [Abstract] | ' | |||||||||
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] | ' | |||||||||
Fiscal Year Ended September 30, | ||||||||||
2013 | 2012 | 2011 | ||||||||
Weighted average risk-free interest rate | 0.44 | % | 0.59 | % | 1.8 | % | ||||
Expected dividend yield | 1.29 | % | 1.39 | % | 1.1 | % | ||||
Weighted average volatility of common stock | 24.22 | % | 25.63 | % | 26.46 | % | ||||
Weighted average expected life of the options | 3.69 years | 3.69 years | 3.83 years | |||||||
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] | ' | |||||||||
Weighted | ||||||||||
Weighted | Average | |||||||||
Average | Remaining | Aggregate | ||||||||
Exercise | Contractual | Intrinsic | ||||||||
Options | Price | Term | Value | |||||||
(000’s) | (000’s) | |||||||||
Outstanding at September 30, 2012 | 16,086 | $28 | 5 years | |||||||
Granted | 3,856 | $41 | ||||||||
Exercised | -4,926 | $23 | ||||||||
Forfeited | -897 | $38 | ||||||||
Outstanding at September 30, 2013 | 14,119 | $33 | 4 years | $402,257 | ||||||
Exercisable at September 30, 2013 | 6,452 | $26 | 3 years | $225,143 | ||||||
Expected to vest after September 30, 2013 | 7,104 | $38 | 5 years | $164,089 | ||||||
Schedule of Nonvested Share Activity Table Text Block | ' | |||||||||
Weighted | ||||||||||
Average | ||||||||||
Grant Date | ||||||||||
Options | Fair Value | |||||||||
(000’s) | ||||||||||
Nonvested at September 30, 2012 | 7,601 | $6 | ||||||||
Granted | 3,856 | $7 | ||||||||
Vested | -2,906 | $6 | ||||||||
Forfeited | -884 | $6 | ||||||||
Nonvested at September 30, 2013 | 7,667 | $7 | ||||||||
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block] | ' | |||||||||
Weighted | ||||||||||
Average | ||||||||||
Restricted | Grant Date | |||||||||
Shares | Fair Value | |||||||||
(000’s) | ||||||||||
Nonvested at September 30, 2012 | 1,058 | $34 | ||||||||
Granted | 448 | $44 | ||||||||
Vested | -318 | $30 | ||||||||
Forfeited | -65 | $37 | ||||||||
Nonvested at September 30, 2013 | 1,123 | $39 |
Employee_Severance_Litigation_1
Employee Severance, Litigation, and Other (Tables) | 12 Months Ended | |||||||||
Sep. 30, 2013 | ||||||||||
Restructuring and Related Activities [Abstract] | ' | |||||||||
Schedule Of Restructuring And Related Costs Text Block | ' | |||||||||
2013 | 2012 | 2011 | ||||||||
Employee severance | $ | 491 | $ | 33,040 | $ | 4,382 | ||||
Litigation costs | - | - | 16,000 | |||||||
Deal-related transaction costs | 22,976 | 11,100 | 3,185 | |||||||
Total employee severance, litigation and other | $ | 23,467 | $ | 44,140 | $ | 23,567 | ||||
Schedule Of Restructuring Reserve By Type Of Cost Text Block | ' | |||||||||
Employee | Litigation and | |||||||||
Severance | Other | Total | ||||||||
Balance as of September 30, 2011 | $3,610 | $20,290 | $23,900 | |||||||
Expense recorded during the period | 33,040 | 11,100 | 44,140 | |||||||
Payments made during the period | -5,668 | -13,537 | -19,205 | |||||||
Balance as of September 30, 2012 | 30,982 | 17,853 | 48,835 | |||||||
Expense recorded during the period | 491 | 22,976 | 23,467 | |||||||
Payments made during the period | -15,671 | -39,597 | -55,268 | |||||||
Balance as of September 30, 2013 | $15,802 | $1,232 | $17,034 |
Business_Segment_Information_T
Business Segment Information (Tables) | 12 Months Ended | ||||||||||
Sep. 30, 2013 | |||||||||||
Segment Reporting [Abstract] | ' | ||||||||||
reconciliation of revenue from segments to consolidated | ' | ||||||||||
Revenue | |||||||||||
Fiscal year ended September 30, | 2013 | 2012 | 2011 | ||||||||
Pharmaceutical Distribution | $ | 86,387,950 | $ | 76,940,544 | $ | 78,444,933 | |||||
Other | 1,763,549 | 1,324,744 | 302,012 | ||||||||
Intersegment eliminations | -192,332 | -184,482 | -51,286 | ||||||||
Revenue | $ | 87,959,167 | $ | 78,080,806 | $ | 78,695,659 | |||||
reconciliation of operating profit | ' | ||||||||||
Operating Income | |||||||||||
Fiscal year ended September 30, | 2013 | 2012 | 2011 | ||||||||
Pharmaceutical Distribution | $ | 919,455 | $ | 1,275,636 | $ | 1,184,673 | |||||
Other | 92,466 | 72,119 | 28,414 | ||||||||
Warrants | -90,055 | - | - | ||||||||
Employee severance, litigation and other | -23,467 | -44,140 | -23,567 | ||||||||
Operating income | 898,399 | 1,303,615 | 1,189,520 | ||||||||
Other loss (income) | 44 | -5,827 | -4,617 | ||||||||
Interest expense, net | 73,897 | 92,569 | 76,148 | ||||||||
Income from continuing operations before income taxes | $ | 824,458 | $ | 1,216,873 | $ | 1,117,989 | |||||
reconciliation of assets from segment to consolidated | ' | ||||||||||
Assets | |||||||||||
At September 30, | 2013 | 2012 | |||||||||
Pharmaceutical Distribution | $ | 17,589,320 | $ | 13,429,646 | |||||||
Other | 1,329,318 | 1,349,757 | |||||||||
Assets held for sale | - | 662,853 | |||||||||
Total assets | $ | 18,918,638 | $ | 15,442,256 | |||||||
Depreciation and Amortization [Member] | ' | ||||||||||
segment reporting | ' | ||||||||||
reconciliation of other significant reconciling items from segment | ' | ||||||||||
Depreciation & Amortization | |||||||||||
Fiscal year ended September 30, | 2013 | 2012 | 2011 | ||||||||
Pharmaceutical Distribution | $ | 116,672 | $ | 106,028 | $ | 90,005 | |||||
Other | 45,514 | 28,347 | 11,357 | ||||||||
Total depreciation and amortization | $ | 162,186 | $ | 134,375 | $ | 101,362 | |||||
Capital Expenditures [Member] | ' | ||||||||||
segment reporting | ' | ||||||||||
reconciliation of other significant reconciling items from segment | ' | ||||||||||
Capital Expenditures | |||||||||||
Fiscal year ended September 30, | 2013 | 2012 | 2011 | ||||||||
Pharmaceutical Distribution | $ | 172,549 | $ | 85,980 | $ | 143,584 | |||||
Other | 29,901 | 47,312 | 12,558 | ||||||||
Total capital expenditures | $ | 202,450 | $ | 133,292 | $ | 156,142 |
Quarterly_Financial_Informatio1
Quarterly Financial Information (Unaudited) (Tables) | 12 Months Ended | ||||||||||||||||||||||||||||||
Sep. 30, 2013 | Sep. 30, 2012 | ||||||||||||||||||||||||||||||
Quarterly Financial Data [Abstract] | ' | ' | |||||||||||||||||||||||||||||
Schedule of Quarterly Financial Information [Table Text Block] | ' | ' | |||||||||||||||||||||||||||||
Fiscal Year Ended September 30, 2013 | Fiscal Year Ended September 30, 2012 | ||||||||||||||||||||||||||||||
First | Second | Third | Fourth | Fiscal | First | Second | Third | Fourth | Fiscal | ||||||||||||||||||||||
Quarter | Quarter | Quarter | Quarter | Year | Quarter | Quarter | Quarter | Quarter | Year | ||||||||||||||||||||||
(In thousands, except per share amounts) | (In thousands, except per share amounts) | ||||||||||||||||||||||||||||||
Revenue | $ | 21,059,811 | $ | 20,523,668 | $ | 21,906,648 | $ | 24,469,040 | $ | 87,959,167 | Revenue | $ | 19,981,185 | $ | 19,708,371 | $ | 19,326,807 | $ | 19,064,443 | $ | 78,080,806 | ||||||||||
Gross profit (a) | $ | 660,828 | $ | 716,989 | $ | 562,450 | $ | 567,552 | $ | 2,507,819 | Gross profit (a) | $ | 573,262 | $ | 679,741 | $ | 667,866 | $ | 713,817 | $ | 2,634,686 | ||||||||||
Distribution, selling and | Distribution, selling and | ||||||||||||||||||||||||||||||
administrative expenses, | administrative expenses, | ||||||||||||||||||||||||||||||
depreciation, and | depreciation and amortization | 286,300 | 293,654 | 339,345 | 367,632 | 1,286,931 | |||||||||||||||||||||||||
amortization | 359,384 | 363,404 | 372,311 | 400,799 | 1,495,898 | Employee severance, litigation | |||||||||||||||||||||||||
Warrants | - | 3,761 | 35,815 | 50,479 | 90,055 | and other | 3,559 | 9,027 | 4,135 | 27,419 | 44,140 | ||||||||||||||||||||
Employee severance, | Operating income | $ | 283,403 | $ | 377,060 | $ | 324,386 | $ | 318,766 | $ | 1,303,615 | ||||||||||||||||||||
litigation and other | 2,004 | -299 | 19,678 | 2,084 | 23,467 | Income from continuing operations | $ | 161,592 | $ | 219,143 | $ | 190,177 | $ | 190,449 | $ | 761,361 | |||||||||||||||
Operating income | $ | 299,440 | $ | 350,123 | $ | 134,646 | $ | 114,190 | $ | 898,399 | Income (loss) from discontinued | ||||||||||||||||||||
Income from continuing operations | $ | 174,621 | $ | 204,143 | $ | 64,110 | $ | 50,561 | $ | 493,435 | operations, net of tax (b) | 524 | -7,038 | -8,906 | -26,955 | -42,375 | |||||||||||||||
(Loss) income from discontinued | Net income | $ | 162,116 | $ | 212,105 | $ | 181,271 | $ | 163,494 | $ | 718,986 | ||||||||||||||||||||
operations, net of tax (b) | -6,010 | -158,509 | 104,329 | 462 | -59,728 | Earnings per share from continuing | |||||||||||||||||||||||||
Net income | $ | 168,611 | $ | 45,634 | $ | 168,439 | $ | 51,023 | $ | 433,707 | operations: | ||||||||||||||||||||
Earnings per share from continuing | Basic | $ | 0.63 | $ | 0.85 | $ | 0.75 | $ | 0.78 | $ | 3.01 | ||||||||||||||||||||
operations: | Diluted | $ | 0.61 | $ | 0.84 | $ | 0.74 | $ | 0.77 | $ | 2.96 | ||||||||||||||||||||
Basic | $ | 0.75 | $ | 0.89 | $ | 0.28 | $ | 0.22 | $ | 2.14 | Earnings per share: | ||||||||||||||||||||
Diluted | $ | 0.74 | $ | 0.87 | $ | 0.27 | $ | 0.22 | $ | 2.1 | Basic | $ | 0.63 | $ | 0.82 | $ | 0.72 | $ | 0.67 | $ | 2.84 | ||||||||||
Earnings per share: | Diluted | $ | 0.62 | $ | 0.81 | $ | 0.71 | $ | 0.66 | $ | 2.8 | ||||||||||||||||||||
Basic | $ | 0.73 | $ | 0.2 | $ | 0.73 | $ | 0.22 | $ | 1.88 | ____________ | ||||||||||||||||||||
Diluted | $ | 0.71 | $ | 0.19 | $ | 0.71 | $ | 0.22 | $ | 1.84 | |||||||||||||||||||||
____________ | |||||||||||||||||||||||||||||||
Schedule_II_Valuation_and_Qual1
Schedule II Valuation and Qualifying Accounts (Tables) | 12 Months Ended | |||||||||||||||
Sep. 30, 2013 | ||||||||||||||||
Valuation and Qualifying Accounts [Abstract] | ' | |||||||||||||||
Schedule of Valuation and Qualifying Accounts Tables [Text Block] | ' | |||||||||||||||
Additions | ||||||||||||||||
Balance at | Charged to | Charged to | Balance at | |||||||||||||
Beginning | Costs and | Other | Deductions- | End of | ||||||||||||
Description | of Period | Expenses (1) | Accounts (2) | Describe (3) | Period | |||||||||||
(In thousands) | ||||||||||||||||
Year Ended September 30, 2013 | ||||||||||||||||
Allowance for doubtful accounts | $ | 85,741 | $ | 20,118 | $ | - | $ | -23,479 | $ | 82,380 | ||||||
Year Ended September 30, 2012 | ||||||||||||||||
Allowance for doubtful accounts | $ | 88,833 | $ | 23,058 | $ | - | $ | -26,150 | $ | 85,741 | ||||||
Year Ended September 30, 2011 | ||||||||||||||||
Allowance for doubtful accounts | $ | 93,849 | $ | 37,878 | $ | 62 | $ | -42,956 | $ | 88,833 | ||||||
___________ | ||||||||||||||||
Summary_of_Significant_Account2
Summary of Significant Accounting Policies (Details) | 3 Months Ended | 12 Months Ended | 12 Months Ended | |||||||
Sep. 30, 2013 | Jun. 30, 2013 | Mar. 31, 2013 | Dec. 31, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2011 | Sep. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2013 | |
USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | CAD | Express Scripts Inc [Member] | Walgreen Co [Member] | |
Concentration Risk [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Trade Receivable Due From Single Customer As Percentage of Accounts Receivable | ' | ' | ' | ' | ' | ' | ' | ' | 13.00% | 32.00% |
Customer Revenue as Percentage of Total Revenue | ' | ' | ' | ' | ' | ' | ' | ' | 24.00% | ' |
Intangible asset impairments | ' | ' | ' | ' | $0 | $0 | $6,506,000 | ' | ' | ' |
Percentage Of LIFO Inventory | 83.00% | ' | ' | ' | 83.00% | 82.00% | ' | ' | ' | ' |
Excess Of Replacement Or Current Costs Over Stated LIFO Value | 533,700,000 | ' | ' | ' | 533,700,000 | 256,700,000 | ' | ' | ' | ' |
Inventory, LIFO Reserve, Period Charge | 154,000,000 | 122,100,000 | -200,000 | 1,100,000 | 277,000,000 | 700,000 | 34,700,000 | ' | ' | ' |
Accrual for Estimated Customer Sales Returns | 275,800,000 | ' | ' | ' | 275,800,000 | 252,500,000 | ' | ' | ' | ' |
Excess tax benefit from the exercise of stock options | ' | ' | ' | ' | 41,222,000 | 25,703,000 | 39,711,000 | ' | ' | ' |
Shipping Handling And Transportation Costs | ' | ' | ' | ' | 267,300,000 | 259,100,000 | 270,200,000 | ' | ' | ' |
Discontinued Operations Note Due from Buyer | ' | ' | ' | ' | ' | ' | ' | 50,000,000 | ' | ' |
Full Value of Warrants | $572,000,000 | ' | $242,400,000 | ' | $572,000,000 | ' | ' | ' | ' | ' |
Acquisitions_Details
Acquisitions (Details) (USD $) | 12 Months Ended | 1 Months Ended | |||
Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2011 | Nov. 30, 2011 | Apr. 30, 2012 | |
Theracom Llc [Member] | World Courier Inc [Member] | ||||
Business Acquisition Line Items | ' | ' | ' | ' | ' |
Cost of acquired companies, net of cash acquired | $0 | $775,670,000 | $45,380,000 | $257,200,000 | $518,000,000 |
Business Acquisition Purchase Price Allocation Goodwill | ' | ' | ' | 180,200,000 | 266,700,000 |
Business Acquisition Purchase Price Allocation Long Term Assets | ' | ' | ' | 68,800,000 | 250,000,000 |
Business Acquisition Purchase Price Allocation Trade Names | ' | ' | ' | 3,800,000 | 110,500,000 |
Business Acquisition Purchase Price Allocation Customer Relationships | ' | ' | ' | 57,100,000 | 130,500,000 |
Business Acquisition Purchase Price Allocation Software Technology | ' | ' | ' | 7,900,000 | 9,000,000 |
Acquired Trade Name Assets Weighted Average Useful Lives | ' | ' | ' | '5 years | ' |
Acquired Customer Relationship Intangible Assets Weighted Average Useful Lives | ' | ' | ' | '15 years | '16 years |
Acquired Software Technology Assets Weighted Average Useful Life | ' | ' | ' | '5 years | '5 years |
Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed Current Assets Receivables | ' | ' | ' | 119,300,000 | ' |
Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed Inventory | ' | ' | ' | 41,700,000 | ' |
Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed Current Liabilities Accounts Payable | ' | ' | ' | $153,200,000 | ' |
Business Acquisition Operational Statistics | ' | ' | ' | ' | 'It operates in over 50 countries and has approximately 2,400 employees |
Discontinued_Operations_Detail
Discontinued Operations (Details) | 12 Months Ended | 12 Months Ended | ||||
Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2011 | Sep. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2013 | |
USD ($) | USD ($) | USD ($) | AmerisourceBergen Canada Corporation [Member] | AmerisourceBergen Canada Corporation [Member] | AndersonBrecon [Member] | |
USD ($) | CAD | USD ($) | ||||
Discontinued Operations Details [Abstract] | ' | ' | ' | ' | ' | ' |
Disposal Group Including Discontinued Operation Revenue | $1,181,231,000 | $1,639,684,000 | $1,521,899,000 | ' | ' | ' |
Disposal Group Including Discontinued Operation Operating Income Loss | -50,090,000 | -37,534,000 | 12,652,000 | ' | ' | ' |
disposal group accounts receivable | ' | 187,179,000 | ' | ' | ' | ' |
disposal group inventory | ' | 249,463,000 | ' | ' | ' | ' |
disposal group property plant and equipment | ' | 131,907,000 | ' | ' | ' | ' |
Disposal Group Goodwill and Other Intangible Assets | ' | 85,163,000 | ' | ' | ' | ' |
disposal group other assets | ' | 9,141,000 | ' | ' | ' | ' |
Assets of Disposal Group | ' | 662,853,000 | ' | ' | ' | ' |
disposal group accounts payable | ' | 152,110,000 | ' | ' | ' | ' |
disposal group accrued liabilities | ' | 16,554,000 | ' | ' | ' | ' |
disposal group other liabilities | ' | 71,042,000 | ' | ' | ' | ' |
Liabilities of Disposal Group | ' | 239,706,000 | ' | ' | ' | ' |
Disposal Group Net Assets | ' | 423,147,000 | ' | ' | ' | ' |
Income Statement, Balance Sheet and Additional Disclosures by Disposal Group Including Discontinued Operations [Line Items] | ' | ' | ' | ' | ' | ' |
Discontinued Operation Gain Loss From Disposal Of Discontinued Operation Before Income Tax | ' | ' | ' | -143,700,000 | ' | 114,100,000 |
Goodwill, Impairment Loss | ' | ' | 3,000,000 | 26,900,000 | ' | ' |
proceeds from sales of business | ' | ' | ' | 67,900,000 | ' | 306,500,000 |
Discontinued Operations Note Due from Buyer | ' | ' | ' | ' | 50,000,000 | ' |
Discontinued Operations Annual Interest Rate on Note Due from Buyer | ' | ' | ' | ' | 3.00% | ' |
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment Realized Upon Sale or Liquidation, Net of Tax | $9,300,000 | ' | ' | ' | ' | ' |
Income_Taxes_Details
Income Taxes (Details) (USD $) | 3 Months Ended | 12 Months Ended | ||||||||||
Sep. 30, 2013 | Jun. 30, 2013 | Mar. 31, 2013 | Dec. 31, 2012 | Sep. 30, 2012 | Jun. 30, 2012 | Mar. 31, 2012 | Dec. 31, 2011 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2011 | Apr. 30, 2012 | |
Income Taxes Details [Abstract] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
incomelossfromcontinuingoperationsbeforeincometaxesdomestic | ' | ' | ' | ' | ' | ' | ' | ' | $793,137,000 | $1,193,047,000 | $1,105,481,000 | ' |
incomelossfromcontinuingoperationsbeforeincometaxesforeign | ' | ' | ' | ' | ' | ' | ' | ' | 31,321,000 | 23,826,000 | 12,508,000 | ' |
Income from continuing operations before income taxes | 96,725,000 | 115,931,000 | 330,864,000 | 280,938,000 | 296,539,000 | 305,400,000 | 353,816,000 | 261,118,000 | 824,458,000 | 1,216,873,000 | 1,117,989,000 | ' |
Current Income Tax Expense Benefit Continuing Operations Abstract | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Current Federal Tax Expense Benefit | ' | ' | ' | ' | ' | ' | ' | ' | 259,457,000 | 356,843,000 | 194,816,000 | ' |
Current State And Local Tax Expense Benefit | ' | ' | ' | ' | ' | ' | ' | ' | 37,602,000 | 32,438,000 | 26,527,000 | ' |
Current Foreign Tax Expense Benefit | ' | ' | ' | ' | ' | ' | ' | ' | 8,391,000 | 4,953,000 | 4,354,000 | ' |
Current Income Tax Expense Benefit | ' | ' | ' | ' | ' | ' | ' | ' | 305,450,000 | 394,234,000 | 225,697,000 | ' |
Deferred Income Tax Expense Benefit Continuing Operations Abstract | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Deferred Federal Income Tax Expense Benefit | ' | ' | ' | ' | ' | ' | ' | ' | 29,189,000 | 47,348,000 | 174,412,000 | ' |
Deferred State And Local Income Tax Expense Benefit | ' | ' | ' | ' | ' | ' | ' | ' | -3,375,000 | 11,959,000 | 20,462,000 | ' |
Deferred Foreign Income Tax Expense Benefit | ' | ' | ' | ' | ' | ' | ' | ' | -241,000 | 1,971,000 | -77,000 | ' |
Provision for deferred income taxes | ' | ' | ' | ' | ' | ' | ' | ' | 25,573,000 | 61,278,000 | 194,797,000 | ' |
Income taxes | 46,164,000 | 51,821,000 | 126,721,000 | 106,317,000 | 106,090,000 | 115,223,000 | 134,673,000 | 99,526,000 | 331,023,000 | 455,512,000 | 420,494,000 | ' |
Effective Income Tax Rate Continuing Operations Tax Rate Reconciliation Abstract | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate | ' | ' | ' | ' | ' | ' | ' | ' | 35.00% | 35.00% | 35.00% | ' |
Effective Income Tax Rate Reconciliation State And Local Income Taxes | ' | ' | ' | ' | ' | ' | ' | ' | 3.00% | 2.30% | 1.70% | ' |
Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential | ' | ' | ' | ' | ' | ' | ' | ' | -0.30% | -0.10% | 0.00% | ' |
Effective Income Tax Rate Reconcilation Warrants | ' | ' | ' | ' | ' | ' | ' | ' | 2.30% | 0.00% | 0.00% | ' |
Effective Income Tax Rate Reconciliation Other Adjustments | ' | ' | ' | ' | ' | ' | ' | ' | 0.20% | 0.20% | 0.90% | ' |
Effective Income Tax Rate Continuing Operations | ' | ' | ' | ' | ' | ' | ' | ' | 40.20% | 37.40% | 37.60% | ' |
Full Value of Warrants | 572,000,000 | ' | 242,400,000 | ' | ' | ' | ' | ' | 572,000,000 | ' | ' | ' |
Components Of Deferred Tax Assets And Liabilities Abstract | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
deferred tax liabilities deferred expense capitalized inventory costs | 1,016,522,000 | ' | ' | ' | 985,571,000 | ' | ' | ' | 1,016,522,000 | 985,571,000 | ' | ' |
Deferred Tax Liabilities Property Plant And Equipment | 128,289,000 | ' | ' | ' | 132,732,000 | ' | ' | ' | 128,289,000 | 132,732,000 | ' | ' |
Deferred Tax Liabilities Goodwill And Intangible Assets | 260,357,000 | ' | ' | ' | 249,913,000 | ' | ' | ' | 260,357,000 | 249,913,000 | ' | ' |
Deferred Tax Liabilities Other | 1,322,000 | ' | ' | ' | 705,000 | ' | ' | ' | 1,322,000 | 705,000 | ' | ' |
Deferred Tax Liabilities | 1,406,490,000 | ' | ' | ' | 1,368,921,000 | ' | ' | ' | 1,406,490,000 | 1,368,921,000 | ' | ' |
deferred tax assets operating loss carryforwards | -61,726,000 | ' | ' | ' | -59,994,000 | ' | ' | ' | -61,726,000 | -59,994,000 | ' | ' |
Deferred Tax Assets Capital Loss Carryforwards | -297,806,000 | ' | ' | ' | -230,395,000 | ' | ' | ' | -297,806,000 | -230,395,000 | ' | ' |
Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts | -30,073,000 | ' | ' | ' | -30,856,000 | ' | ' | ' | -30,073,000 | -30,856,000 | ' | ' |
Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities | -16,731,000 | ' | ' | ' | -9,651,000 | ' | ' | ' | -16,731,000 | -9,651,000 | ' | ' |
Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Other | -4,884,000 | ' | ' | ' | -17,392,000 | ' | ' | ' | -4,884,000 | -17,392,000 | ' | ' |
Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost | -29,356,000 | ' | ' | ' | -28,197,000 | ' | ' | ' | -29,356,000 | -28,197,000 | ' | ' |
Deferred Tax Assets Other | -66,537,000 | ' | ' | ' | -57,596,000 | ' | ' | ' | -66,537,000 | -57,596,000 | ' | ' |
Deferred Tax Assets Gross | -507,113,000 | ' | ' | ' | -434,081,000 | ' | ' | ' | -507,113,000 | -434,081,000 | ' | ' |
Deferred Tax Assets Valuation Allowance | 327,546,000 | ' | ' | ' | 254,182,000 | ' | ' | ' | 327,546,000 | 254,182,000 | ' | ' |
Deferred Tax Assets Net | 179,567,000 | ' | ' | ' | 179,899,000 | ' | ' | ' | 179,567,000 | 179,899,000 | ' | ' |
Deferred Tax Assets Liabilities Net | 1,226,923,000 | ' | ' | ' | 1,189,022,000 | ' | ' | ' | 1,226,923,000 | 1,189,022,000 | ' | ' |
Potentaial Tax Benefits From Federal Net Operating Loss Carryforwards | 14,500,000 | ' | ' | ' | ' | ' | ' | ' | 14,500,000 | ' | ' | ' |
Potential Tax Benefits From State Net Operating Loss Carryforwards | 59,800,000 | ' | ' | ' | ' | ' | ' | ' | 59,800,000 | ' | ' | ' |
Potential Tax Benefits From Foreign Net Operating Loss Carryforwards | 6,400,000 | ' | ' | ' | ' | ' | ' | ' | 6,400,000 | ' | ' | ' |
Potential Tax Benefits That Would Be Recorded As Paid In Capital | 9,300,000 | ' | ' | ' | ' | ' | ' | ' | 9,300,000 | ' | ' | ' |
Potential Tax Benefits From Capital Loss Carryforwards | 297,800,000 | ' | ' | ' | ' | ' | ' | ' | 297,800,000 | ' | ' | ' |
Foreign Tax Credit Carryforward | 5,900,000 | ' | ' | ' | ' | ' | ' | ' | 5,900,000 | ' | ' | ' |
State Tax Credit Carryforwards | 1,400,000 | ' | ' | ' | ' | ' | ' | ' | 1,400,000 | ' | ' | ' |
Acquired Net Operating Loss Carryforwards | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 78,000,000 |
Increase Decrease in Valuation Allowance on Deferred Tax Assets | ' | ' | ' | ' | ' | ' | ' | ' | 73,400,000 | 4,300,000 | ' | ' |
Excess tax benefit from the exercise of stock options | ' | ' | ' | ' | ' | ' | ' | ' | 41,222,000 | 25,703,000 | 39,711,000 | ' |
Income Taxes Paid Net | ' | ' | ' | ' | ' | ' | ' | ' | 313,700,000 | 302,100,000 | 214,600,000 | ' |
Unrecognized Tax Benefits Including Federal Benefit | 55,400,000 | ' | ' | ' | 43,300,000 | ' | ' | ' | 55,400,000 | 43,300,000 | ' | ' |
Unrecognized Tax Benefits That Would Impact Effective Tax Rate | 39,100,000 | ' | ' | ' | 30,100,000 | ' | ' | ' | 39,100,000 | 30,100,000 | ' | ' |
Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued | 9,100,000 | ' | ' | ' | 6,300,000 | ' | ' | ' | 9,100,000 | 6,300,000 | ' | ' |
Unrecognized Tax Benefits Schedule [Abstract] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Unrecognized Tax Benefits Beginning of Period | ' | ' | ' | 36,990,000 | ' | ' | ' | 35,803,000 | 36,990,000 | 35,803,000 | 36,830,000 | ' |
Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions | ' | ' | ' | ' | ' | ' | ' | ' | 5,272,000 | 6,094,000 | 5,866,000 | ' |
Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions | ' | ' | ' | ' | ' | ' | ' | ' | 2,825,000 | 1,045,000 | 3,592,000 | ' |
unrecognized tax benefits increase from acquisition | ' | ' | ' | ' | ' | ' | ' | ' | 2,500,000 | 2,748,000 | ' | ' |
Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions | ' | ' | ' | ' | ' | ' | ' | ' | ' | -5,177,000 | -386,000 | ' |
Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities | ' | ' | ' | ' | ' | ' | ' | ' | -519,000 | -2,286,000 | -7,136,000 | ' |
Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations | ' | ' | ' | ' | ' | ' | ' | ' | -801,000 | -1,237,000 | -2,963,000 | ' |
Unrecognized Tax Benefits End of Period | 46,267,000 | ' | ' | ' | 36,990,000 | ' | ' | ' | 46,267,000 | 36,990,000 | 35,803,000 | ' |
Significant Change In Unrecognized Tax Benefits Is Reasonably Possible Amount Of Unrecorded Benefit | 8,200,000 | ' | ' | ' | ' | ' | ' | ' | 8,200,000 | ' | ' | ' |
undistributed earnings of foreign subsidiaries | $125,600,000 | ' | ' | ' | ' | ' | ' | ' | $125,600,000 | ' | ' | ' |
Goodwill_and_Other_Intangible_2
Goodwill and Other Intangible Assets (Details) (USD $) | 3 Months Ended | 12 Months Ended | |||||||||
Sep. 30, 2013 | Jun. 30, 2013 | Mar. 31, 2013 | Dec. 31, 2012 | Sep. 30, 2012 | Jun. 30, 2012 | Mar. 31, 2012 | Dec. 31, 2011 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2011 | |
goodwill | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Goodwill | ' | ' | ' | $2,942,984,000 | ' | ' | ' | $2,497,162,000 | $2,942,984,000 | $2,497,162,000 | ' |
Goodwill Acquired During Period | ' | ' | ' | ' | ' | ' | ' | ' | 3,000,000 | 444,420,000 | ' |
Goodwill, Translation Adjustments | ' | ' | ' | ' | ' | ' | ' | ' | -1,014,000 | 1,402,000 | ' |
Goodwill | 2,944,970,000 | ' | ' | ' | 2,942,984,000 | ' | ' | ' | 2,944,970,000 | 2,942,984,000 | 2,497,162,000 |
Indefinite Lived Intangible Assets Excluding Goodwill | 343,892,000 | ' | ' | ' | 344,004,000 | ' | ' | ' | 343,892,000 | 344,004,000 | ' |
Finite Lived Intangible Assets Line Items | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
intangible assets gross excluding goodwill | 679,052,000 | ' | ' | ' | 677,881,000 | ' | ' | ' | 679,052,000 | 677,881,000 | ' |
Intangible Assets Accumulated Amortization Excluding Goodwill | -124,309,000 | ' | ' | ' | -97,433,000 | ' | ' | ' | -124,309,000 | -97,433,000 | ' |
Intangible Assets Net Excluding Goodwill | 554,743,000 | ' | ' | ' | 580,448,000 | ' | ' | ' | 554,743,000 | 580,448,000 | ' |
Amortization | 6,786,000 | 6,743,000 | 6,799,000 | 6,811,000 | 6,944,000 | 5,981,000 | 4,630,000 | 3,992,000 | 27,139,000 | 21,547,000 | 12,602,000 |
Future Amortization Expense Year One | 25,600,000 | ' | ' | ' | ' | ' | ' | ' | 25,600,000 | ' | ' |
Future Amortization Expense Year Two | 21,700,000 | ' | ' | ' | ' | ' | ' | ' | 21,700,000 | ' | ' |
Future Amortization Expense Year Three | 20,800,000 | ' | ' | ' | ' | ' | ' | ' | 20,800,000 | ' | ' |
Future Amortization Expense Year Four | 17,000,000 | ' | ' | ' | ' | ' | ' | ' | 17,000,000 | ' | ' |
Future Amortization Expense Year Five | 14,800,000 | ' | ' | ' | ' | ' | ' | ' | 14,800,000 | ' | ' |
Future Amortization Expense, after Year Five | 111,000,000 | ' | ' | ' | ' | ' | ' | ' | 111,000,000 | ' | ' |
Impaired Intangible Assets Other Than Goodwill [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Intangible asset impairments | ' | ' | ' | ' | ' | ' | ' | ' | 0 | 0 | 6,506,000 |
Goodwill, Impairment Loss | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 3,000,000 |
Customer Relationships Impaired [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Impaired Intangible Assets Other Than Goodwill [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Intangible asset impairments | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 3,500,000 |
Customer Relationships Member | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Finite Lived Intangible Assets Line Items | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Finite Lived Intangible Assets Gross | 265,810,000 | ' | ' | ' | 265,981,000 | ' | ' | ' | 265,810,000 | 265,981,000 | ' |
Finite Lived Intangible Assets Accumulated Amortization | -80,767,000 | ' | ' | ' | -61,865,000 | ' | ' | ' | -80,767,000 | -61,865,000 | ' |
Finite Lived Intangible Assets Net | 185,043,000 | ' | ' | ' | 204,116,000 | ' | ' | ' | 185,043,000 | 204,116,000 | ' |
Other Finite Lived Intangibles [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Finite Lived Intangible Assets Line Items | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Finite Lived Intangible Assets Gross | 69,350,000 | ' | ' | ' | 67,896,000 | ' | ' | ' | 69,350,000 | 67,896,000 | ' |
Finite Lived Intangible Assets Accumulated Amortization | -43,542,000 | ' | ' | ' | -35,568,000 | ' | ' | ' | -43,542,000 | -35,568,000 | ' |
Finite Lived Intangible Assets Net | 25,808,000 | ' | ' | ' | 32,328,000 | ' | ' | ' | 25,808,000 | 32,328,000 | ' |
Pharmaceutical Distribution [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
goodwill | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Goodwill | ' | ' | ' | 2,422,975,000 | ' | ' | ' | 2,421,707,000 | 2,422,975,000 | 2,421,707,000 | ' |
Goodwill Acquired During Period | ' | ' | ' | ' | ' | ' | ' | ' | 0 | -134,000 | ' |
Goodwill, Translation Adjustments | ' | ' | ' | ' | ' | ' | ' | ' | -1,014,000 | 1,402,000 | ' |
Goodwill | 2,421,961,000 | ' | ' | ' | 2,422,975,000 | ' | ' | ' | 2,421,961,000 | 2,422,975,000 | ' |
Other Segment [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
goodwill | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Goodwill | ' | ' | ' | 520,009,000 | ' | ' | ' | 75,455,000 | 520,009,000 | 75,455,000 | ' |
Goodwill Acquired During Period | ' | ' | ' | ' | ' | ' | ' | ' | 3,000,000 | 444,554,000 | ' |
Goodwill, Translation Adjustments | ' | ' | ' | ' | ' | ' | ' | ' | 0 | 0 | ' |
Goodwill | $523,009,000 | ' | ' | ' | $520,009,000 | ' | ' | ' | $523,009,000 | $520,009,000 | ' |
Debt_Details
Debt (Details) (USD $) | 12 Months Ended | ||
Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2011 | |
Debt Instrument Line Items | ' | ' | ' |
Long Term Debt | $1,396,606,000 | $1,395,931,000 | ' |
Long Term Debt Maturities Repayments Of Principal In Year Two | 500,000,000 | ' | ' |
Long Term Debt Maturities Repayments Of Principal After Year Five | 900,000,000 | ' | ' |
Interest Paid | 68,500,000 | 84,500,000 | 74,200,000 |
Debt Related Commitment Fees And Debt Issuance Costs | 4,200,000 | 5,200,000 | 4,700,000 |
Receivables Securitization Facility [Member] | ' | ' | ' |
Debt Instrument Line Items | ' | ' | ' |
Long Term Debt | 0 | 0 | ' |
Debt Instrument Interest Rate Effective Percentage Rate Range | 'prevailing market rates for short-term commercial paper or LIBOR plus a program fee of 75 basis points | ' | ' |
Debt Instrument Fee Rate Effective Percentage Rate Range | '40 basis points, annually | ' | ' |
Debt Instrument Ability to Increase Commitment Subject to Lender Approval | 250,000,000 | ' | ' |
Line of Credit Facility Maximum Borrowing Capacity | 950,000,000 | ' | ' |
Multi Currency Revolving Credit Facility [Member] | ' | ' | ' |
Debt Instrument Line Items | ' | ' | ' |
Long Term Debt | 0 | 0 | ' |
Debt Interest Rate at Period End | '90 basis points over LIBOR/EURIBOR/Bankers Acceptance Stamping Fee | ' | ' |
Debt Instrument Interest Rate Effective Percentage Rate Range | '68 basis points to 130 basis points over LIBOR/EURIBOR/Bankers Acceptance Stamping Fee; on borrowings denominated in Canadian dollars, the greater of the Canadian prime rate or the CDOR rate | ' | ' |
Debt Instrument Fee Rate Effective Percentage Rate Range | '7 basis points to 20 basis points, annually, of the total commitment | ' | ' |
Debt Instrument Fee Rate at Period End | '10 basis points | ' | ' |
Line of Credit Facility Maximum Borrowing Capacity | 1,400,000,000 | ' | ' |
Revolving Credit Note [Member] | ' | ' | ' |
Debt Instrument Line Items | ' | ' | ' |
Long Term Debt | 0 | 0 | ' |
Line of Credit Facility Maximum Borrowing Capacity | 45,000,000 | ' | ' |
Senior Notes Due 2015 [Member] | ' | ' | ' |
Debt Instrument Line Items | ' | ' | ' |
Long Term Debt | 499,377,000 | 499,091,000 | ' |
Long Term Debt Principal Balance | 500,000,000 | ' | ' |
Debt Instrument Issuance Discount Percentage | 99.50% | ' | ' |
Debt Instrument Effective Yield Percentage | 5.94% | ' | ' |
Senior Notes Due 2019 [Member] | ' | ' | ' |
Debt Instrument Line Items | ' | ' | ' |
Long Term Debt | 397,803,000 | 397,485,000 | ' |
Long Term Debt Principal Balance | 400,000,000 | ' | ' |
Debt Instrument Issuance Discount Percentage | 99.20% | ' | ' |
Debt Instrument Effective Yield Percentage | 4.98% | ' | ' |
Senior Notes Due 2021 [Member] | ' | ' | ' |
Debt Instrument Line Items | ' | ' | ' |
Long Term Debt | 499,426,000 | 499,355,000 | ' |
Long Term Debt Principal Balance | $500,000,000 | ' | ' |
Debt Instrument Issuance Discount Percentage | 99.86% | ' | ' |
Debt Instrument Effective Yield Percentage | 3.52% | ' | ' |
Stockholders_Equity_and_Earnin2
Stockholders Equity and Earnings per Share (Details) (USD $) | 1 Months Ended | 12 Months Ended | 12 Months Ended | 1 Months Ended | 12 Months Ended | 1 Months Ended | 12 Months Ended | 1 Months Ended | 12 Months Ended | 1 Months Ended | 12 Months Ended | 1 Months Ended | 12 Months Ended | 1 Months Ended | |||||||||||||||
Nov. 30, 2012 | Oct. 31, 2012 | Aug. 31, 2012 | Dec. 31, 2011 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2011 | Mar. 31, 2013 | Sep. 30, 2013 | Sep. 30, 2013 | Mar. 31, 2013 | Mar. 31, 2013 | Mar. 31, 2013 | Mar. 31, 2013 | Nov. 30, 2009 | Sep. 30, 2011 | Sep. 30, 2010 | Sep. 30, 2010 | Sep. 30, 2011 | Aug. 31, 2011 | Sep. 30, 2012 | Sep. 30, 2011 | Nov. 30, 2012 | 31-May-12 | Sep. 30, 2013 | Sep. 30, 2012 | Nov. 30, 2012 | Sep. 30, 2013 | Aug. 31, 2013 | |
First Group of Tranches [Member] | Second Group of Tranches [Member] | Walgreens Warrant 1 [Member] | Walgreens Warrant 2 [Member] | Alliance Boots Warrant 1 [Member] | Alliance Boots Warrant 2 [Member] | November 2009 Share Repurchase Program [Member] | November 2009 Share Repurchase Program [Member] | November 2009 Share Repurchase Program [Member] | September 2010 Share Repurchase Program [Member] | September 2010 Share Repurchase Program [Member] | August 2011 Share Repurchase Program [Member] | August 2011 Share Repurchase Program [Member] | August 2011 Share Repurchase Program [Member] | May 2012 Share Repurchase Program [Member] | May 2012 Share Repurchase Program [Member] | May 2012 Share Repurchase Program [Member] | May 2012 Share Repurchase Program [Member] | November 2012 Share Repurchase Program [Member] | November 2012 Share Repurchase Program [Member] | August 2013 Share Repurchase Program [Member] | |||||||||
Stockholders Equity and Earnings Per Share Details [Abstract] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Common stock, shares authorized | ' | ' | ' | ' | 600,000,000 | 600,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Common stock, par value | ' | ' | ' | ' | $0.01 | $0.01 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Preferred Stock Shares Authorized | ' | ' | ' | ' | 10,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Preferred Stock Par Or Stated Value Per Share | ' | ' | ' | ' | $0.01 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Accumulated Other Comprehensive Income Loss Defined Benefit Pension And Other Postretirement Plans Net Of Tax | ' | ' | ' | ' | ($34,612,000) | ($45,828,000) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax | ' | ' | ' | ' | -844,000 | 13,337,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Accumulated Other Comprehensive Income Loss Other Net of Tax | ' | ' | ' | ' | -27,000 | -166,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Accumulated other comprehensive loss | ' | ' | ' | ' | -35,483,000 | -32,657,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Treasury Stock Program [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Stock Repurchase Program, Authorized Amount | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 500,000,000 | ' | ' | 500,000,000 | ' | 750,000,000 | ' | ' | ' | 750,000,000 | ' | ' | 750,000,000 | ' | 750,000,000 |
Treasury Stock Acquired Shares | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 3,200,000 | 14,400,000 | ' | 13,300,000 | ' | 13,400,000 | 6,600,000 | ' | ' | 600,000 | 200,000 | ' | 3,600,000 | ' |
Purchases of common stock | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 98,100,000 | 401,900,000 | ' | 500,000,000 | ' | 500,000,000 | 250,000,000 | ' | ' | 25,700,000 | 5,900,000 | ' | 199,400,000 | ' |
Treasury Stock Purchase Program Availability | ' | ' | ' | ' | 1,113,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 363,000,000 | ' |
treasury stock shares retired | ' | ' | ' | 238,800,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Accelerated Share Repurchase Program Authorized Amount | 250,000,000 | ' | 650,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Accelerated Stock Repurchase Program Initial Delivery of Shares | 6,200,000 | ' | 16,800,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1,700,000 | ' | ' | ' | 4,500,000 | ' | ' |
Accelerated Share Repurchase Program Initial Funding Allocated to Share Purchases | 248,500,000 | ' | 647,200,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 71,200,000 | ' | ' | ' | 187,600,000 | ' | ' |
Accelerated Share Repurchase Program Initial Funding Allocated to Prepaid Dividends | 1,300,000 | ' | 2,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Accelerated Share Repurchase Program Initial Funding Allocated to Fees | 200,000 | ' | 800,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Accelerated Share Repurchase Program Incremental Shares Received Upon Settlement | ' | 100,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Basic | ' | ' | ' | ' | 231,067,000 | 252,906,000 | 272,471,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Incremental Common Shares Attributable To Share Based Payment Arrangements | ' | ' | ' | ' | 4,278,000 | 3,997,000 | 5,246,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Diluted | ' | ' | ' | ' | 235,345,000 | 256,903,000 | 277,717,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount | ' | ' | ' | ' | 0 | 2,100,000 | 2,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Class of Warrant or Right [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Class of Warrant or Right, Date from which Warrants or Rights are Exercisable | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1-Mar-16 | 1-Mar-17 | 1-Mar-16 | 1-Mar-17 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 11,348,456 | 11,348,456 | 11,348,456 | 11,348,456 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Class of Warrant or Right, Exercise Price of Warrants or Rights | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $51.50 | $52.50 | $51.50 | $52.50 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Shares to Which Framework Agreement Allows Open Market Purchases | ' | ' | ' | ' | ' | ' | ' | 19,859,795 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Percentage of Common Stock Purchases in Open Market Granted under Framework Agreement | ' | ' | ' | ' | ' | ' | ' | 7.00% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Fair Value per Share of First Tranche of Warrants | ' | ' | ' | ' | $12.30 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Fair Value per Share of Second Tranche of Warrants | ' | ' | ' | ' | $12.90 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Full Value of Warrants | ' | ' | ' | ' | 572,000,000 | ' | ' | 242,400,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Forward Contract Indexed to Issuer's Equity [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Forward Contract Indexed to Issuer's Equity, Forward Rate | ' | ' | ' | ' | ' | ' | ' | ' | $51.50 | $52.50 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Derivative, Cost of Hedge | ' | ' | ' | ' | $163,400,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Percentage of Warrant Dilution Intended to be Hedged with Contract | ' | ' | ' | ' | 60.00% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Shares Covered Under Derivative Purchases | ' | ' | ' | ' | 15,300,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Pension_and_Other_Benefit_Plan2
Pension and Other Benefit Plans (Details) (USD $) | 12 Months Ended | |||
Share data in Millions, unless otherwise specified | Sep. 30, 2014 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2011 |
Pension and Other Benefit Plans Details [Abstract] | ' | ' | ' | ' |
Pension and Other Postretirement Benefit Expense | ' | $22,100,000 | $20,300,000 | $19,300,000 |
Retirement Benefit Plans Net Actuarial Loss Included in Accumulated Other Comprehensive Income Gross | ' | 59,300,000 | ' | ' |
Retirement Benefit Plans Net Actuarial Loss Included in Accumulated Other Comprehensive Loss Net of Tax | ' | 34,600,000 | ' | ' |
Retirement Benefit Plans Net Actuarial Loss Expected Amortization Gross | ' | 3,600,000 | ' | ' |
Retirement Benefit Plans Expected Net Actuarial Loss Amortization Net of Tax | ' | 2,100,000 | ' | ' |
Defined Contribution Pension And Other Postretirement Plans Disclosure Abstract | ' | ' | ' | ' |
Defined Contribution Plan Cost Recognized | ' | 17,400,000 | 16,400,000 | 15,400,000 |
Deferred Compensation Arrangements Abstract | ' | ' | ' | ' |
Deferred Compensation Arrangement with Individual, Shares Authorized for Issuance | ' | 2.96 | ' | ' |
Deferred Compensation Arrangement With Individual Recorded Liability | ' | 13,300,000 | 10,500,000 | ' |
equity securities | ' | ' | ' | ' |
defined benefit plan | ' | ' | ' | ' |
Defined Benefit Plan Weighted Average Asset Allocations | ' | 42.00% | 42.00% | ' |
Defined Benefit Plan Assets Target Allocations Abstract | ' | ' | ' | ' |
Definited Benefit Plan Target Plan Asset Allocations | ' | 41.00% | 41.00% | ' |
debt securities | ' | ' | ' | ' |
defined benefit plan | ' | ' | ' | ' |
Defined Benefit Plan Weighted Average Asset Allocations | ' | 57.00% | 57.00% | ' |
Defined Benefit Plan Assets Target Allocations Abstract | ' | ' | ' | ' |
Definited Benefit Plan Target Plan Asset Allocations | ' | 58.00% | 58.00% | ' |
cash and cash equivalents | ' | ' | ' | ' |
defined benefit plan | ' | ' | ' | ' |
Defined Benefit Plan Weighted Average Asset Allocations | ' | 1.00% | 1.00% | ' |
Defined Benefit Plan Assets Target Allocations Abstract | ' | ' | ' | ' |
Definited Benefit Plan Target Plan Asset Allocations | ' | 1.00% | 1.00% | ' |
Pension Plans Defined Benefit Member | ' | ' | ' | ' |
Change in Benefit Obligation [Abstract] | ' | ' | ' | ' |
Benefit obligation at beginning of year | 149,404,000 | 166,244,000 | 154,887,000 | ' |
Defined Benefit Plan Interest Cost | ' | 6,104,000 | 6,560,000 | ' |
Defined Benefit Plan Actuarial Net Gains Losses | ' | -15,560,000 | 17,942,000 | ' |
Defined Benefit Plan Benefits Paid | ' | -7,384,000 | -13,134,000 | ' |
Defined Benefit Plan Changes Other | ' | 0 | -11,000 | ' |
Benefit obligation at end of year | ' | 149,404,000 | 166,244,000 | 154,887,000 |
Change in Plan Assets [Abstract] | ' | ' | ' | ' |
Fair value of plan assets at beginning of year | 159,966,000 | 158,391,000 | 122,242,000 | ' |
Defined Benefit Plan Actual Return On Plan Assets | ' | 8,005,000 | 26,775,000 | ' |
Defined Benefit Plan Contributions By Employer | ' | 2,173,000 | 23,444,000 | ' |
Defined Benefit Plan Expenses | ' | -1,219,000 | -936,000 | ' |
Benefit Plan Asset Rollforward Benefits Paid | ' | -7,384,000 | -13,134,000 | ' |
Fair value of plan assets at end of year | ' | 159,966,000 | 158,391,000 | 122,242,000 |
Defined Benefit Plan Funded Status Of Plan Abstract | ' | ' | ' | ' |
Defined Benefit Plan Funded Status Of Plan | ' | 10,562,000 | -7,853,000 | ' |
Defined Benefit Plan Amounts Recognized In Balance Sheet | ' | 10,562,000 | -7,853,000 | ' |
defined benefit plan assets for plan benefits noncurrent | ' | 16,563,000 | 0 | ' |
Pension And Other Postretirement Defined Benefit Plans Current Liabilities | ' | -2,826,000 | -4,456,000 | ' |
Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent | ' | -3,175,000 | -3,397,000 | ' |
Defined Benefit Plan Weighted Average Assumptions Used In Calculating Benefit Obligation Abstract | ' | ' | ' | ' |
Defined Benefit Plan Assumptions Used Calculating Benefit Obligation Discount Rate | ' | 4.65% | 3.70% | ' |
Defined Benefit Plan Rate of Increase in Compensation Levels String | ' | 'N/A | 'N/A | ' |
Defined Benefit Plan Net Periodic Benefit Cost Abstract | ' | ' | ' | ' |
Net Periodic Benefit Interest Cost | ' | 6,104,000 | 6,560,000 | 7,036,000 |
Defined Benefit Plan Expected Return On Plan Assets | ' | -9,955,000 | -10,475,000 | -9,289,000 |
Defined Benefit Plan Amortization Of Gains Losses | ' | 5,963,000 | 4,758,000 | 4,768,000 |
Defined Benefit Plan Recognized Net Gain Loss Due To Settlements And Curtailments | ' | 985,000 | 1,518,000 | 828,000 |
Defined Benefit Plan Net Periodic Benefit Cost | ' | 3,097,000 | 2,361,000 | 3,343,000 |
Net Pension Cost of Multi Employer Plans | ' | 156,000 | 294,000 | 340,000 |
Total Pension Expense | ' | 3,253,000 | 2,655,000 | 3,683,000 |
Defined Benefit Plan Weighted Average Assumptions Used In Calculating Net Periodic Benefit Cost Abstract | ' | ' | ' | ' |
Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Discount Rate | ' | 3.70% | 4.60% | 5.00% |
Net Periodic Benefit Cost Compensation Increase Level String | ' | 'N/A | 'N/A | 'N/A |
Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Expected Long Term Return On Assets | 5.75% | 6.75% | 8.00% | 8.00% |
defined benefit plan | ' | ' | ' | ' |
Defined Benefit Plan Weighted Average Asset Allocations | ' | 100.00% | 100.00% | ' |
Defined Benefit Plan Assets Target Allocations Abstract | ' | ' | ' | ' |
Definited Benefit Plan Target Plan Asset Allocations | ' | 100.00% | 100.00% | ' |
Pension Plan Assets Money Market Funds | ' | 1,500,000 | 900,000 | ' |
Pension Plan Assets Commingled Equity Funds | ' | 66,800,000 | 66,400,000 | ' |
Pension Plan Assets Commingled Fixed Income Funds | ' | 91,700,000 | 91,100,000 | ' |
Pension Plan Voluntary Contribution | ' | 0 | 15,000,000 | ' |
Defined Benefit Plan Estimated Future Benefit Payments Abstract | ' | ' | ' | ' |
Defined Benefit Plan Expected Future Benefit Payments In Year One | ' | 9,071,000 | ' | ' |
Defined Benefit Plan Expected Future Benefit Payments In Year Two | ' | 6,794,000 | ' | ' |
Defined Benefit Plan Expected Future Benefit Payments In Year Three | ' | 7,548,000 | ' | ' |
Defined Benefit Plan Expected Future Benefit Payments In Year Four | ' | 7,897,000 | ' | ' |
Defined Benefit Plan Expected Future Benefit Payments In Year Five | ' | 7,514,000 | ' | ' |
Defined Benefit Plan Expected Future Benefit Payments In Five Fiscal Years Thereafter | ' | 42,582,000 | ' | ' |
Pension Plan Contribution Ten Year Total | ' | 81,406,000 | ' | ' |
Other Postretirement Benefit Plans Defined Benefit Member | ' | ' | ' | ' |
Change in Benefit Obligation [Abstract] | ' | ' | ' | ' |
Benefit obligation at beginning of year | ' | 10,810,000 | 11,500,000 | ' |
Defined Benefit Plan Interest Cost | ' | 383,000 | 501,000 | ' |
Defined Benefit Plan Actuarial Net Gains Losses | ' | -539,000 | 116,000 | ' |
Defined Benefit Plan Benefits Paid | ' | -1,200,000 | -1,307,000 | ' |
Benefit obligation at end of year | ' | 9,454,000 | 10,810,000 | 11,500,000 |
Change in Plan Assets [Abstract] | ' | ' | ' | ' |
Defined Benefit Plan Contributions By Employer | ' | 1,200,000 | 1,307,000 | ' |
Defined Benefit Plan Funded Status Of Plan Abstract | ' | ' | ' | ' |
Defined Benefit Plan Funded Status Of Plan | ' | -9,454,000 | -10,810,000 | ' |
Defined Benefit Plan Amounts Recognized In Balance Sheet | ' | -9,454,000 | -10,810,000 | ' |
Pension And Other Postretirement Defined Benefit Plans Current Liabilities | ' | -729,000 | -943,000 | ' |
Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent | ' | -8,725,000 | -9,867,000 | ' |
Defined Benefit Plan Weighted Average Assumptions Used In Calculating Benefit Obligation Abstract | ' | ' | ' | ' |
Defined Benefit Plan Assumptions Used Calculating Benefit Obligation Discount Rate | ' | 4.65% | 3.70% | ' |
Defined Benefit Plan Health Care Cost Trend Rate Assumed For Next Fiscal Year | ' | 7.54% | 7.82% | ' |
Defined Benefit Plan Ultimate Health Care Cost Trend Rate | ' | 4.50% | 4.50% | ' |
Defined Benefit Plan Year That Rate Reaches Ultimate Trend Rate | ' | '2023 | '2022 | ' |
Defined Benefit Plan Net Periodic Benefit Cost Abstract | ' | ' | ' | ' |
Net Periodic Benefit Interest Cost | ' | 383,000 | 501,000 | 604,000 |
Defined Benefit Plan Amortization Of Gains Losses | ' | -669,000 | -958,000 | -455,000 |
Total Pension Expense | ' | -286,000 | -457,000 | 149,000 |
Defined Benefit Plan Estimated Future Benefit Payments Abstract | ' | ' | ' | ' |
Defined Benefit Plan Expected Future Benefit Payments In Year One | ' | 765,000 | ' | ' |
Defined Benefit Plan Expected Future Benefit Payments In Year Two | ' | 733,000 | ' | ' |
Defined Benefit Plan Expected Future Benefit Payments In Year Three | ' | 702,000 | ' | ' |
Defined Benefit Plan Expected Future Benefit Payments In Year Four | ' | 644,000 | ' | ' |
Defined Benefit Plan Expected Future Benefit Payments In Year Five | ' | 636,000 | ' | ' |
Defined Benefit Plan Expected Future Benefit Payments In Five Fiscal Years Thereafter | ' | 3,121,000 | ' | ' |
Pension Plan Contribution Ten Year Total | ' | 6,601,000 | ' | ' |
Defined Benefit Plan Effect Of One Percentage Point Change In Assumed Health Care Cost Trend Rates Abstract | ' | ' | ' | ' |
Defined Benefit Plan Effect Of One Percentage Point Increase On Service And Interest Cost Components | ' | 44,000 | ' | ' |
Defined Benefit Plan Effect Of One Percentage Point Decrease On Service And Interest Cost Components | ' | -37,000 | ' | ' |
Defined Benefit Plan Effect Of One Percentage Point Increase On Accumulated Postretirement Benefit Obligation | ' | 975,000 | ' | ' |
Defined Benefit Plan Effect Of One Percentage Point Decrease On Accumulated Postretirement Benefit Obligation | ' | ($834,000) | ' | ' |
Beginning of Year Net Periodic Benefit Cost Assumptions [Abstract] | ' | ' | ' | ' |
Beginning of Year Discount Rate | ' | 3.70% | 4.60% | 5.00% |
Beginning of Year Estimate of Subsequent Year Health Care Trend Rate | ' | 7.82% | 8.10% | 8.39% |
Beginning of Year Estimate of Ultimate Health Care Trend Rate | ' | 4.50% | 4.50% | 4.50% |
Beginning of Year Estimate of Year Rate Reaches Ultimate Trend Rate | ' | '2023 | '2022 | '2021 |
ShareBased_Compensation_Detail
Share-Based Compensation (Details) (USD $) | 12 Months Ended | ||
Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2011 | |
Share Based Compensation Details [Abstract] | ' | ' | ' |
Share Based Compensation Arrangement By Share Based Payment Award Number of Shares Available for Grant Under AmerisourceBergen Equity Incentive Plan | 28,000,000 | ' | ' |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value | $6.54 | $6.36 | $7.43 |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate | 0.44% | 0.59% | 1.80% |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate | 1.29% | 1.39% | 1.10% |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate | 24.22% | 25.63% | 26.46% |
Option Award Fair Value Assumptions Expected Term | '3.69 years | '3.69 years | '3.83 years |
Stock or Unit Option Plan Expense | $20,200,000 | $15,400,000 | $18,800,000 |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number | 14,119,000 | 16,086,000 | ' |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period | 3,856,000 | ' | ' |
Stock Option Exercises | -4,926,000 | ' | ' |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period | -897,000 | ' | ' |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number | 6,452,000 | ' | ' |
Options Expected to Vest | 7,104,000 | ' | ' |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price | $33 | $28 | ' |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price | $41 | ' | ' |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price | $23 | ' | ' |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price | $38 | ' | ' |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price | $26 | ' | ' |
Options Expected to Vest Weighted Average Exercise Price | $38 | ' | ' |
Weighted Average Contractual Term Options Outstanding | '4 years | '5 years | ' |
Weighted Average Contractual Term Options Exercisable | '3 years | ' | ' |
Weighted Average Contractual Term Options Expected to Vest | '5 years | ' | ' |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value | 402,257,000 | ' | ' |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Intrinsic Value Old | 225,143,000 | ' | ' |
Options Expected to Vest Intrinsic Value | 164,089,000 | ' | ' |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value | 131,800,000 | 82,100,000 | 118,500,000 |
Nonvested Options Outstanding | 7,667,000 | 7,601,000 | ' |
Options Vested | -2,906,000 | ' | ' |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period | -884,000 | ' | ' |
Nonvested Options Weighted Average Fair Value | $7 | $6 | ' |
Options Vested Weighted Average Fair Value | $6 | ' | ' |
Options Forfeited Weighted Average Fair Value | $6 | ' | ' |
Option Compensation Not Yet Recognized | 35,800,000 | ' | ' |
Weighted Average Period of Unrecognized Option Compensation | '2.4 years | ' | ' |
ABC Restricted Stock Expense | 12,100,000 | 9,000,000 | 8,500,000 |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number | 1,123,000 | 1,058,000 | ' |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period | 448,000 | ' | ' |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period | -318,000 | ' | ' |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period | -65,000 | ' | ' |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value | $39 | $34 | ' |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value | $44 | ' | ' |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value | $30 | ' | ' |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period Weighted Average Grant Date Fair Value | $37 | ' | ' |
Restricted Stock Compensation Not Yet Recognized | 19,300,000 | ' | ' |
Weighted Average Period of Unrecognized Restricted Stock Compensation | '1.5 years | ' | ' |
Performance share expense | 3,700,000 | 1,500,000 | ' |
ESPP Shares Authorized | 4,000,000 | ' | ' |
ESPP Shares Acquired | 93,813 | 113,692 | 106,959 |
ESPP Withholdings | 1,100,000 | ' | ' |
Fair Value Stock Options Vested During Year | 17,400,000 | 17,200,000 | 18,000,000 |
Fair Value Restricted Stock Vested During Year | $9,700,000 | $6,100,000 | $7,300,000 |
Leases_and_Other_Commitments_D
Leases and Other Commitments (Details) (USD $) | 12 Months Ended | |||
In Millions, unless otherwise specified | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2011 | Sep. 30, 2014 |
Commitments and Contingencies Disclosure [Abstract] | ' | ' | ' | ' |
Operating Leases Future Minimum Payments Due | $284 | ' | ' | ' |
Operating Leases Future Minimum Payments Due Current | 54.5 | ' | ' | ' |
Operating Leases Future Minimum Payments Due In Two Years | 49.2 | ' | ' | ' |
Operating Leases Future Minimum Payments Due In Three Years | 42.3 | ' | ' | ' |
Operating Leases Future Minimum Payments Due In Four Years | 32.3 | ' | ' | ' |
Operating Leases Future Minimum Payments Due In Five Years | 29.7 | ' | ' | ' |
Operating Leases Future Minimum Payments Due Thereafter | 76 | ' | ' | ' |
Lease And Rental Expense | 79.6 | 65.3 | 53.3 | ' |
Remaining Purchase Commitment Estimate for Flu Vaccine | 36.9 | ' | ' | ' |
Remaining Purchase Commitment Estimate for IBM Global Services | 54.1 | ' | ' | ' |
Remaining Purchase Commitment for IBM Global Services Current | ' | ' | ' | $31.30 |
Employee_Severance_Litigation_2
Employee Severance, Litigation, and Other (Details) (USD $) | 3 Months Ended | 12 Months Ended | |||||||||
Sep. 30, 2013 | Jun. 30, 2013 | Mar. 31, 2013 | Dec. 31, 2012 | Sep. 30, 2012 | Jun. 30, 2012 | Mar. 31, 2012 | Dec. 31, 2011 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2011 | |
Facility Consolidations Employee Severance and Other Details [Abstract] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Other Restructuring Costs | ' | ' | ' | ' | ' | ' | ' | ' | $491,000 | $33,040,000 | $4,382,000 |
Business Combination, Acquisition Related Costs | ' | ' | ' | ' | ' | ' | ' | ' | 22,976,000 | 11,100,000 | 3,185,000 |
Gain (Loss) Related to Litigation Settlement | ' | ' | ' | ' | ' | ' | ' | ' | 0 | 0 | 16,000,000 |
Employee severance, litigation and other | 2,084,000 | 19,678,000 | -299,000 | 2,004,000 | 27,419,000 | 4,135,000 | 9,027,000 | 3,559,000 | 23,467,000 | 44,140,000 | 23,567,000 |
Employees Terminated Under Restructuring Activities | ' | ' | ' | ' | ' | ' | ' | ' | '103 314 | ' | ' |
Restructuring Reserve Line Items | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Restructuring Reserve | ' | ' | ' | 48,835,000 | ' | ' | ' | 23,900,000 | 48,835,000 | 23,900,000 | ' |
Employee severance, litigation and other | 2,084,000 | 19,678,000 | -299,000 | 2,004,000 | 27,419,000 | 4,135,000 | 9,027,000 | 3,559,000 | 23,467,000 | 44,140,000 | 23,567,000 |
Restructuring Reserve Settled With Cash | ' | ' | ' | ' | ' | ' | ' | ' | -55,268,000 | -19,205,000 | ' |
Restructuring Reserve | 17,034,000 | ' | ' | ' | 48,835,000 | ' | ' | ' | 17,034,000 | 48,835,000 | 23,900,000 |
Pension Expense Included Within Restructuring Charges | ' | ' | ' | ' | ' | ' | ' | ' | 10,300,000 | ' | ' |
Expenses Incurred for Deal Related Costs | ' | ' | ' | ' | ' | ' | ' | ' | 23,000,000 | 11,100,000 | ' |
Employee Severance Costs [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Facility Consolidations Employee Severance and Other Details [Abstract] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Employee severance, litigation and other | ' | ' | ' | ' | ' | ' | ' | ' | 491,000 | 33,040,000 | ' |
Restructuring Reserve Line Items | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Restructuring Reserve | ' | ' | ' | 30,982,000 | ' | ' | ' | 3,610,000 | 30,982,000 | 3,610,000 | ' |
Employee severance, litigation and other | ' | ' | ' | ' | ' | ' | ' | ' | 491,000 | 33,040,000 | ' |
Restructuring Reserve Settled With Cash | ' | ' | ' | ' | ' | ' | ' | ' | -15,671,000 | -5,668,000 | ' |
Restructuring Reserve | 15,802,000 | ' | ' | ' | 30,982,000 | ' | ' | ' | 15,802,000 | 30,982,000 | ' |
Lease Cancellation Costs and Other [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Facility Consolidations Employee Severance and Other Details [Abstract] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Employee severance, litigation and other | ' | ' | ' | ' | ' | ' | ' | ' | 22,976,000 | 11,100,000 | ' |
Restructuring Reserve Line Items | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Restructuring Reserve | ' | ' | ' | 17,853,000 | ' | ' | ' | 20,290,000 | 17,853,000 | 20,290,000 | ' |
Employee severance, litigation and other | ' | ' | ' | ' | ' | ' | ' | ' | 22,976,000 | 11,100,000 | ' |
Restructuring Reserve Settled With Cash | ' | ' | ' | ' | ' | ' | ' | ' | -39,597,000 | -13,537,000 | ' |
Restructuring Reserve | $1,232,000 | ' | ' | ' | $17,853,000 | ' | ' | ' | $1,232,000 | $17,853,000 | ' |
Litigation_Settlements_Details
Litigation Settlements (Details) (USD $) | 3 Months Ended | 12 Months Ended | ||||||
In Millions, unless otherwise specified | Sep. 30, 2013 | Jun. 30, 2013 | Mar. 31, 2013 | Dec. 31, 2012 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2011 |
Gain (Loss) Related to Litigation Settlement [Abstract] | ' | ' | ' | ' | ' | ' | ' | ' |
Antitrust Settlements Gain | $1.10 | $6 | $3.50 | $12.30 | $14.80 | $22.90 | $14.80 | $2.10 |
Business_Segment_Information_D
Business Segment Information (Details) (USD $) | 3 Months Ended | 12 Months Ended | |||||||||
In Thousands, unless otherwise specified | Sep. 30, 2013 | Jun. 30, 2013 | Mar. 31, 2013 | Dec. 31, 2012 | Sep. 30, 2012 | Jun. 30, 2012 | Mar. 31, 2012 | Dec. 31, 2011 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2011 |
Business Segment Information Details [Abstract] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Distribution of Pharmaceuticals as Historic Percentage of Total Revenue | ' | ' | ' | ' | ' | ' | ' | ' | 95.00% | ' | ' |
segment reporting information | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Revenue | $24,469,040 | $21,906,648 | $20,523,668 | $21,059,811 | $19,064,443 | $19,326,807 | $19,708,371 | $19,981,185 | $87,959,167 | $78,080,806 | $78,695,659 |
Operating income | 114,190 | 134,646 | 350,123 | 299,440 | 318,766 | 324,386 | 377,060 | 283,403 | 898,399 | 1,303,615 | 1,189,520 |
Warrants | 50,479 | 35,815 | 3,761 | 0 | ' | ' | ' | ' | 90,055 | 0 | 0 |
Employee severance, litigation and other | 2,084 | 19,678 | -299 | 2,004 | 27,419 | 4,135 | 9,027 | 3,559 | 23,467 | 44,140 | 23,567 |
Other loss | 1,207 | -525 | -749 | 23 | 910 | 4,785 | 131 | 1 | -44 | 5,827 | 4,617 |
Interest expense, net | -18,672 | -18,190 | -18,510 | -18,525 | -23,137 | -23,771 | -23,375 | -22,286 | -73,897 | -92,569 | -76,148 |
Income from continuing operations before income taxes | 96,725 | 115,931 | 330,864 | 280,938 | 296,539 | 305,400 | 353,816 | 261,118 | 824,458 | 1,216,873 | 1,117,989 |
Assets | 18,918,638 | ' | ' | ' | 15,442,256 | ' | ' | ' | 18,918,638 | 15,442,256 | ' |
depreciation and amortization | ' | ' | ' | ' | ' | ' | ' | ' | 162,186 | 134,375 | 101,362 |
Capital expenditures | ' | ' | ' | ' | ' | ' | ' | ' | 202,450 | 133,292 | 156,142 |
Pharmaceutical Distribution [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
segment reporting information | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Revenue | ' | ' | ' | ' | ' | ' | ' | ' | 86,387,950 | 76,940,544 | 78,444,933 |
Operating income | ' | ' | ' | ' | ' | ' | ' | ' | 919,455 | 1,275,636 | 1,184,673 |
Assets | 17,589,320 | ' | ' | ' | 13,429,646 | ' | ' | ' | 17,589,320 | 13,429,646 | ' |
depreciation and amortization | ' | ' | ' | ' | ' | ' | ' | ' | 116,672 | 106,028 | 90,005 |
Capital expenditures | ' | ' | ' | ' | ' | ' | ' | ' | 172,549 | 85,980 | 143,584 |
Other Segment [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
segment reporting information | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Revenue | ' | ' | ' | ' | ' | ' | ' | ' | 1,763,549 | 1,324,744 | 302,012 |
Operating income | ' | ' | ' | ' | ' | ' | ' | ' | 92,466 | 72,119 | 28,414 |
Assets | 1,329,318 | ' | ' | ' | 1,349,757 | ' | ' | ' | 1,329,318 | 1,349,757 | ' |
depreciation and amortization | ' | ' | ' | ' | ' | ' | ' | ' | 45,514 | 28,347 | 11,357 |
Capital expenditures | ' | ' | ' | ' | ' | ' | ' | ' | 29,901 | 47,312 | 12,558 |
Intersegment eliminations [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
segment reporting information | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Revenue | ' | ' | ' | ' | ' | ' | ' | ' | -192,332 | -184,482 | -51,286 |
Assets held for sale for seg disclosure [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
segment reporting information | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Assets | $0 | ' | ' | ' | $662,853 | ' | ' | ' | $0 | $662,853 | ' |
Fair_Value_of_Financial_Instru1
Fair Value of Financial Instruments (Details) (USD $) | Sep. 30, 2013 | Sep. 30, 2012 |
Fair Value Disclosures [Abstract] | ' | ' |
Other Assets Fair Value Disclosure | $0 | $230,000,000 |
Long Term Debt | 1,396,606,000 | 1,395,931,000 |
Debt Instrument Fair Value | $1,502,000,000 | $1,584,700,000 |
Quarterly_Financial_Informatio2
Quarterly Financial Information (Unaudited) (Details) (USD $) | 3 Months Ended | 12 Months Ended | |||||||||
Sep. 30, 2013 | Jun. 30, 2013 | Mar. 31, 2013 | Dec. 31, 2012 | Sep. 30, 2012 | Jun. 30, 2012 | Mar. 31, 2012 | Dec. 31, 2011 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2011 | |
Quarterly Financial Information Unaudited Details [Abstract] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Revenue | $24,469,040,000 | $21,906,648,000 | $20,523,668,000 | $21,059,811,000 | $19,064,443,000 | $19,326,807,000 | $19,708,371,000 | $19,981,185,000 | $87,959,167,000 | $78,080,806,000 | $78,695,659,000 |
Cost of goods sold | 23,901,488,000 | 21,344,198,000 | 19,806,679,000 | 20,398,983,000 | 18,350,626,000 | 18,658,941,000 | 19,028,630,000 | 19,407,923,000 | 85,451,348,000 | 75,446,120,000 | 76,236,682,000 |
Gross profit | 567,552,000 | 562,450,000 | 716,989,000 | 660,828,000 | 713,817,000 | 667,866,000 | 679,741,000 | 573,262,000 | 2,507,819,000 | 2,634,686,000 | 2,458,977,000 |
Distribution, selling and administrative | 358,303,000 | 331,173,000 | 323,536,000 | 320,700,000 | 329,138,000 | 303,812,000 | 262,421,000 | 257,185,000 | 1,333,712,000 | 1,152,556,000 | 1,138,022,000 |
Depreciation | 35,710,000 | 34,395,000 | 33,069,000 | 31,873,000 | 31,550,000 | 29,552,000 | 26,603,000 | 25,123,000 | 135,047,000 | 112,828,000 | 88,760,000 |
Amortization | 6,786,000 | 6,743,000 | 6,799,000 | 6,811,000 | 6,944,000 | 5,981,000 | 4,630,000 | 3,992,000 | 27,139,000 | 21,547,000 | 12,602,000 |
Distribution, selling and administrative expenses, depreciation and amortization | 400,799,000 | 372,311,000 | 363,404,000 | 359,384,000 | 367,632,000 | 339,345,000 | 293,654,000 | 286,300,000 | 1,495,898,000 | 1,286,931,000 | ' |
Warrants | 50,479,000 | 35,815,000 | 3,761,000 | 0 | ' | ' | ' | ' | 90,055,000 | 0 | 0 |
Employee severance, litigation and other | 2,084,000 | 19,678,000 | -299,000 | 2,004,000 | 27,419,000 | 4,135,000 | 9,027,000 | 3,559,000 | 23,467,000 | 44,140,000 | 23,567,000 |
Intangible asset impairments | ' | ' | ' | ' | ' | ' | ' | ' | 0 | 0 | 6,506,000 |
Operating income | 114,190,000 | 134,646,000 | 350,123,000 | 299,440,000 | 318,766,000 | 324,386,000 | 377,060,000 | 283,403,000 | 898,399,000 | 1,303,615,000 | 1,189,520,000 |
Other loss (income) | -1,207,000 | 525,000 | 749,000 | -23,000 | -910,000 | -4,785,000 | -131,000 | -1,000 | 44,000 | -5,827,000 | -4,617,000 |
Interest expense, net | 18,672,000 | 18,190,000 | 18,510,000 | 18,525,000 | 23,137,000 | 23,771,000 | 23,375,000 | 22,286,000 | 73,897,000 | 92,569,000 | 76,148,000 |
Income from continuing operations before income taxes | 96,725,000 | 115,931,000 | 330,864,000 | 280,938,000 | 296,539,000 | 305,400,000 | 353,816,000 | 261,118,000 | 824,458,000 | 1,216,873,000 | 1,117,989,000 |
Income taxes | 46,164,000 | 51,821,000 | 126,721,000 | 106,317,000 | 106,090,000 | 115,223,000 | 134,673,000 | 99,526,000 | 331,023,000 | 455,512,000 | 420,494,000 |
Income from continuing operations | 50,561,000 | 64,110,000 | 204,143,000 | 174,621,000 | 190,449,000 | 190,177,000 | 219,143,000 | 161,592,000 | 493,435,000 | 761,361,000 | 697,495,000 |
(Loss) income from discontinued operations, net of income tax expense of $9,638, $4,841, and $3,523 for fiscal 2013, 2012, and 2011, respectively | 462,000 | 104,329,000 | -158,509,000 | -6,010,000 | -26,955,000 | -8,906,000 | -7,038,000 | 524,000 | -59,728,000 | -42,375,000 | 9,129,000 |
Net income | 51,023,000 | 168,439,000 | 45,634,000 | 168,611,000 | 163,494,000 | 181,271,000 | 212,105,000 | 162,116,000 | 433,707,000 | 718,986,000 | 706,624,000 |
Earnings Per Share From Continuing Operations [Abstract] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Continuing operations basic | $0.22 | $0.28 | $0.89 | $0.75 | $0.78 | $0.75 | $0.85 | $0.63 | $2.14 | $3.01 | $2.56 |
Discontinued operations basic | $0 | $0.45 | ($0.69) | ($0.03) | ($0.11) | ($0.04) | ($0.03) | ' | ($0.26) | ($0.17) | $0.03 |
Basic rounding | ' | ' | ' | $0.01 | ' | $0.01 | ' | ' | ' | ' | ' |
Continuing operations | $0.22 | $0.27 | $0.87 | $0.74 | $0.77 | $0.74 | $0.84 | $0.61 | $2.10 | $2.96 | $2.51 |
Earnings Per Share From Net Income [Abstract] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Earnings per Share Basic | $0.22 | $0.73 | $0.20 | $0.73 | $0.67 | $0.72 | $0.82 | $0.63 | $1.88 | $2.84 | $2.59 |
Discontinued operations | $0 | $0.44 | ($0.68) | ($0.03) | ($0.11) | ($0.03) | ($0.03) | ' | ($0.25) | ($0.16) | $0.03 |
Diluted rounding | ' | ' | ' | ' | ' | ' | ' | $0.01 | ($0.01) | $0 | $0 |
Earnings Per Share Diluted | $0.22 | $0.71 | $0.19 | $0.71 | $0.66 | $0.71 | $0.81 | $0.62 | $1.84 | $2.80 | $2.54 |
Antitrust Settlements Gain | 1,100,000 | 6,000,000 | 3,500,000 | 12,300,000 | 14,800,000 | ' | ' | ' | 22,900,000 | 14,800,000 | 2,100,000 |
Inventory, LIFO Reserve, Period Charge | $154,000,000 | $122,100,000 | ($200,000) | $1,100,000 | ' | ' | ' | ' | $277,000,000 | $700,000 | $34,700,000 |
Subsequent_Events_Details
Subsequent Events (Details) (USD $) | 1 Months Ended | 12 Months Ended | |||
Oct. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2011 | Nov. 30, 2013 | |
Subsequent Events [Abstract] | ' | ' | ' | ' | ' |
Dividend Increase Percentage | ' | ' | ' | ' | 12.00% |
Common Stock Dividends Per Share Cash Paid | $0.24 | $0.84 | $0.52 | $0.43 | ' |
Schedule_II_Valuation_and_Qual2
Schedule II - Valuation and Qualifying Accounts (Details) (USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2011 |
Valuation and Qualifying Accounts [Abstract] | ' | ' | ' |
Balance of Allowance at Beginning of Period | $85,741 | $88,833 | $93,849 |
Valuation Allowances And Reserves Charged To Cost And Expense | 20,118 | 23,058 | 37,878 |
Valuation Allowances And Reserves Charged To Other Accounts | 0 | 0 | 62 |
Valuation Allowances And Reserves Deductions | -23,479 | -26,150 | -42,956 |
Balance of Allowance at End of Period | $82,380 | $85,741 | $88,833 |